









Synthesis and expression of the Exythrina trypsin/tissu~ 
plasminogen activator (tPA) inhibitor encoding-gene. Genetic 
dissection to correlate the interaction of Exythrina and 
Soybean trypsin inhibitors with tPA. 
Avelino V. Teixeira 
.... 
Thesis presented for the Degree of 
DOCTOR OF PHILOSOPHY 
in the Department of Biochemistry, 
Faculty of Science 
University of Cape •.rown 
Cape Town, August 1992. 
The Uor~ersfty of 
the right to Cape Town has been 
or In Part . c{epro;Juce this thesis I 9!:'_!;n 
. opynght is held b then w.""e 
•-=-u....,, .... Y author . 



















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 





ABBREVIATIONS USED IN TEXT AND FIGURES 
CHAPTER 1 INTRODUCTION 
CHAPTER 2 DESIGN AND SYNTHESIS OF AN 
ETI-ENCODING GENE 
CHAPTER 3 EXPRESSION OF THE SYNTHETIC ETI 
GENE IN E.COLI 
CHAPTER 4 DETERMINATION OF. THE ACTIVITY OF 
val-ETI AND asp7ETI AGAINST.t-PA 
CHAPTER 5 CONCLUSIONS 


















I am indebted to the following people: 
My supervisor Professor Dawie Botes for his guidance and 
assistance during the course of this work. 
Ms T. Pitout for assistance in synthesis and purification of 
all oligonucleotides used in this work. 
Dr c. Heussen-Schemmer, Ms Sandra Coetzee and Professor E.B.D. 
Dowdle for their assistance with all tPA assays in this work. 
Dr P. Smith and Mrs F. Davids of ·the Biochemistry Department, 
UCT for their assistance with all antibody preparations and 
Western blotting. 
The Foundation for Research Development for their financial 
support. 
My Mother and late Father for their constant encouragement. 
My Wife Dianne for her continuous support and abundant patience 
during the course of this work and my two little girls Rachel 
and Angie for being themselves. 
ii 
ABSTRACT 
A trypsin inhibitor had previously been isolated from Erythrina 
caffra, a member of the Leguminosae family. The inhibitor, 
Erythrina trypsin inhibitor (ETI), is unique among plant-
derived inhibitors, in that in addition to trypsin, it inhibits 
chymotrypsin and tissue plasminogen activator (tPA). ETI was 
previously sequenced and its crystal structure determined from 
which it could be seen that ETI has good homology to soybean 
trypsin inhibitor (STI). However, STI does not inhibit tPA. 
From the three-dimensional structure of ETI it was known that 
the amino-terminus of the molecule forms a finger-like 
structure stabilized by hydrogen bonds and hydrophobic 
interactions. In addition, the N-terminal finger region is 
located in close proximity to the reactive site loop and the N-
terminal residue (Val) is bound up in the finger region. In STI 
the N-terminal region is located in close proximity to the 
reactive site loop and is folded into a structure similar to 
that in ETI. While the crystal structure of STI was not 
detailed enough to determine secondary interactions such as 
hydrogen bonds it was hypothesized that the N-terminal region 
is stabilized as in ETI. It was further hypothesized that the 
N-terminal residue of STI (Asp), because of its hydrophilic 
nature, is not involved in the structured N-terminal finger 
region of this protein. This leaves this Asp residue of STI 
free to form an ion pair with Lys at position 60 in trypsin 
when STI and trypsin interact. 
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When amino acid sequences of trypsin and the B-chain of tPA are 
aligned for optimum homology it is seen that there are a number 
of insertion sequences in tPA that are thought to be 
accommodated in the form of protrusions. One of these can be 
seen to occur in the region that lies opposite the Lys60 region 
of trypsin. It is suggested in this work that the N-terminal 
Asp of STI and this protrusion of tPA sterically prevent the 
two proteins from approaching close enough to allow for binding 
and inhibition to occur. 
Plant codon preferences differ sufficiently from codon 
preferences of E. coli to make high levels of expression in 
E.coli, of a gene cloned from a plant, unpredictable. For this 
reason, a gene for ETI was designed from the published amino 
acid sequence. In order to alter the gene and produce modified 
forms of ETI, it was designed to allow removal and replacement 
of sections by strategically placed unique restriction sites. 
The design was divided into 8 sections for each of which the 
non-coding strand was synthesized:with additional 15 base arms 
to anchor the oligonucleotide (oligo) across the gap created by 
digestion of the synthesis plasmid by Bsmi. The entire gene was 
assembled in consecutive steps in the 3'- 5' direction, by 
bridging the gap created by digestion of the plasmid containing 
the prior oligo with Bsmi with the sequential oligo and 
allowing E.coli to fill in the missing strand. At each step and 
on completion, the gene was sequenced to confirm that no 
mutation had occurred during synthesis. 
iv 
The ETI-encoding gene was originally designed for expression . 
under the control of the tac promoter in a system that allowed 
for accumulation in the cytoplasm. This system proved 
unsuccessful. The gene was then cloned into the pMal gene and 
expressed as a fusion to maltose binding protein (MBP). The two 
domains of the protein in this system are separated by the 
cleavage site for factor Xa (FXa)· The MBP domain allowed for 
purification of fusion protein but FXa was unable to separate 
the two domains and produced a fragment smaller than ETI. FXa 
produced a similar sized fragment from pure natural ETI and it 
was concluded that ETI 1 even in the form of a fusion with MBP 
was able to inhibit FXa which is a serine protease with 
reactive site similar to that of trypsin. As the facile 
enzymatic approach to producing ETI with a natural Val N-
terminus had failed a Met residue was engineered just upstream 
of the required N-terminal residue. This construct was 
expressed in pET12a which supplies a signal sequence for export 
to the periplasm. Most of the expressed protein w~s located in 
the cytoplasm but because the periplasm is an environment 
conducive to the formation of disulphide bridges only 
periplasmic protein was isolated. The remaining two N-terminal 
amino acids after signal sequence cleavage in the periplasm 
were cleaved carboxy-terminal to the engineered Met residue 
with CNBr. 
Two forms of ETI were produced 1 one with the sequence of 
natural ETI including a Val N-terminus (val-ET!) 1 the other 
with an Asp residue N-terminal to Val ( asp-ETI) 1 to simulate 
the N-terminal region of STI. The active sites in each were 
titrated against trypsin and assayed against tPA. The results 
/ 
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showed val-ET! to have much the same activity towards tPA as 
natural ETI while asp-ETI had activity towards tPA similar to 
that of STI. This evidence indicates strongly that the N-
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Biologically active proteins are often synthesized at a 
location in the organism that is distant from where they are 
required to function. In addition, they may need to be stored 
until their activity is required. Whatever the case, their 
activity is such that untimely performance of the specific 
biological function for which they are responsible can be 
detrimental to the organism. It is for this reason that living 
organisms have developed sophisticated mechanisms to prevent 
the activity of such proteins until it is required. Preventing 
the activity of physiologically active proteins can be achieved 
by synthesizing them as inactive precursors (zymogens). These 
are subsequently converted to active forms by cleavage of often 
only one peptide bond (limited proteolysis) by very sel~ctive 
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proteolytic enzymes (proteases). Another mechanism widely 
utilized by all classes of organisms for control of active 
proteins is to simultaneously synthesize proteins that bind 
specifically to a protein or group of proteins and inhibit its 
activity. 
The subject of this study is an inhibitor protein that was 
isolated from an Erythrina species. It is an inhibitor of the 
powerful digestive proteases: trypsin, chymotrypsin and the 
plasma protein, tissue plasminogen activator (tPA). As a 
result, the inhibitor is known as Erythrina trypsin inhibitor 
(ETI). ETI will be described later in Chapter 1 after some of 
the properties of proteases and their inhibitors have been 
introduced in relation to the target proteases of ETI: trypsin 
and tPA. 
1.2 Proteases 
Hydrolysis of peptides in neutral solutions is slow because 
there are high energy barriers between starting materials and 
products. Enzymes allow the reactants to follow a different 
pathway and new intermediate states are established in which 
the enzyme stabilizes the states of highest energy thereby 
lowering internal energy barriers (Stroud, 1974). 
Proteolytic enzymes from the gastrointestinal tract of humans 
were among the first recognized enzymes and have counterparts 
in blood plasma, sperm and other tissues as well as in simpler 
organisms such as bacteria whete they serve in a control 
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function (Walsh, 1975). Proteases have been arranged into 
families which are mechanistically, but not necessarily 
structurally related viz i) aspartic ii) cysteine iii) metallo 
and v) serine proteinases (Bond and Butler, 1978). 
The aspartic family of proteinase~ include inter alia the very 
important gastric enzymes such as chymosins, gastrins and 
pepsins as well as the renin group from the kidneys. These have 
been placed in this family because they share a common 
catalytic mechanism provided by the carboxyl side- chains of 
two aspartic acid residues which are positioned distant from 
each other on the polypeptide chain. For example, in pepsin, 
Asp32 and 215 are implicated in catalysis and they are brought 
into close proximity in a deep cleft between ~-sheet regions by 
the folding of the protein. The cysteine proteases, of which 
the papains are an examp·le use a nucleophilic cysteine residue 
for their reaction mechanism. Metalloproteases are 
characterized by the use of a chelated metal atom, such as Zn 
as an electron sink to polarize the peptide bond under attack. 
For example, carboxypeptidase A uses a hydrophobic pocket and 
Argl45 to bind the amino acid C terminal to the target peptide 
bond. This is then attacked in a concerted manner by a general 
acid (Tyr248) and a general base (Glu270). 
The serine proteases are a very large family of related enzymes 
which are important in biological control. They are also of 
interest to the current work as. the target enzymes of ETI: 
trypsin, chymotrypsin and t-PA a11 belong to this family of 
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enzymes. The detailed structure and mechanism of action of one 
member of a mechanistic set can provide a model for 
understanding the structure, mechanism, 
specificity of other members of the same set. 
function and 
As a result, 
serine proteases are further divided into trypsin-like (the 
subfamily to which the target enzymes of ETI belong) and 
subtilisin-like enzymes (Stroud, 1974). 
The specificity and mechanism of action of an enzyme is 
determined by two key factors. 
First is the presence of three groups of important amino acids. 
which are involved in contact with the substrate. 
1) The amino acids involved in cleavage (the active site 
amino acids). In the three serine protease digestive 
enzymes trypsin, chymotrypsin and elastase, the most 
important amino acids in this group are Ser195, His57 
and Asp102 (chymotrypsin numbering) and their 
immediate neighbours. ·These 3 units are brought 
together by the folding of the polypeptide chain and 
to form the active site. 
2) Those amino acids that form the binding site (or 
pocket) which is the region of the enzyme that 
accommodates the side-chain of the amino acid on the 
carboxy side of the target peptide bond to orient it 
for cleavage·. This is the region that determines 
specificity of the different members of a mechanistic 
family of enzymes. Trypsin is the most selective of 
the digestive enzymes discussed above. It has a large 
binding pocket at the back of which is an Asp residue 
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which is negatively charged. Trypsin cleaves on the 
carboxy-terminal side of Arg or Lys residues which 
are large, positive and hydrophilic and can be 
accommodated in the binding pocket and held in place 
by electrostatic attraction. Chymotrypsin is specific 
to peptide bonds next to amino acids with large 
hydrophobic side chains. The elastase binding pocket 
is blocked to all but the smallest side chains in the 
substrate and hence it cleaves bonds adjacent to Gly, 
Ala or Ser the smallest of the amino acids (Stroud, 
1974). 
3) Those apart from the catalytic and binding sites 
discussed above that are located on the enzyme and 
stabilize the enzyme-substrate complex (Walsh, 1975). 
The second factor determining specificity and mechanism of 
action of an enzyme is the overall structure of the enzyme. To 
illustrate this the serine proteases trypsin, chymotrypsin and 
elastase are structurally similar :and have analogous assemblies 
. of components at their active centers but alignment of their 
amino acid sequences reveals only 40-50% identity. Evidently 
the important sequences that control conformation have been 
preserved. The three differ in specificity and this is 
explained by changes in the amino acids that shape their 
binding sites (Walsh, 1975). 
The need for timely activity of physiologically active 
proteins has been discussed earlier. For example, .the digestive 
enzymes trypsin and chymotrypsin· are very active enzymes and 
would degrade the cells of the p~ncreas and its ducts if they 
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were not produced as the inactive proenzymes, trypsinogen and 
chymotrypsinogen ·respectively. Activation of trypsin is 
achieved by cleavage of the peptide bond between the 15th and 
16th amino acid of trypsinogen by enterokinase, another 
proteolytic enzyme produced by the intestinal mucosa, releasing 
a 6 amino acid fragment. The new amino terminal at unit 16 
interacts ionically with Asp194, · altering the orientation of 
Lys145 and inducing a structural change that generates the 
specific binding site. Each molecule of trypsin released can 
activate another molecule of trypsinogen which then activates 
the other digestive proenzymes (Stroud, 1974). 
The catalytic mechanism of trypsin, which acts as a model for 
the mechanism of action of the trypsin-like serine proteases, 
is characterized by the concerted attack on the carbonyl carbon 
of the peptide bond by Ser195. and His57 to yield an oxyanion 
tetrahedral intermediate stabilized in an "oxyanion hole" in 
which the negative charge on the carbonyl carbon is stabilized 
by hydrogen bonds to the enzym_e. The charge relay system 
consists of a proton exchange between the side chain imidazole 
of His57 and the carboxylate of Asp102. This releases the amine 
portion of cleaved peptide and produces an acyl enzyme. A water 
molecule replaces the amine and the process is reversed to 
deacylate the enzyme (Walsh, 1975; Kraut, 1977; Carter and 
Wells, 1988). It is important to note that the unusual 
electronic state of His57 and Aspl02 in the interior of the 
protein 'allows for the efficient shuttle of protons which is 
the key to the enzymatic activity (Stroud, 1974). Serine 
proteases employ the same three amino acids to hydrolyse 
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peptide bonds. Their specificity results from the way in which 
they accommodate their substrates. 
1.2.1 A brief look at some of the serine proteases in blood 
clotting and fibrinolysis. 
When tissues are broken the first requirement of the body's 
defence system is to stop the leakage of blood. This process is 
begun immediately since the injury itself releases activating 
agents, one of which is Hageman factor that initiates a cascade 
of enzyme-controlled reactions. Some of these are serine 
proteases, and are activated in sequence. The last in this 
cascade is thrombin, a serine protease very much like trypsin 
(but after between Arg and Gly) which removes 4 short highly 
charged peptides from fibrinogen converting it to insoluble 
fibrin. Fibrinogen is a major blood glycoprotein that plays an 
essential role in haemostasis and the maintenance of blood 
viscosity (Cook and Ubben, 1990). The fibrin matrix is 
initially held together by hydrogen bonds but fibrin 
stabilizing factor (FSF or factor XIII), which is activated by 
thrombin, activates fibrinoligase from its precursor. 
Fibrinoligase links the fibrin molecules covalently by cross-
linking the side chains of Gln and Lys residues between fibrin 
molecules. The resulting mass of tangled threads is what is 
called a clot (Lorand, 1972). 
Thrombin is produced as an inactive precursor called 
prothrombin (also known as coagulation factor or Factor II), 
which is a single polypeptide cha1n with intrachain disulphide 
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bonds and carbohydrate side chains. The conversion of 
prothrombin to thrombin is brought about by thromboplastin 
(Factor III) in the presence of (factor IV). 
Thromboplastin is derived from various tissues through the 
mediation of platelets, platelet factors and other factors viz 
proaccelerin (accelerator globulin or Factor V); proconvertin 
(serum prothrombin conversion acc~lerator, SPCA or Factor VII); 
antihemophilic globulin (AHG) (an~ihemophilic factor, AHF, also 
called Factor VIII); and the Christmas factor (antihemophilic 
factor B or Factor IX). On activation, prothrombin is cleaved 
to produce two polypeptide chains linked by a disulphide 
bridge. The A chain contains 36 residues and B chain 259 
residues with carbohydrate attached. The sequence of the B 
chain is homologous to that of trypsin, chymotrypsin and 
elastase. Thrombin is involved only in the release of 
fibrinopeptides and cleaves only one Arg-Lys bond at the NH2 
terminus of the~ and~ chains of fibrinogen (Mann, 1987). 
Conditions other than wounding can lead to clot formation in 
the blood vessels, for example a defect such as an 
atherosclerotic deposit on the vessel wall. The formation of a 
thrombus (clot) on this defect almost invariably results in the 
interruption of blood flow through that vessel (Haber et al., 
1989). Thus it is crucial that there be a mechanism for the 
breakdown of clots in the vascular system; this is known as the 
fibrinolytic system. The enzyme ultimately responsible for 
dissolution of clots is the serine protease plasmin, which is 
produced as the proenzyme plasminogen. The native form of human 
plasminogen, Glu-plasminogen, is a 90 kDa glycoprotein with ± 
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2% carbohydrate and is a single polypeptide of 791 amino acids. 
All mammalian plasminogens exist in two variant forms differing 
in their carbohydrate composition. In the human system the 
carbohydrate difference is due to the presence of an 
oligosaccharide on Asn228 of variant 1 but not on variant 2. 
Activation of Glu-plasminogen occurs through cleavage of a 
single peptide bond by a plasminogen activator (PA). The Glu-
plasmin formed consists of two polypeptides ( 25 and 65 kDa) 
linked by two disulphide bonds. The smaller subunit contains 
the active site and resembles in sequence thrombin, trypsin, 
chymotrypsin, and elastase. The larger subunit contains several 
fibrin binding sites with an affinity for Lys and an 8 kDa 
activation peptide at the amino terminal end which is released 
by autocatalysis after the initial activation. When fibrin is 
formed, Glu-plasminogen is specifically bound to it and can be 
activated by a PA for breakdown of the clot (Saksela, 1985). 
1.2.2 Plasminogen activation 
The activation of plasminogen is ·regulated at several levels. 
Firstly, the proactivator needs activation. Secondly, the 
active activator is bound by specific inhibitors. Thirdly, 
other molecules such as fibrin affect the activation rate. 
Fourthly, the active plasmin creates a positive feedback effect 
by activating proactivator. In addition, plasmin itself is 
inhibited by a variety of proteinase inhibitors (Saksela, 
1985). Plasminogen activators hydrolyze the Arg560-Val561 
peptide bond of plasminogen and convert it to active plasmin 
(Lijnen and Collen, 1988). In addition, streptokinase, a 
protein from Streptococci can also activate plasminogen when 
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complexing with it. In doing so streptokinase induces a 
conformational change which exposes the active site of 
plasminogen allowing it to function as a plasminogen activator 
(Van Zonneveld et al., 1986). 
Two types of plasminogen activator have been shown to be 
responsible for ·fibrinolysis in the human vascular system: 
tissue plasminogen activators (tPA) and urokinase plasminogen 
activator (uPA) both of which are ·tr~sin-like serine proteases 
but are immunologically distinct. UPA was originally isolated 
from urine where it is the major PA but subsequently both PAs 
have been isolated from many human cell types (Rijken et al., 
1981). Both plasminogen activa~ors are produced as single chain 
proenzymes and require cleavage of a single bond for activation 
(Wallen et al., 1983). While plasmin and trypsin can activate 
PAs, activating activity has also been attributed to other 
serine proteases such as plasma kalikrein, Factor XIa and 
Factor XIIa (Skriver et al., 1982; Laug et al., 1983). However, 
tPA is active in both the single and two chain forms which is 
unusual for serine proteases as ·most of the members of this 
group are produced as zymogens and require proteolytic cleavage 
to a two chain form to release full enzymatic activity (Urano, 
1989; Rijken, 1982). 
Active uPA is a 54 kDa protein of two subunits (30 and 24 kDa) 
linked by a disulphide bond. The active site is located on the 
30 kDa fragment (Saksela, 1985). Native tPA has molecular 
weight of 70 kDa and is glycosylated at 3/4 of the possible 
glycosylation positions (Saksela, 1985). Single-chain tPA, by 
proteolytic cleavage at residues '275-276, is converted into a 
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two-chain activator (30 and 40 kDa) linked by a disulphide bond 
(Pennica et al., 1983;). The light chain contains the active 
site (the serine protease domain) and the heavy chain contains 
four identifiable domains: a fibronectin-like finger, an 
epidermal growth factor homologous region and two kringle 
structures (triple disulphide loops). The structure of uPA is 
homologous to that of tPA, except that it has only one kringle 
domain and it does not posses the fibronectin-like finger 
(Bennett et al., 1991). 
A central goal of tPA biochemistry is to relate the details of 
this structure to the diverse functionalities displayed by the 
enzyme. Physical analysis, for example by crystallography, has 
· been difficult because of the large size of tPA · and its 
heterogeneous glycosylation in mammalian cells. Enzyme kinetic 
studies are complicated by the size, complexity and 
heterogeneity of tPA's substrate (plasminogen) and its most 
important modulators, fibrin and tissue plasminogen activator 
inhibitor 1 (tPAI-1). Thus much of the hope for understanding 
the relationship between the struqtural elements of tPA and its 
various functional properties has become invested in the study 
of mutant proteins (Bennett, 1991). 
The 43 residue amino terminal region of the tPA heavy chain 
(the fibronectin-like finger domain) is homologous with the 
finger domains responsible for the fibrin affinity of -
fibronectin (Banyai et al., 1983). This region, the growth 
factor domain and to a lesser extent the kringle 2 domain of 
tPA has been shown to be involved in binding of the molecule to 
fibrin (van Zonneveld et al., 1986; Markland et al., 1989). It 
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is suggested that kringle 2 carries the Lys binding sites that 
are utilized for purification of tPA (Cleary et al., 1989; 
Bennett et al., 1991). Kalyan et al., (1988) have gone further 
and suggest in addition, a role for the fibronectin-like finger 
domain (and the NH2-terminus of the light chain) in clearance 
of tPA from plasma in vivo (tPA has a high turnover rate) 
mediated by receptors in the liver (Bakhit, 1987). 
Evidence suggests that there are several different types of tPA 
variant ( Pohl et al., 1984a) . About 50% of the single chain 
form lacks the N-terminal sequence Gly-Ala-Arg, which has been 
removed by plasmin. In addition, the heavy chain occurs in 37 
and 40 kDa variants. The difference has been attributed to the 
carbohydrate structure (Pohl et al., 1984b). 
Several hormones and hormone-like substances alter ·the 
secretion rate of PAs. Secretion of uPA particularly is 
extremely sensitive to various stimuli affecting the cell cycle 
which suggests some still unknown-role for this enzyme. Mapping 
of the genomic structure of eDNA produced from the uPA gene has 
revealed a potential hormone receptor binding site and a 
sequence in the genome that is possibly involved in activation 
of transcription by cAMP (Nagamine et al., 1984). 
The fibrin binding properties of tPA ensures that the 
activation of plasminogen is localized predominantly on the 
surface of a fibrin clot and in addition, enhances its ability 
to activate plasminogen. Plasminogen and tPA form a cyclic 
ternary complex bound to fibrin. This substantially increases 
the catalytic efficiency of tPA fpr free plasminogen over that 
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of unboun1 tPA or tPA in the absence of fibrin. UPA binds 
poorly to fibrin and lacks such fibrin-mediated plasminogen 
activation. (Ranby, 1982; Hoylearts et al., 1982). The fibrin 
dependency and higher fibrin-binding properties of tPA make it 
a specific and efficient thrombolytic (clot digesting) agent. 
This suggested that tPA could be used clinically to 
specifically facilitate breakdown of clots without the side-
effects of bleeding associated with uPA and streptokinase (van 
de Werf, 1984). However as tPA .binds to fibrin during clot 
formation, clots prepared from tPA poor plasma are only slowly 
degraded after addition of tPA (Brommer, 1984). As tPA 
fibrinolytic therapy activates plasminogen indiscreetly and 
plasmin modifies platelet function and degrades circulating 
fibrinogen and clotting Factors V and VIII as well as thrombus 
bound fibrin, plasminogen activator therapy also carries the 
risk of hemorrhage (Haber, 1989). Thus, tPA fibrinolytic 
activity may possibly be best suited to preventative treatment, 
in appropriate and well controlled doses, in cases in which tPA 
can be shown to be lacking. 
The role of plasmin in fibrinolysis has been discussed above 
but it has also been shown that several cell types other than 
cells of the vascular system produce tPA and that plasmin 
contributes directly and indirectly via conversion of latent , 
collagenase into active collagenase to the degradation of and 
turnover of the extracellular matrix (Kruithof, 1988). The 
intracellular activator proenzyme has been localized to the 
Golgi-derived secretory vesicles and may be bound to the 
internal surface of the vesicle membrane, where it is able to 
• 
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activate extracellular plasminogen after fusion of the vesicle 
with the plasma membrane (Laug et al., 1983). The cascade 
reactions leading to plasminogen activation provide effective 
proteolytic activity which can thus be regulated at the level 
of single cells and used for strictly controlled proteolysis 
and degradation of extracellular matrixes (Saksela, 1985; 
Lawrence et al., 1990). Thus plasmin, and by inference, 
plasminogen and its activators are important in many human 
physiological processes. Some of these are discussed below. 
Plasmin plays an important role in reproduction, for example, a 
few hours before ovulation, the granulosa cells of the ovaries 
secrete high levels of tPA and uPA (controlled by follicle 
stimulating hormone, FSH) which activates plasmin and causes 
disruption of the follicle wall in preparation for release of 
the egg (Beers, 1975; Moscatelli and Rifkin, 1988). In culture, 
the sertoli cells of the testis also secrete PAs under 
regulation of FSH. The activated plasmin is required to degrade 
the matrix between primary spermatocytes and the basal membrane 
of the seminiferous tubules· (Lacroix, 1982). After 
fertilization of the egg, trophoblasts, which are derivatives 
of the trophoectodermal cell layer of the embryo, attach it to 
the uterine wall during implantation, in doing so they have 
been shown in mice, to secrete PAs (Strickland et al., 1976). 
Plasmin is also implicated in the conversion of the prohormone 
of placental lactogen into its more active form (Russell et 
al., 1979). 
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Plasmin is also involved in general metabolism and 
endocrinology as there have been suggestions that it may be 
involved in insulin metabolism (Grieger and Binder, 1984). It 
is known that the cells of the pituitary gland of the rat 
secrete uPA and tPA. In pituitary cell cultures, extracellular 
ACTH has been found to be exclusively of the inactive proenzyme 
form when the culture medium is depleted of plasmin (Granelli-
Piperno and Reich, 1983). 
Plasmin has been shown to be important 
cancer cells which by their nature 
separating various tissues and cell 
in proliferation of 
penetrate structures 
types such as the 
endothelium and basement membrane of the vessel wall. The PAs 
secreted by cancer cells assist in this process by mediating 
degradation of the glycoproteins fibronectin and laminin found 
in the basement membrane and the extracellular matrix (Liotta 
et al., 1981). The collagenous components present in these 
structures are resistant to plasmin digestion but latent 
collagenases secreted by the cells themselves or by adjacent 
tissues can be activated by plasmin (O'Grady et al., 1981). 
Three types of enzyme seem to be· needed for effective matrix 
breakdown: PA, plasminogen and collagenases. The conclusion is 
drawn that plasminogen activation is required during the very 
early stages of the metastatic process when, for example 
infiltrative growth is required. Proteinase inhibitors 
leupeptin and antipain (Streptomyces and Actinomyces) can 
inhibit carcinogen and radiation induced transformation of 
cells and both substances are known to inhibit PAs (Kinsella, 
1980). Furthermore, exposure of various fibroblasts to 
ultraviolet light or other agents producing DNA damage induces 
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synthesis and secretion of PAs (Miskin, 1980). Clearly, solely 
the production of PAs does not define a cell as malignant but 
rather, possible defects in the control of the enzyme activity 
(or the activation of the secreted proenzyme) at the 
pericellular level may account for several of the growth 
properties of individual cells in the heterogeneous population 
of tumor cells (Dexter and Calabresi, 1982; Lawrence et al., 
1990). 
1.3 Protease inhibitors 
As discussed above, plasmin is a wide spectrum protease that is 
responsible for fibrinolysis and indirectly for turnover of 
extracellular matrix by activation of latent collagenases. It 
was mentioned previously that one method for regulation of 
plasminogen 
which bind 
activation is by the use of specific inhibitors 
to and prevent the activity of plasminogen 
activators. Protein inhibitors of proteinases are found in all 
living organisms where their function is the prevention of any 
unwanted proteolysis. They comprise ± 10% of the human plasma 
proteins and belong to one of two main groups. The first group, 
~-2-Macroglobulin (~2M), is a 725 kDa glycoprotein with 8-11% 
carbohydrate. While it can inhibit all four mechanistic classes 
of proteases the main function of ~2M is to bind and remove 
active proteases from the system. It is only when the local or 
systemic concentrations of an inhibitor become lowered 
significantly, for example in physiological disturbances such 
as disseminated intravascular coagulation, during which the 
majority of the anti-thrombin III (the specific inhibitor of 
thrombin) is exhausted, and during thrombolytic therapy, in 
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which ~2 anti-plasmin (the specific inhibitor of plasmin) 
levels drop precipitously that ~2M exerts . any signi_ficant 
control of the coagulation and fibrinolytic systems (Travis and 
Salvesen, 1983). For this reason it is seen by some as a backup 
system for protease control. Functionally, ~2M hab 3 centers a) 
Bait region which is susceptible to proteolysis by proteinases. 
b) Internal thioester region, possibly involved in 
conformational changes of the molecule and binding of the 
protease. The inhibited enzyme i"s irreversibly bound because 
the protease cleaves a peptide bond of the bait region. This 
results in conformational change of the inhibitor which is 
thought to wrap around the protease and to inhibit it by steric 
hindrance. In ·this complex, the active site of the protease is 
blocked to large substrates but remains accessible to small 
substrates (Barrett and Starkey, 1973). c) The receptor 
recognition region which is the region of ~2M revealed after 
conformational change of the molecule. Complex formation 
signals the start of degradation and the complex is absorbed 
into the reticuloendothelial system by receptor mediated 
endocytosis and destroyed (Van· Leuven, 1982; Travis and 
Salvesan, 1983. 
The second group of inhibitors contains those with class-
specific reactive sites. These are the specific inhibitors of 
the aspartic, cysteine, metallo and serine proteases (Travis 
and Salvesen, 1983). The protein inhibitors directed against 
serine proteinases are not all homologous and can be grouped 
into at least 11 different families based on sequence 
similarity, topological similarity, and mechanism of binding 
(Bode and Huber, 1992) and are listed below. 
1. Bovine pancreatic trypsin inhibitor (BPTI) (Kunitz). 
2. Kazal. 
3. Soybean trypsin inhibitor (STI-Kunitz). 
4. Streptomyces subtilisin inhibitor (SSI). 
5. Potato inhibitor 1 (PI-1) family. 
6. Potato inhibitor 2 (PI-2). 
7. Chelonianin. 
8. Bowman-Birk. 
9. Squash seed inhibitors. 
1 0 . Serpins :·. 
11. Hirudin 
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Of these, the serpins and the STI-Kunitz family are of special 
significance to this work as the physiological plasminogen 
activator inhibitors (PAis) are members of the serpin family 
while ETI and soybean trypsin inhibitor ( STI, which will be 
discussed later) are members of STI-Kuni tz family. Most of 
these serine-protease-directed inhibitors react competitively 
with their cognate enzymes according to a common, substrate-
like standard mechanism (Laskowski and Kato, 1980). This group 
of 'canonical' inhibitors (to .which ETI and STI belong) 
comprises relatively small proteins (or protein domains of 
multiheaded inhibitors) of between 29 and ± 190 amino acid 
residues. They all posses an exposed binding loop of 
characteristic conformation, but are otherwise unrelated in 
structure (Bode and Huber, 1992). In all cases the inhibitors 
(or their individual domains) have a compact shape and contain 
a hydrophobic core which in some cases consists mostly of the 
cross-connecting disulphide bridges. The core inhibitor forms a 
scaffold on which the exposed protease binding loop is held. 
Interactions between the loop and individual elements of the 
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core give additional stability to the loop which has a flat 
shape that fits into the active-site cleft of its cognate 
serine proteases. The reactive site loop is relatively flexible 
compared to the core of the inhibitor and acts as if hinged to 
this core. This was observed by superposing the structures of 
certain inhibitors in their free state and when complexed with 
a cognate enzyme. In doing so the major differences were found 
in the active site loop whereas the core of the molecule was 
seen to be structurally highly co~served (Onesti et al., 1991). 
Regions of the domain are a1s9 involved in bringing the 
inhibitor and protease together to allow for inhibition and 
stabilizing this interaction. Inhibition, in this group of 
inhibitors is achieved by competitively blocking the enzyme's 
active site to its substrate and all enzymatic activity of the 
protease is prevented. Under appropriate conditions of time, pH 
and relative concentrations of inhibitor and enzyme, the 
inhibitor is cleaved at a single scissile bond that is situated 
at the reactive site and is positioned over the catalytic site 
of the enzyme in a stable enzyme:inhibitor complex. By 
convention, the residue on the amino-terminal side of the 
scissile bond is referred to a·s P1 while that on the carboxy 
terminal side as P'l. Trypsin inhibitors have Arg or Lys as the 
Pl residue; Ala, Leu, Ile and Ser have been found at the P'l 
position (Tschesche et al., 1976). X-ray analyses reveal that 
the geometry of the reactive sites of certain inhibitors is 
such that they should act as good substrates. Indeed some 
inhibitors are hydrolyzed by their cognate proteases while 
blocking access of their active sites to substrates. At neutral 
pH and typical enzyme: inhibitor concentrations, because kcat 
and km for the process of inhibition are very much smaller than 
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for normal reactions, hydrolysis of the bond is extremely slow 
(Laskowski and Kato, 1980). In the case of those inhibitors 
obeying the standard mechanism, hydrolysis of the reactive sLte 
peptide bond does not proceed to completion and an equilibrium 
is established between the form of the inhibitor with peptide 
bond intact (virgin inhibitor) and the form with peptide bond 
cleaved(modified inhibitor). The following simplified kinetic 
scheme summarizes the reaction: 
E + I <-> EI <-> C <-> EI* <-> E + I* 
Where E = protease. 
I and I* = virgin and modified inhibitor respectively. 
C = stable complex. 
The stable complex C is formed from either virgin or modified 
inhibitor, both of which are thermodynamically strong 
inhibitors however the apparent rate of association of modified 
inhibitor with enzyme is generally slower than the 
corresponding rate for virgin inhibitor. X-ray analysis reveals 
that the reactive-site peptide bond · is intact within the 
complex, but that the carbonyl function is partially 
tetrahedral rather than trigonal, as it is in its uncomplexed 
state. The distortion of this bond is caused by attraction of 
the carbonyl oxygen to the oxyaniop binding pocket and is 
envisaged as one of the attractions that help stabilize the 
enzyme inhibitor complex. Other interactions including hydrogen 
bonds, Van der Waals forces, and possibly salt bridges, in the 
close contact area between the reactive site and the 
corresponding substrate-binding region of the protease all 
contribute to the characteristic stability of the complex 
(Travis and Salvesen, 1983). 
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The serpins are a superfamily of homologous 50-100 kDa 
glycoproteins which, like the canonical inhibitors, have a 
reactive centre located on an exposed loop, referred to as the 
strained loop, situated near the carboxy terminus of the 
molecule (Loeberman et al., 1984; Huber and Carrell, 1989). As 
with the canonical inh£bitors, they interact with their target 
proteases by providing a 'bait' residue (P1 residue) located on 
the strained loop that mimics the normal substrate of the 
target protease. In doing so they form 1:1 complexes with the 
target protease and as the intermediate acyl-enzyme complex is 
hydrolyzed only very slowly, the enzyme is in effect trapped in 
an inactive state (Cohen et al., 1977; Stephens et al., 1987; 
Bruch et al., 1988). Several factors contribute to the protease 
specificity of serpins: 1) the amino acid sequence, especially 
residue P1, around the reactive site which is highly variable 
between serpins and is postulated to have undergone much more 
rapid evolutionary variation than the remainder of the 
molecule. 2) specific domains in the serpins involved in 
specialized functions such as a site in cx2-antiplasmin which 
binds to a lysine-binding site in kringle 1 and/or kringle 4 of 
plasmin. The initial docking is_the rate limiting step and thus 
of major importance for the rapid reaction between the active 
site of plasmin and the reactive site of cx2-antiplasmin. 3) The 
absence or presence of small highly charged non-protein 
molecules which interact with the inhibitor at a site remote 
from the active site and are referred to by Chmielewska et al. 
(1988) as second site interactions. These interactions have the 
effect of increasing the stability of the complex formed 
between the inhibitor and the protease, for example, heparin 
interacts with antithrombin III and increases its association 
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rate constant by about 1000 fold (Jordan et al., 1979). The 
serpin family contains most of the plasma protease inhibitors, 
some examples of which are: 1) Alpha-1-protease inhibitor, a 53 
kDa protein which inhibits inter alia plasmin, uPA and tPA. It 
has the physiological role of controlling elastolytic activity 
secreted by neutrophils (Murano et al., 1980; Rijken et al., 
1983). 2) Antithrombin III, a 58 kDa protein that inhibits 
inter alia plasmin, trypsin, chymotrypsin and uPA. 3) Alpha-2-
antiplasmin (oc2AP), is a 65-70 kDa glycoprotein that is an 
extremely efficient, fast-reacting inhibitor of plasmin and the 
primary inhibitor of plasmin in :circulation. However several 
reports indicate that it can also inactivate trypsin, plasma 
kallikrein, chymotrypsin, thrombin, Factor Xa and Factor XIa. 
The inhibition of all of these enzymes, with the exception of 
trypsin is very slow and it is unlikely that oc2AP plays any 
role in controlling these activities (Lucas et al., 1983). 4) 
Inter-alpha-trypsin-inhibitor, a 180 kDa glycoprotein that 
inhibits trypsin, chymotrypsin and plasmin. 5) Protease nexin 
(PN) is a glycoprotein of 47 kDa. Besides uPA and two chain tPA 
it inhibits thrombin rapidly and also trypsin, plasmin and 
factor Xa. The wide inhibitory spectrum of PN and the'different 
functions attributed to PN sugges·:t that the function of PN is 
probably not inhibition of PAs, but rather the general control 
of local serine protease activity (Scott and Baker, 1983; Scott 
et al., 1985). Some important specific physiological inhibitors 
of plasminogen activators are also members of the serpin 
family. 
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1.3.1 Plasminogen activator inhibitors 
Several cell types grown in vitro secrete proteins which are 
capable of directly and specifically inhibiting the plasminogen 
activation reaction. Three proteins have thus far been 
identified that efficiently react with tPA and uPA: PA 
inhibitor 1 (PAI-l), PA inhibitor 2 (PAI-2) and PA inhibitor 3 
(PAI-3) (Kruithof, 1988). The indication is that all three PAis 
each react equally well with single chain and two chain forms 
of tPA and the same is true of uP A ( Chmielewska et al. , 
1980).PAI-l was first identified in conditioned media of human 
endothelial cells and rat hepatoma cells. It is found in a wide 
variety of other sources such as plasma, platelets, placenta 
and conditioned media of fibrosarcoma cells and hepatocytes. 
PAI-l levels are regulated by glucocorticoids, endotoxin, 
interleukin-1, transforming growth factor f3, tumor necrosis 
factor and thrombin. The inhibitor has been purified from 
endothelial cells, hepatoma cells, fibrosarcoma cells, smooth 
muscle cells and melanoma cells. It was found to be a 52 kDa 
glycoprotein that is responsible for 60% of PA inhibitory 
activity (Sprengers and Kluft, 1987). In accordance with the 
Arg specifity of tPA and uPA all PAis have an Arg at the active 
site and tPA in particular has been shown to cleave PAI-l at 
the scissile bond Arg346-Met347 (Lindall et al., 1990). In the 
PAI-1-tPA inhibition complex, residues 296-302 and 304 of tPA 
which are located on the lip of the active site cleft and are 
not involved in catalyltic functions are also involved in 
stabilization of the intermediate complex (Madison et al. , 
1989; Monge et al., 1991). The complex can be further 
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increase the inhibition 
increases it sixfold 
(Chmielewska et al., 1988; Edelberg et al., 1991). Furthermore, 
the work of Erlich et al. (1990) has shown that vitronectin can 
dramatically enhance the reactivity of PAI-l towards thrombin 
without decreasing its capacity to inhibit PA. They propose, as 
a result, that PAI-l is a versatile inhibitor which in the 
presence of vitronectin can modulate both coagulation and 
fibrinolysis. 
PAI-2 is found in human placenta where it is localized in the 
trophoblastic epithelium, pregnancy plasma and is secreted by 
leukocytes, leukocyte-derived cell lines and fibrosarcoma 
cells. Its biosynthesis and secretion is regulated by endotoxin 
and by phorbol ester, the latter stimulates PAI-2 gene 
transcription over fiftyfold. PAI-2 was purified from placenta, 
leukocytes and phorbol ester stimulated U-937 cells. It exists 
in two different forms, a 47 kDanonglycosylatedform and a 60 
kDa glycosylated form, with similar PA inhibition 
characteristics. The reaction rate of PAI-2 with uPA is at 
least one order of magnitude slower than that of PAI-l 
(Sprengers and Kluft, 1987). PAI-l and PAI-2 share only about 
25% homology with each other at the active site whereas PAI-l 
and PAI-2 both share some 33% and 38% homology with other 
serpins. Furthermore, a complete comparison of the primary 
structure of PAI-l and PAI-2 failed to show other regions of 
homology significantly greater than those with other serpins. 
It thus appears that PAI-l and PAI-2 are two evolutionary very 
distant serpins that somehow acquired the same enzyme 
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specificity (Lawrence et al. 1 1990). They constructed three 
chimeric ~utants of PAI-l where the strained loop was replaced 
with the similar region from PAI-2 1 antithrombin III or with an 
artificial serine protease inhibitor superfamily consensus 
strained loop. Their results suggested that structures outside 
of the strained loop are responsible for the major differences 
in specificity between PAI-l and PAI-2. 
PAI-3 is a 51 kDa protein purified from urine which has been 
shown to react slowly with the two chain forms of u-PA and t-PA 
and with thrombin (Sprengers and Kluft, 1987). 
1.3.2 Exythrina trypsin inhibitor 
The trees and shrubs of the genus Erythrina which belongs to 
the Leguminosae family 1 are distributed throughout, tropical to 
warm regions of the world (Raven, 1974). As is the case with 
other legumes, it was established that seeds from the Southern 
African species of Erythrina, viz. E.acanthrocarpa, E.caffra, 
E.decora 1 E.latissima, E.lysistemon and E.zeyheri contain large 
concentrations of trypsin and chymotrypsin inhibitors (Joubert 
et al., 1981). A number of· these were purified by gel 
filtration on Sephadex G-50 followed by ion-exchange 
chromatography with DEAE-cellulose and DEAE-sepharose and 
numbered according to the fraction in which they were located 
(Joubert, 1982). The Erythrina protease inhibitors were found 
to resemble other inhibitors of the STI Kunitz family of serine 
protease inhibitors. They have molecular weights of 
approximately 20 kDa and contain about 170 amino acids that 
include four half cysteine residues. The inhibitors can be 
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allocated to three groups on the basis of their relative 
abilities to inhibit chymotrypsin, trypsin and tPA. Group a 
inhibitors were relatively specific for chymotrypsin (which 
they inhibited strongly) but were relatively poor inhibitors of 
trypsin and had no apparent effect on tPA. Proteins in this 
group had blocked amino-termini . Group b proteins inhibited 
trypsin strongly and chymotrypsin less effectively. They had no 
effect upon tPA. None of the proteins of this group had free 
amino-terminal amino acids. Group c comprised proteins that 
were potent inhibitors of trypsin, a-chymotrypsin and tPA. All 
of the proteins in this group have the same free amino-terminal 
amino acid (valine) and all inhibit tPA strongly (Heussen et 
al., 1987). This genus is unusual in that other plant-derived 
Kunitz-type inhibitors that have been tested have no effect on 
plasminogen activators (Zimmerman et al., 1978; Dano and Reich, 
1979). One of the group c inhibitors, isolated ,in the DE-3 
fraction of E.latissima was examined further and was found to 
have the selective ability to inhibit tPA without affecting the 
action of uPA. (Heussen et al., 1984). When coupled to agarose 
it was used to purify both one- and two-chain forms of tPA. 
Another group c inhibitor from. the DE-3 fraction of E. caffra 
called Erythrina trypsin inhibitor (ETI) was found to have the 
same selective properties but a higher specific tPA inhibitory 
activity (Joubert et al., 1987). This is remarkable as the 
primary structures of these two inhibitors are identical except 
for a difference of four amino acids at positions 65, 72, 123 
and 160. Both are proteins of 172 amino acids (about 20 kDa) 
with four half-cysteine residues and a scissile bond at Arg63-
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Figure 1.1 Comparison of the amino acid sequence of Kunitz-
type trypsin inhibitors from three seeds :a) E.caffra (ETI), b) 
winged beans (WTI) and c) soybeans (STI). * =·trypsin reactive 
site. Circles in boxed regions indicate invariant amino acids. 
From Joubert and Dowdle (1987). 
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trypsin inhibitor (WTI) as shown in Figure 1.1. However, STI 
and WTI are inactive against t-PA (Joubert and Dowdle, 1987). 
It is argued by Joubert and Dowdle ( 1987) ·that the change at 
position 72 from an acidic Glu residue in E.latissima 
trypsin/t-PA inhibitor to a basic Lys residue in ETI may be 
responsible for the difference in t-PA- affinity between the 
two molecules. WTI has a very hydrophobic Leu residue at the 
corresponding position and has no t-PA inhibitory activity, 
they suggest that hydrophilicity in this region may be required 
for inhibition. 
The position of the scissile bond was determined by treatment 
of ETI with catalytic amounts of trypsin at pH 3. 5. This 
resulted in cleavage of the inhibitor into two fragments of 
molecular weights 12.4 kDa and 7. 5 kDa. The cleaved peptide 
bond was resynthesized by incubation of the purified trypsin-
cleaved products with trypsin at pH 8. ETI was not cleaved by 
tPA under the same conditions that led to its being cleaved by 
trypsin. In addition, tPA was· not able to resynthesize the 
cleaved peptide bond of trypsin-cleaved ETI products. This 
indicated that the interaction of ETI with trypsin is 
kinetically different from its mode of interaction with tPA 
( Schemmer-Heussen and Dowdle, in press) . The cleavage of ETI 
resulted in an apparent decrease in hydrophobicity of the 
molecule and this was used to separate modified from unmodified 
ETI by chromatography on phenyl-sepharose after trypsin and 
trypsin-inhibitor complexes had been removed from the reaction 
mixture by ion exchange chromatography on DEAE-cellulose. 
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The specific inhibitory activity of ETI for both trypsin and 
tPA was however reduced when the inhibitor was cleaved at the 
reactive site. On average 5. 8 times more cleaved than native 
inhibitor was needed to inhibit 50% of the trypsin activity in 
this assay. In the case of tPA 9.8 times more cleaved inhibitor 
was required. When the Arg residue at P1 had been removed by 
treatment of cleaved ETI with carboxypeptidase B, the specific 
inhibitory activity towards tryp~in was reduced 146-fold and 
that towards tPA 243-fold. Thus the integrity of the ETI 
reactive site Arg6 3 is important for activity against both 
trypsin and tPA (Heussen-Schemmer et al., 1991). 
To confirm this observation, Heussen-Schemmer et al. ( 1991), 
converted the reactive site Arg of ETI to citrulline by 
peptidyl arginine deiminase. ETI and STI are very similar in 
their primary structure as can be seen in Figure 1.1. It was 
shown by Takahara et al. (1985) that treatment of STI with 
peptidyl arginine deiminase specifically modified the inhibitor 
at its reactive site Arg preven:ting its ability to inhibit 
trypsin. ETI modified in this manner had its ability to inhibit 
trypsin or tPA reduced to undetectable levels in the 
chromogenic assay. 
X-ray crystallographic data on complexes between STI and 
trypsin (Sweet et al., 1974) and between pancreatic trypsin 
inhibitor and trypsin ( Ruhlmann et al. , 19 7 3; Huber et; al. , 
1974) have shown that in addition to points of contact at the 
active site there is contact between enzyme and inhibitor at a 
30 
small number of residues in both molecules. This was also seen 
to be the case with interaction between· PAI-l and tPA as 
discussed previously. Secondary contact sites are probably also 
important in the interaction between tPA and ETI, since tPA 
which has been inactivated at its active site serine residue 
with diiso-propyl-fluorophosphate will still bind to 
immobilized ETI ( Schemmer-Heussen and Dowdle, in press) . ETI 
has been crystallized and its. structure solved and will be 
discussed in more detail later. This has shown that ETI, like 
STI, has an external loop structure that contains the reactive 
site, Arg63-Ser64 through which ETI interacts with both trypsin 
and tPA. The external loop structure is typical of the 
canonical group of serine proteinase inhibitors which was shown 
(as discussed earlier) to be stabilized by the rest of the 
molecule (the core molecule). 
To examine the ability of the active site loop region of ETI to 
function as an 
hexadecapeptide 
inhibitor of trypsin and tPA a synthetic 
. * 
Glu-Ser-Arg-L~u-Arg -Ser-Thr-Phe-Ile-Pro-Asp-
Asp-Asp-Lys-Val-Arg which includes the trypsin reactive site 
* (Arg -Ser) of ETI was produced and tested for its inhibitory 
activity. On a molar basis, approximately ten thousand times 
more peptide than native ETI was required to achieve the same 
degree of inhibition of trypsin. No inhibition of tPA by the 
linear peptide was observed (Heussen-Schemmer et al., 1991). 
These results illustrate the need for contact regions in the 
inhibitor other than those surrounding the Pl residue and for 
the overall tertiary structure of ETI to confer a sui table 
conformation on the reactive site loop. 
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The salient features of ETI are: 
1) It is an inhibitor of trypsin, chymotrypsin and tPA. 
2) The active site residue is Arg63 and the scissile bond is 
between Arg63-Ser64. 
3) The active site is on an external loop that relies on 
structure that is imparted and stabilized by the rest of 
the molecule, for its ability to inhibit the activity of 
trypsin and tPA. 
The three dimensional structure of ETI was determined to 2.5 A 
resolution by the ·isomorphous replacement method ( Onesti et 
al., 1991). It is composed largely of twelve ~-strands joined 
by long loops. Six of these form an antiparallel, roughly cone 
shaped barrel. The wider end is capped by the remaining 
antiparallel ~-strands arranged in pairs and joined to the 
barrel by six loops extending outside and perpendicular to the 
axis of the barrel. This gives the molecule a roughly spherical 
shape with diameter of ±40 A (44 ~ 40 x 40 A). The structure is 
stabilized by two disulphide bri~ges: Cys39-Cys83 and Cys132-
Cys139, which are well removed from Arg63 and do not contribute 
to its stability. The active site loop, the N-terminal loop 
and a short segment bearing the C-terminus protrude from the 
bottom of the barrel. ETI shows approximate 3-fold symmetry 
about the axis of the barrel, the repeating unit consisting of 
four sequential ~-strands and the connecting loops. The 
structure is shown in Figure 1.2. 
The structure of the active-site loop (residue 61 to 67) is 
stabilized by hydrogen bonds and not by secondary structure 
Figure 1.2 
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A stereo-ribbon drawing of ETI showing the 
twelve 13-strands and their interconnecting 
loops. The top righthand six of these are 
arranged in antiparallel pairs into the form of 
a roughly cone shaped barrel. The axis of the 
barrel lies in a north-easterly direction in 
this figure from Bode and Huber (1992). At the 
bottom lefthand of the figure, the six 13-strands 
are arranged antiparallel in pairs and close off 
the wider end of the barrel. At the uppermost 
righthand of the figure, the active site loop, 
the N-terminal finger and the C-terminus can be 
seen to project from the narrow end of the 
barrel and lie in close proximity to each other. 
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elements such as disulphide bridges that could limit its 
conformational freedom as is usual with other peptide protease 
inhibitors. Hydrogen bonds of particular importance are from 
two residues within the loop, Leu62 (oxygen atom) and Ser60 
(hydroxyl group and nitrogen atom), to the side chain amide 
group of Asnl2. In addition, the residues 65 to 67 of the 
active site loop are involved in hydrogen bonding with residues 
1 to 4 and 8 to 12. The three segments form the sides of a 
triangle which is stabilized by . a molecule of water at its 
centre and antiparallel ~-type hydrogen bonds at the angles. In 
addition to stabilizing the active site loop these interactions 
give structure and stability to a finger-like region that 
contains the N-terminal Val of ETI and involves residues 1 
through 12. The interactions stabilizing the N-terminal finger 
have been modelled by Onesti et al. (1991) and depicted in the 
form of a schematic diagram shown in Figure 1. 3. This same 
region was modelled by computer (Maeder, 1989 unpublished) and 
shown in Figure 1.4 as the carbon backbone and molecular 
surface of the region in relation to the reactive site loop. 
There are a number of hydrophobic residues, viz. Vall, Leu2, 
Leu3, Val9, VallO, Ala65, Phe66, Pro67, Ile68, involved in the 
N-terminal region and it appears from the structures shown in 
Figures 1.3 and 1.4, that hydrophobic interactions add to the 
stability of this N-terminal structure. Through these 
interactions, the N-terminal finger of ETI is fixed to the 
reactive site loop and rendered immobile relative to the loop. 
As a result, in ETI-protease complexes, the N-terminal finger 
is positioned close to the protease. 
Figure 1.3 
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Schematic diagram of the amino-terminal finger 
region of ETI from Onesti et al. (1991). 
Interactions between residues 65 to 67 of the 
reactive loop interact with residues 1 to 4 and 
8 to 12 in a triangular formation with a water 
molecule to produce and stabilize this amino 
terminal finger-like region of the molecule. 
Figure 1.4 
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Computer model of the N-terminal region of ETI 
in relation to the reactive site loop (Maeder, 
1989 unpublished). The backbone of ETI in this 
region and the molecular surface is shown. 
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It was shown in Figure 1.1. that there is good homology between 
ETI and STI ·and between ETI and WTI. The homology between ETI 
(a 172 amino acid protein) and WTI (171 amino acids) is greater 
at 113 homologous amino acids, than that between ETI and STI 
(181 amino acids) where there are 75 homologies. In addition, 
STI is similar to ETI also from the point of view that STI can 
be reversibly hydrolyzed at its scissile bond Arg63-Ile64. 
Nonetheless, while they inhibit trypsin, both STI and WTI do 
not inhibit tPA. Thus it was considered that comparison of the 
three-dimensional structures •of ·these three molecules would 
help to understand the unique ability of ETI to inhibit tPA. 
However, the crystal structure for WTI has not as yet been 
determined. 
The structure of the complex between STI and porcine trypsin 
has been determined at 2. 6 A resolution (Sweet et al., 1974; / 
Blow et al., 1974). The resulting electron de·nsity maps of some 
parts of the inhibitor were not clear and a precise 
interpretation could be made ot" the residues 1-93 of STI. 
Another short stretch of density which appeared clearly on the 
map was tentatively assigned to residues 116 to 122. For the 
segments 94 to 115 and 123 to 176, only a Co: tracing was 
available. Despite these difficulties, a model for STI was 
derived with a certain amount of confidence. This structure 
shows an unusual symmetrical three-lobed fold consisting of a 
/3-sheet barrel of six antiparallel strands interconnected by 
irregular loops (McLachlan, 1979). This gives an overall 
spherical structure to STI with diameter of ± 35 A. Two 
disulphide bridges are found, both of which are on the surface 
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of the molecule. Cys39-Cys86 is found on the bottom half, the 
half that contains the carboxy terminal section of the 
molecule. Cys138-Cys145 is on the top half of STI along with 
its amino terminal section. The region that interacts with 
trypsin is found on a curved loop of residues 61 to 66 which 
protrudes from the core of the inhibitor and contains the 
active site Arg63 and scissile bond Arg63-Ile64. In addition, 
the carbonyl group of Asp1 of STI forms an ion pair with the e-
amino group of Lys60 of trypsin: This is the only ion pair 
interaction between STI and trypsin outside the primary binding 
site. The STI structure that was modelled by Sweet et al., 
(1974) from, inter alia, the data discussed above is shown in 
Figure 1.5. 
STI has a topology very similar to that of ETiconferred by the 
degree of amino acid homology between the two inhibitors. 
Eighty three c~ positions were superposed in the two structures 
with an r.m.s. deviation of 1.34 A as shown in Figure 1.6a 
(Onesti et al., 1991). The superposition of the two models 
shows that qualitatively the ~-strands are similar while some 
of the loops are not. In particular, the loop between residues 
61 and 67 (the reactive site loop), is shifted such that the 
reactive site of ETI is displaced by ± 4 A with respect to the 
reactive site loop of STI. The differences in conformation do 
not disappear even if a more local superposition of atoms is 
performed, overlapping residues 60 to 65 gives an r.m.s. 
difference of 0. 64 A. This is shown in Figure 1. 6b. As a 




The three-dimensional structure of STI as 
determined from the crystal structure of the 
complex with trypsin and the amino acid 
sequence. The residues 107-115, 123-129 and 177-
181 of STI could not be found, thus the 
assignment of residues 116-122 was tentative. 
The two disulphide bridges are shown, the 
residues that make contact with the trypsin are 
blackened and the arrow indicates the scissile 
bond (taken from Sweet et al., 1974 and Blow et 





Stereoscopic superposition of the c~ backbone of 
ETI (thick line) and STI (thin line). From 
Onesti et al. (1991). 
ETI and STI have similar topology and 83 c~ 
positions can be superposed in the two 
structures. The axis of the barrel runs in a 
north-easterly direction as in Figure 1. 2 but 
here the reactive site loop (loop A4-B1 in this 
diagram) and N-terminal finger region (on loop 
A1) are at the bottom left corner of the 
diagram. From this diagram it can be seen that 
STI has an N-terminal region structured 
similarly to that in ETI. 
b)Examination of superposition of the reactive 
site loop regions of ETI and STI with scissile 
bond, Asn12 and N-terminus indicated. From this 
it can be seen that the active site of ETI in 
the crystal lattice is displaced relative to 
that of STI. In addition, the position of the N-
terminal residue of STI in relation to its 
reactive site loop is indicated. 
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large size and globular shape of ETI, when the loop is modelled 
such that the residues P4-P'3 of ETI overlap with the 
corresponding STI residues, the alignment of the two molecules 
has to be altered in relation to the STI: trypsin alignment. 
This gives rise to new potential interactions that are not 
present in the STI:trypsin complex. Onesti et al. (1991) argue 
that since ETI and STI show high sequence and structural 
homology and the strength of their interaction with trypsin is 
of the same order of magnitude, it seems unlikely that the 
region in each molecule in contact with trypsin is very 
different. Thus they suggest that the observed displacement may 
be as result of intermolecular contacts in the crystal lattice 
involving the reactive site loop and the loop 20 to 23 of a 
symmetry-related molecule. Within these regions the guanidinium 
group of Arg63 makes strong hydrogen bonds with the carbonyl of 
Pro20 on the adjacent molecule, while the hydrophobic segment 
of the Arg side chain is packed against the aromatic group of 
Trp23 (Onesti et al., 1991). Taking this into account, allowed 
the building of an ETI:trypsin complex that is very similar to 
the model built by Sweet et al. ( 1974) of the STI :trypsin 
complex. 
From Figure 1.6a it can be seen that the N-terminus of STI is 
arrangea into a finger-like structure similar to that of ETI. 
The STI model is not of sufficient quality to allow an analysis 
of secondary structure elements in terms of hydrogen bonds. 
However, Figure 1.6b indicates that the two N-terminal regions 
follow each other closely and that the N-terminus of STI 
appears to be a residue longer than that of ETI as expected 
from the alignment of homologous sequences of the two proteins 
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(Figure 1. 1) . Furthermore 1 where the sequence of the ETI and 
STI N-terminal finger regions are not homologous 1 there has 
been a conservation of the hydrophobic and hydrophilic residues 
as can be seen in Figure 1.1. This suggests that the structure 
of this finger-like region of STI is stabilized by hydrogen 
bonds and hydrophobic interactions as in ETI. 
It is reasoned that Asp! of STI is not included in the 
structure of the N-terminal finger because of the need of its 
hydrophilic side chain to remain outside of the area of 
hydrophobic interactions between Phe2 1 Phe66, Ile67 and perhaps 
Ala68. This leaves the carboxyl group of the Aspl side chain 
free to form an ion pair with Lys60 of trypsin. The proximity 
of the Asp1 side chain of STI to the side chain of the trypsin 
Lys 6 0 side chain when the two molecules interact is shown in 
Figures 1. 7 and 1. 8. Both figures, modelled from the X-ray 
crystallographic coordinates of Sweet et al. (1974) 1 show the 
the active site cleft of trypsin in relation to the reactive 
site loop and N-terminal region of STI when the two molecules 
interact. 
Vall of ETI has neither the proximity nor the side chain groups 
needed to form an ion pair interaction with Lys60 of ETI. The 
proximity of these groups is indicated in Figure 1.9 in which 
ETI was modelled on the c~ skeleton of STI. The fact that the 
strength of inhibition of trypsin by STI and ETI is of the same 
order of magnitude indicates that ETI does not require the ion 
pair interaction in this region to inhibit trypsin. But in the 
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Model based on the crystallographic data of 
Sweet et al. (1974) of the area of interaction 
between STI and trypsin (Maeder, 1989 
unpublished) . Emphasizes the proximity of the 
side chains of Asp1 of STI and Lys60 of trypsin 
when the reactive site loop of STI is positioned 
over the corresponding residues of trypsin. 
Figure 1.8 
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Model of the same region as shown in Figure 1.7 
viewed from a different angle. From this view it 
appears that the aromatic ring of Phe2 of STI 
interacts with Lys60 of trypsin which is not the 
case as can be seen in Figure 1.7. Here the N-
terminal finger of STI is indicated with a white 
arrow and the reactive site loop (indistinct in 
this photo.) by a red arrow. 
Figure 1.9 
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Model of the reactive site and N-terminal finger 
region of ETI modelled on the c~ backbone of STI 
is shown bound to the active site of trypsin. 
The N-terminal Val of ETI, numbered Val2 by STI 
numbering is shown with a yellow arrow and the 
reactive site of ETI by an orange arrow (Maeder, 
1989 unpublished). 
45 
itself and trypsin is essential to the stability of the 
inhibition complex. 
However, it has been hypothesized, on the basis of computer 
aided molecular modelling studies, that the N-terminal Asp of 
STI is the key to the inability of this protein to inhibit tPA 
(Maeder, unpublished) . While there is currently no crystal 
structure available for tPA, its C-terminal domain (residues 
260 to 527) is homologous with a number of serine proteinases 
of known structure ( Onesti et; a-!-. , 19 91) . Alignments of the 
amino acid sequence of the C-ten:ninal domain of tPA with the 
sequences ot trypsin and chymotrypsin suggests that there are a 
number of insertions in tPA not seen in either trypsin or 
chymotrypsin. Based on the work of Bode et; al. ( 19 89) on 
thrombin, these insertions are likely to beaccommodated in the 
form of protrusions. As discussed earlier, the B-chain of human 
~-thrombin is homologous to ch¥motrypsin and trypsin. Thrombin 
cleaves similarly to trypsin, carboxy terminal to basic amino 
acid residues, but thrombin is much more specific and cleaves 
fewer bonds in macromolecular substrates. Comparison of the 
crystallographic structures of trypsin, chymotrypsin and 
thrombin has shown that the specificity properties of thrombin 
towards macromolecular substrates are mainly determined by its 
insertions. Some of these result in a narrower and deeper 
active site cleft in thrombin in comparison with that of 
chymotrypsin and trypsin, while others prevent inhibition of it 
by protease inhibitors that inhibit trypsin and/or chymotrypsin 
(Bode et; al., 1989). Thus the insertion of five amino acids 
between positions 62 and 63 (trypsin numbering) is thought to 
be accomodated by a protrusion in this area. Part of the 
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aligned sequences of trypsin and tPA, including the region in 
question, is shown in Figure 1.10. It is hypothesized that the 
presence of this protrusion, not seen in trypsin, clashes with 
Asp1 of STI preventing it sterically from approaching close 
enough to tPA to form an STI:tPA inhibitory complex. _As ETI has 
one less residue in its N-terminal finger region than STI, it 
is able to approach close enough to complex with tPA. Models of 
the interaction of STI and ETI with tPA (modelled on 
chymotrypsin structure) to illustrate the concepts described 
above are shown in Figures 1.11 and 1.12. 
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Partial alignment· of the amino acid sequences 
of: a) trypsin and b) tPA showing the region of 
interest around Lys60 the residue that is 
involved in ion pairing with STI. Five residues 
have been inserted in tPA between residues 63 
and 62 by trypsin numbering. 
1.4 Aims of this work 
The unique ability of ETI to inhibit tPA as well as trypsin and 
chymotrypsin as well, has endowed it with potential commercial 
value. In addition, the accumulated knowledge on ETI and its 
homology with other important protease inhibitors makes it a 
good candidate for further study. Questions on the nature of 
the interaction between inhibitor and protease can be addressed 
by making modifications to , the protein. The simplest, and ·in 
many cases the only way to achieve this is to make 
Figure 1.11 
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Model of the interaction of STI and tPA showing 
the reactive site loop (red arrow) and N-
terminal finger region of STI (white arrow), the 
active site cleft of tPA and the approach of 
Asp1 of STI to the insertion sequence of tPA 
which prevents the formation of the STI:tPA 
complex. Here STI is modelled on the coordinates 




Model of ETI: tPA complex showing proximity of 
Vall of ETI (white arrow) to the tPA surface 
when the reactive site loop of ETI is bound to 
the tPA active site (orange arrow). Again ETI 
was modelled on the STI backbone and tPA is 
modelled on chymotrypsin. 
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modifications to the gene that encodes the protein, and to 
measure the change in activity produced in the expressed 
protein. Gene expression technology has been well established 
in E.coli. However, plant gene codon preferences differ 
sufficiently from codon preferences of E.coli (Murray et al., 
1989) to make high levels of expression in E.coli, of a gene 
cloned from a plant, unpredictable. Thus the aims of this work 
were to design a gene encoding ETI that would allow for easy 
manipulation to produce modified forms of the protein. The 
unaltered gene was to be expressed in an appropriate E. coli 
expression system to produce ETI·with tPA specific inhibitory 
activity of the same order of ma9nitude as ETI isolated from 
E.caffra. Activity of modified forms of ETI could be compared 
with that determined for the unmodified protein. 
The synthetic ETI-encoding gene could then be altered to 
produce any number of modified forms of ETI as an aid to 
understanding its inhibitory activities and protease inhibtion 
in general. The question to be addressed in this work is the 
hypothesis that the N-terminal Asp of STI prevents it from 
inhibiting tPA. To this end an altered form of ETI would be 
produced in which the N-terminus . had been extended by an Asp 
residue. The prediction, based on.the model described above is 
that this form of ETI would have much reduced activity against 
tPA as compared with the unaltered protein from this gene. 
.. 
CHAPTER 2 
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The purpose of synthesizing an ETI-encoding gene was to produce 
the protein in abundance from a cloned gene and, most 
importantly, to have a useful gene to allow modifications of 
the protein as a method for studying interactions between ETI 
and its target enzymes. To this end it was necessary to have, 
at regular intervals in the gene, unique restriction sites for 
tailoring ETI to different studies. 
The first step in designing a gene is to translate the known 
amino acid sequence of the protein for which that gene codes 
into a DNA sequence using preferred codons for the chosen host. 
Prior to designing, a decision has to be made regarding the 
organism(s) that will be used for eventual expression, as this 
will influence the codon choice for each amino acid. Therefore, 
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it is important at the outset, to have some insight into the 
effect that codon choice can have on translation rate and 
accuracy as it may be necessary to use less favoured codons, in 
order to introduce restriction sites. Secondly, an expression 
vector should be chosen if this is to be different from the 
synthesis vector. This will influence the restriction sites 
required for excision of the gene from the synthesis vector and 
for insertion into the expression vector. 
The establishment of the genetic code has given rise to 61 
sense codons that code for 20 amino acids and 3 stop codons. 
The result is that most of the amino acids are coded for by 
more than one codon. Where more than one codon is used to code 
for an amino acid, these are called degenerate codons. When the 
frequency of use of these degenerate codons is examined, it is 
seen that different taxonomic groups favour certain codons for 
particular amino acids. In addition, it is reported that within 
species, individual genes tend to prefer characteristic codon 
distributions (Gouy and Gautier, 1982; Bennetzen and Hall, 
1982). 
Indeed, in unicellular organisms _there appears to be a direct 
relationship between the level of expression of a gene and its 
degree of codon bias (Grosjean and Fiers, 1982). In these 
organisms there is a group of genes coding for example, 
ribosomal proteins, the elongation factors and outer membrane 
proteins for which codon choice is strongly biased toward a 
subset of the available codons which are thus called the major 
codons (Shields and Sharp, 1987; Sharp et al., 1986). In this 
highly biased group there may be as much as a 100-fold 
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variation in the usage frequency for preferred as opposed to 
avoided or rare codons. It is observed that the higher the 
level of protein production the greater the tendency to use 
only major codons in the gene (Bennetzen and Hall, 1982; 
Grosjean and Fiers 1 1982). 
Studies of codon usage patterns in various species have been 
undertaken and the results expressed in tables from which the 
preferred codon for an amino acid in highly biased (or highly 
expressed) 1 as well as those for lowly biased genes 1 can be 
determined. A table of relative synonymous codon usage (RSCU) 
values was produced by Sharp et al. ( 1988) for inter alia 1 
E.coli and S. _cerevisiae. An RSCU value is_ obtained by dividing 
the number of codons observed by the number of codons expected 
if · all codons for that amino acid were· used equally. The 
observed codons for determining these RSCU values· were taken 
from the highest 10% and lowest 10% of 165 E.coli genes and 154 
S.cerevisiae genes. From these and similar tables, the 
preferred codon for an amino aciQ. that would be. utilized by. a 
highly expressed gene can be determined. A summary of these 
codons for E.coli and S.cerevisiae as used in the design of the 
ETI-encoding gene is presented in-Table 2.1, 
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Codons 
' Amino E.coli S.cerevisiae 
Acids High Low High Low Compromise 
Ala GCU GCG GCU GCA ---
Cys UGC UGC UGU UGU UGC 
Asp GAC GAU GAC GAU ---
Glu GAA GAA GAA GAA ---
Phe uuc uuu uuc uuu ---
Gly GGU . GGC GGU GGC ---
His CAC CAU CAC CAU ---
Ile AUC AUU AUC AUU ---
Lys AAA AAA AAG AAA AAA 
Leu CUG CUG UUG UUA CUG 
Met AUG AUG AUG .. AUG ---
Asn AAC AAU AAC AAU ---
Pro CCG CCG CCA CCA CCA 
Gln CAG CAG CAA CAA CAA 
Arg CGU CGC AGA AGA CGU 
Ser ucu AGC ucu ucu ---
Thr ACC ACC ACC ACA ---
Val GUU GUG GUU GUA ---
Trp U~G UGG UGG UGG ---
-
Tyr UAC UAU UAC UAU ---
Table 2.1 A summary of the preferred codons for highly 
expressed and lowly expressed genes in E.coli and 
S.cerevisiae and the compromise codons used in design of 
the ETI gene when differences exist in major codon 
preferences between the two species. 
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It has been postulated that the preferred codons reflect the 
optimization of codon: anticodon interaction energies (Grosjean 
and Fiers, 1982). However, examination of codon preference 
tables such as the RSCU tables of Sharp et al. ( 1988) shows 
that different organisms use different subsets of major codons. 
Andersson and Kurland (1990) argue further that every codon is 
used as a major codon by some system and as a minor codon by 
another. This, they feel, indicates strongly that the intrinsic 
nature of the codons cannot account for their preferred usage. 
There is evidence to suggest that translation rates can differ 
at different codons. For example, Sorensen et al. (1989) 
inserted a piece of a ribosomal gene into the lacz gene either 
directly or flanked by a few frame shifting bases, leaving the 
reading frame of the lacz gene/unchanged. This gave minor, 
codons in one reading frame and major codons in the other. The 
translation time for these modified lacz mRNAs was found to be 
faster by six-fold for major codons than for minor codons. In 
addition, Andersson and Kurland (1990) quote results of 
Sorensen and Pedersen (Abstr. 13th Int. Transfer RNA Meet. 
1989, abstr. no. mo-am-13). These workers measured the 
translation rates of strings of GAA and GAG, respectively the 
major and minor codons for Glu. Both are thought to be served 
by the same tRNA, tRNA2Glu, but the GAA string is translated 
about 3 times faster in vivo than the GAG string. Thus it can 
be concluded that the major codons are recognized and 
translated at higher rates than minor codons. 
Available data indicates that the relative amounts of the 
different tRNA species are not constant but vary in systematic 
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ways. For example, it was found that the concentration of the 
rna jor Leu isoacceptor CUG increases progressively at higher 
growth rates. Likewise, the level of a minor Leu species that 
can also translate the major Le~.- codon (tRNA3Leu, CUA, CUG) 
increases almost threefold while concentration of the remaining 
Leu species decreases as growth rate increases. In parallel to 
this, the heterogeneity of the protein population of a cell is 
also growth rate dependent. Under low growth conditions, the 
proteins produced by bacteria are fairly equally represented in 
their protein population. In contrast at highest growth rates, 
mRNA that codes for key growth components such as 
translational, transcriptional and membrane proteins (which are 
coded for by major codons), represents most of the mRNA 
species. From this it is clear that under good growth 
conditions the concentrations of the cognate tRNAs for the 
major codons increase. Conversely, their concentrations 
decrease as growth conditions detericrate. From this evidence 
the conclusion can be drawn that translation rates for most 
major codons of an organism are limited by the availability of 
their cognate tRNA species. Furthermore, it is suggested that 
the selective pressure for major codon preferences in primitive 
organisms such as E. coli and S. cerevisiae is a strategy to 
maximize their growth rates in relatively rich media (Pedersen, 
1984; Sorensen et al., 1989; Curran al!d Yarus, 1989; Andersson 
and Kurland, 1990). 
While it is important to utilize the major codons required by 
the expression organism, introduction of less preferred codons, 
where necessary, will not of necessity lower the expression 
level of the synthetic gene. In fact, high expression levels 
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are routinely achieved for genes with a relatively high content 
of less preferred codons. For example, the chloramphenicol 
acetyltransferase gene which has codon usage similar to that of 
poorly expressed ·genes in E. coli has been expressed to high 
/. 
levels when cloned under the control of a strong promoter 
(Robinson et al., 1984). The same phenomenon was reported 
(Kniskern et a1.,1986) for S.cerevisiae in which the hepatitis 
B virus core antigen was expressed to high levels even though 
it has a high level of less preferred codons for this organism. 
It may seem that the above argument indicates that it is 
immaterial to ensure the incorporation into the. sequence of as 
many major codons as possible in order to achieve high 
expression of a synthetic gene. However, it would seem prudent 
to utilize every strategy possible to ensure good expression of 
the planned gene before the investment of the resources 
required to synthesize a gene. In support of this, there are 
examples where judicious use of major codons in a synthetic 
gene has led to increased expression over that of cloned genes 
that have poor representation of highly utilized codons for 
that organism. For example, Williams et al. (1988) synthesized 
the gene for human interleukin-2 (IL-2). Here the percentage of 
preferred codons for E.coli was increased from 43% as found in 
the native eDNA to 85% in the synthetic sequence. Both genes 
were placed under the control of the trc promoter and expressed 
in JM101, and it was shown that the synthetic gene was able to 
direct up to 16 times more IL-2 in E.coli than the native eDNA 
sequence even though both genes produce mRNA with similar half 
lives. 
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The presence of rare codons, or even short strings of such 
codons, in a gene is thought by some to constitute pause sites 
that transiently slow down the movement of ribosomes over mRNA 
and allow the proper folding of a protein domain. This could be 
of particular importance when the incomplete polypeptide can 
take up different secondary structur83. A pause site could 
allow one domain to form before the rest of the polypeptide is 
produced and interferes with folding of the first domain. In 
addition, where a protein has more than one disulphide bridge, 
a pause in synthesis at an appropriate position in the 
polypeptide chain may allow the correct sequence of -SH 
pairings to form (Purvis et al., 1987; Swafield et al., 1987). 
While ETI was known, from its similarities to STI, not to be a 
multi-domained protein it does require the two disulphide 
bridges Cys39-Cys83 and Cys132-Cys139 (Sweet et al., 1974; 
Onesti et al.,199l). In addition, the need for pause sites was 
not considered to be important in designing an ETI gene for 
expression in E.coli because heterologous proteins have rarely 
been recovered, in a native state from the cytoplasm of this 
organism, regardless of the inclusion of any required pause 
sites. The reason for this is that foreign proteins often are 
not able to attain their native conformation in the cytoplasm 
of E. coli, especially where the structure is stabilized by 
disulphide bridges (of which ETI ·flas two) as these apparently 
cannot form in the reducing conditions found in E.coli 
(Goeddel, 1990). In addition, accumulation of heterologous 
proteins in E.coli often causes precipitation of these proteins 
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which are sequestered into inclusion bodies. Stringent chemical 
conditions are then required to release the proteins from the 
inclusion bodies. Such treatment of inclusion bodies often 
results in denaturation of all the resident proteins and 
conditions have to be established which allow for refolding of 
the required protein (Marston, 1987). Where the protein has 
been exported from the cell to conditions which may be more 
conducive to disulphide bridging, pause sites are also of no 
value since the fol?ing takes place after complete translation 
of the protein. 
It is often not possible to avoid rare codons in the design of 
a gene because of the need to introduce unique restriction 
sites. Nonetheless, Robinson et al. (1984) advise avoidance of 
strings of codons which are rarely used in the expression 
organism. They have found that such a string can lead to 
unnecessary pausing of mRNA translation and even uncoupling of 
ribosomes, which can lower the expression level or even prevent 
it altogether. Moreover, at strings of rare codons, 
translational accuracy could be compromised (Dix and Thompson, 
19 8 9) . This guideline is very important in the design of a 
compromise sequence - one that can be utilized by more than one 
host, for example E.coli and S.cerevisiae, which is the 
strategy adopted by Adams et al. (1988) in their design of a 
gene for HIV transactivator protein. 
It is very important to appreciate that the rate of translation 
of an mRNA species will normally not affect the expression 
level of the corresponding protein unl0'3B the rnRNA species can 
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capture a major fraction of the ribosomes in the cell. This 
objective can be achieved by the mRNA becoming the dominant, or 
one of the dominant, mRNA species of the cell. Thus, in the 
design of a synthetic gene, it is important not only to use as 
many major codons of the intended expression organism as 
possible, but also to place the gene under control of strong 
regulatory elements ie. promoter and ribosome binding site. 
This will ensure high transcription level and allow it to 
become a dominant mRNA species of the cell. Nevertheless, all 
mRNA is inherently unstable and in bacteria the half lives for 
most messages are a small fraction of cell generation time. 
Blundell et al. (1972) have shown that. each E.coli mRNA species 
decays at a unique rate with half-lives ranging from 30 seconds 
to more than 8 minutes at 37°C. This is thought to be a 
strategy for rapid adaptation to changes in growth conditions 
(Kennell, 1986). Thus, even when-cor..ditions of major codon 
usage and strong regulatory elements are present, mRNA may not 
accumulate to high levels in the cell. 
As yet no unique recognition target for initiation of decay has 
been identified. The most likely primary target is thought to 
be any single stranded region of the mRNA or regions of weak 
secondary structure (Kenell, 1986). 
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2.2 Design of an ETI-encoding gene 
As has been discussed, the trypsin and plasminogen activator 
inhibitor from Erythrina caffr17- contains 172 amino acids 
(Joubert and Dowdle, 1987). Because of the predicted time and 
expense of synthesizing a gene for ETI and the uncertainty of 
being able to express a eukaryotic gene in E. coli, it was 
decided to design the gene so that it could be expressed by 
E.coli and if necessary by s.cerevisiae. 
These two organisms differ in major codon preference for only 6 
amino acids. Using the RSCU values of Sharp et al. ( 1988), 
which are summarized in Table 2 .1, codons for these 6 amino 
acids were chosen that would not be disfavoured by either 
organism. 
For 3 of these amino acids viz Cys, Lys and Leu the major'codon 
for E. coli was used as it could be utilized by S. cerevisiae. 
The rest were assigned codons that could be read by both 
organisms and the sequence was terminated with a TAA stop 
codon. 
The sequence was then scanned for restriction sites using the 
GCG program database of 181 restriction enzymes. These were 
compared with restriction sites for pUC9 (the intended vector 
for synthesis) to find those sites-unique to ETI ie sites that 
occur once in ETI and not in pUC9. The only such site found was 
Kpnl. 
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Consequently, the sequence was scanned for partial restriction 
sites using the GCG program which determines where in a 
sequence, changes in the wobble base of degenerate codons would 
introduce restriction sites and still code for the same amino 
acid. Where such sites would be useful and unique, the 
appropriate bases were changed so as to introduce the 
restriction site. This approach allowed the introduction of 15 
new restriction sites viz Xbai, Apai, Bani, Nhei, BspEI, Bglii, 







sites introduced are unique to 
site Hindi!! occurs in the pUC9 
mul ticloning site but was considered useful in the position 
into which it was introduced in ET:i:. In addition, BspEI which 
does not appear in pUC9 was introduced twice in ETI on either 
side of the trypsin/tPA reactive site loop (Joubert et al. , 
1987). This allows for removal of the reactive site region with 
a single digest making this a useful construct for future work 
aimed at investigation of the reactive site of ETI. The unique 
restriction sites are shown in Figure 2.2 while the changes to 
the major codon sequence that were required for these sites is 
shown in Figure 2.1 and its related notes. 
i. 2 3 20 
ii. H2N-Val Leu Leu Asp Gly Asn Gly Glu Val Val Gln Asn Gly Gly Thr Tyr Tyr Leu Leu Pro 
iii. --- CTG CTG GAC GGT AAC GGT GAA GTT GTT CAG AAC GGT GGT ACC TAC TAC CTG CTG CCG 
iv. GAA TTC ATG --T --A --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --A 
i. 24 25 31 
ii. Gln Val Trp Ala Gln Gly Gly Gly Val Gln Leu Ala Lys Thr Gly Glu Glu Thr Cys Pro Leu Thr 
iii.CAG GTT TGG GCT CAG GGT GGT GGT GTT CAG CTG GCT AAA ACC GGT GAA GAA ACC TGC CCA CTG ACC 
iv. --- --- --- --C --A --- --- --- --- --- --A --- --- --- --- --- --- --- --- --- --- ---
i. 45 47 55 - 57 63 
ii. Val Val Gln Ser Pro Asn Glu Leu Ser Asp Gly Lys Pro Ile Arg Ile Glu Ser Arg Leu Arg Ser 
iii.GTT GTT CAG TCT CCG AAC GAA CTG TCT GAC GGT AAA CCG ATC CGT ATC GAA TCT CGT CTG CGT TCT 
iv. --- --- --A --- --A --- --- --- --- --- --- --- --A--- --G --- --- --- --- --- AGA ---
i. 67 73 81 85 
ii. Ala Phe Ile Pro Asp Asp Asp Lys Val ArgIle Gly Phe Ala Tyr Ala Pro Lys Cys Ala Pro Ser 
iii.GCT TTC ATC CCG GAC GAC GAC AAA GTT CGT ATC GGT TTC GCT TAC GC1 CCG AAA TGC GCT CCG TCT 
iv. --- --- --T --- --- --- --- --- --A ·-- --- --- --- --- --- --- --A --- --- --- --A ---
i. 87 96 98 102 103 
ii. Pro Trp Trp Thr Val Val Glu Asp Glu Gln Glu Gly Leu Ser Val Lys Leu Ser Glu Asp Glu Ser 
iii.CCG TGG TGG ACC GTT GTT GAA GAC GAA CAG GAA GGT CTG TCT GTT AAA CTG TCT GAA GAC GAA TCT 
iv. --A --- --- --- --- --- --- --- --- --A --- --C --- --- --- --G --T --- --- --- --- ---
i. 110 114 119 122 123 130 
ii. Thr Gln Phe Asp Tyr Pro Phe Lys Phe Glu Gln Val Ser Asp Gln Leu His Ser Tyr Lys Leu Leu 
iii.ACC CAG TTC GAC TAC CCG TTC AAA TTC GAA CAG GTT TCT GAC CAG CTG CAC TCT TAC AAA CTG CTG 
iv. --- --A --- --- --- --A --- --- --- --- --A --- --- --T --A --- --- --- --- --- --- --T 
i. 137 138 140 141 
ii. Tyr Cys Glu Gly Lys His Glu Lys Cys Ala Ser Ile Gly Ile Asn Arg Asp Gln Lys Gly Tyr Arg 
iii TAC TGC GAA GGT AAA CAC GAA AAA TGC GCT TCT ATC GGT ATC AAC CG1 GAC CAG AAA GGT TAC CGT 
iv. --- --- --- --- --- --- --G --G --- --A --G --- --- ·--- --- --- --- --- --- ---
i. 161 162 167 168 170 171 
ii. Arg Leu Val Val Thr Glu Asp Tyr Pro Leu Thr Val Val Leu Lys Lys Asp Glu Ser Ser-OH 
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iii. CGT CTG GTT GTT ACC GAA GAC TAC CCG CTG ACC GTT GTT CTG AAA AAA GAC GAA TCT TCT TAA TGC AGG GAT CC 
iv. --- --- --- --- --- --- --- --- -- -T-A --- --- --- --- --G --G --- --G AGC --- --- --- --- --- --
Figure 2.1 Sequence of Erythrina trypsin inhibitor. 
i. Position of amino acid whose codon has been changed 
from preferred to less preferred for E. coli see 
notes below. 
ii. Shows published amino acid sequence for Erythrina 
trypsin inhibitor (ETI). 
iii. Translation of amino acid sequence into preferred 
codons for E.coli. 
i v. Base changes made to · the sequence in 111 above to 
introduce unique restriction sites or to accommodate 
expression by S.cerevisiae 
Notes to Figure 2.1 
1 Val changed to Met - see text. 
2 Leu from CTG to CTT and 
3 Leu to CTA to introduce Xbai site. 
20 Pro from CCG to compromise codon CCA for expression in 
S.cerevisiae as per text. 
24 Ala from GCT to GCC introduces Apai site. 
25 Gln CAG to compromise codon CAA. 
31 Leu to CTA gains Nhei site. 
45 Gln CAG to compromise CAA. 
47 Pro CCG to CCA compromise. · 
55 As above. 
57 Arg CGT to CGG to introduce BspEI site. 
63 Arg to AGA to gain Bglii site. 
67 Ile from ATC to ATT gives a second BspEI site. 
73 Val GTT to GTA introduces SnaBI. 
81 Pro compromise codon. 
85 As above. 
87 As above and introduces unique Nco! site. 
96 Gln compromise codon. 
98 Gly GGT to GGC to gain Stu! site. 
102 Lys AAA to AAG and 
103 Leu to CTT produces a Hindiii site in ETI. 
110 Gln CAA compromise. 
114 Pro CCA compromise. 
119 As for 110. 
122 Asp GAC to GAT to gain Bel! site. 
123 As for 110. 
130 Leu CTG to compromise CTT. , 
137 Glu GAA to GAG to break string of,A s. 
138 Lys AAA to AAG breaks string of A s. 
140 Ala GCT to GCA and 
141 Ser TCT to TCG makes Clai site. 
161 Pro proceeds rare codon for Leu at 162 thus E.coli 
preferred codon CCG used. 
162 Leu from CTG compromise to TTA gatns unique Hpal site. 
167 Lys AAA to AAG breaks string of As. 
168 As above 
170 Glu GAA to GAG and 
171 Ser TCT to AGC introduces Sac! site. 
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Figure 2.2. DNA sequence for synthetic ETI gene showing the 
restriction sites unique within the context of 
the synthesis vector pSyn.l. 
Numbered arrows indicate the division points for 
construction of olig~s for the synthesis of the 
entire gene. 
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There were some deviations from the intended strategy discussed 
above. The natural Val NH2 terminus of ETI was replaced with 
Met because E.coli requires an initiator codon to precede the 
gene coding sequence. In most E. coli genes sequenced ( 91%), 
this codon is AUG, the codon for Met. A further 8% utilize GUG, 
a minor codon for Val 1 while onl-y ·1% have been recorded that 
use UUG in this position (Stormo, 1986). An initiator AUG codon 
in E.coli elicits the insertion of a formyl methionine (f-Met) 
at this position. 
After translation, f-Met peptides are deformylated and the N-
terminal Met may be removed dependiny on the nature of the 
second amino acid. Ala, Ser, Gly, Pro, Thr or Val as second 
amino acid permit N-terminal Met to be removed, whereas Arg, 
Asn, Asp, Gln, Glu, Ile, Leu, Lys and Met do not (Tsunasawa et 
al., 1985). However, Marston (1986) has found that methionyl-
aminopeptidase, the N-terminal M~:t removal enzyme of E. coli, 
functions poorly with recombinant proteins regardless of .the 
amino acid following the N-terminal Met. 
Rather than rely on the N-terminal Met removal system of 
E.coli, it was decided to forfeit the Val and utilize a Met in 
this position. Met is a hydrophobic amino acid and should keep 
the N-terminal finger region of ETI intact and not interfere 
with the interaction of ETI with tPA and was considered an 
acceptable replacement for Val. Nonetheless, if necessary, the 
5' end of the gene can be altered to conform to other vectors 
or hosts by using the Xbai site th.p.t was placed near to the 5' 
end of the gene. 
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The two restriction sites EcoRI and BamHI were chosen to be the 
sites of excision of the synthetic gene as they are compatible 
for forced cloning into the expr~ssion vector of choice at this 
stage viz pBtacr from Boehringer Mannheim. Another set of 
changes made to the original sequencE') for ETI were n-tade to 
break up a string of 5 and 6 ade~9sines respectively. This was 
done to avoid misreadings during bridge mutagenesis (the 
technique that was to be used for the synthesis of this gene). 
The termination codon TAA was placed directly after the ~oding 
sequence. Termination of protein synthesis can be achieved with 
two other termination codons viz TGA or TAG, recognized by 
E.coli release factors RF2 and RF1 respectively, both of which 
are rare in the cell relative to charged tRNA species. TAA was 
used in the ETI-encoding gene as it· is recognized by both RF1 
and RF2 and thus is more efficient a t .. erminator than TGA or TAG 
(Maitra et al., 1982; Andersson and Kurland, 1990). These 
positions of change are shown in F.;_gure 2.1. 
/ 
The completed sequence was examined by .the Fold program of GCG 
which determines the most stable theoretical mRNA secondary 
structure. The constraints used were minimum stem of six base 
pairs and minimum loop size of th:ree bases. The resultant 
structure is shown in Fig 2.3. 
The structure presented in Fig 2.3 is one with extensive double 
stranded regions which produces a thermodynamically stable 
structure with a 6G of about -143 KCal/mol. Such a structure 





Most stable comput~r genarated theoretical mRNA 
secondary structure for ETI as produced by the 
Fold program of the GCG program portfolio. 
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From the point of view of accessibility of a compact mRNA to 
the ribosomes, the work of Sorensen et al. (1989) on the lacZ 
gene has shown that theoretically stable mRNA structures do not 
necessarily cause translation delays. However, this may not be 
the case with the mRNA produced by the ETI encoding gene 
designed for this work. If this turned out to be the case, the 
option of placing a leader sequence upstream of ~he ETI 
encoding mRNA to enhance its translational efficiency would be 
used. This approach has been used with success by a number of 
workers eg Schaner et al., (1984) and Sung et al., (1986). 
Thus, the theoretical mRNA structure produced by the synthetic 
ETI gene appears to be satisfactory and no consideration was 
given to changing bases in order to alter it. 
2.3 Alteration of pUC9 to produce the synthesis vector pSyn 
The gene was to be synthesized by the serial cloning of 
oligonucleotides as described by Hayden and Mandecki ( 1988). 
The method requires the use of a synthesis vector containing a 
unique Bsmi site. The restriction enzyme Bsmi cuts one strand 
of DNA within its recognition site and the other strand just 




5'--G A AT G C N--3' 
3'--C T T A C G N--5' 
A 
I 
inserted a Bsmi 
/ 
site into pUC9 by 
oligonucleotide-directed double-strand break-repair or bridge 
mutagenesis (Mandecki, 1986). This technique forms the basis of 
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the gene synthesis methodology of Hayden and Mandecki ( 1988) 
and makes use of alpha-complementation as an initial screen to 
. select for cells containing plasmid into which DNA had been 
correctly inserted. 
Alpha-complementation was described in 1967 by Ullman et al. 
They showed that deletion of the j' end of the lacz gene gives 
rise to an inactive N-terminal fragment of ~-galactosidase 
called the ex-fragment. This deleted form of the lacZ gene is 
referred to as the lacZ' or lacZcx gene and is incorporated in 
many plasmid vectors such as the pUC series of vectors. 
Conversely, deletions of the 5' end of the lacz gene expressed 
as ~ ( lac-proAB), gives rise to an inactive C-terminal of ~­
galactosidase called the w-fragment. This fragment is usually 
supplied by an F' plasmid resident in the host E.coli cell (eg. 
JMlOS) and is controlled by the lacZ promoter and its operator. 
In cells such as JM105 the F' plasmid also codes for Lac 
repressor which prevents expression of the lacZ w-fragment. 
Cells of JM105, that contain a vector such as pUC9, grown in 
the presence of isopropyl-~-D-thiogalactosidase ( IPTG) which 
derepresses the gene for the w-fragment, are able to synthesize 
this fragment. When the two fragments, ex-· and w- are present in 
a cell they complement, which can be detected by activity on 
the synthetic lactose analogue 5-brom'J-4-chloro-3-indolyl-13-D-
galactopyranoside (X-gal) which gives a blue reaction product 
(Ausubel et al., 1987). 
The E.coli strain JM83 [ara, ~(lac-proAB), rpsL(=strA), 
¢80, lacZ~M15], which was used . ~for synthesizing the ETI-
encoding gene, is also an w-fragment producing strain. However, 
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it does not produce Lac repressor and as a result w-fragment is 
produced continuously and pUC containing cells do not require 
derepression with IPTG to allow assembly of an active ~-
galactosidase complex (Viera and Messing, 1982). 
Rather than apply to the authors Hayden and Mandecki (1988) for 
their synthesis plasmid, a similar-plasmid was produced as part 
I 
of this work. T,his exercise was used to gain experience in 
double-strand break-repair and to gauge the efficacy of the 
procedure. 
To this end a 37 base (37-mer) oligonucleotide (oligo) was 
synthesized and purified as described in Chapter 6.7. Fifteen 
bases of the 5' and 3' ends of this oligo were designed to be 
complementary to the coding strand of pUC9 on either side of 
the Smai cleavage site. This is shown in Figure 2.4. The 
methodology here requires only a fe,,.· simple steps which are 
discussed in detail in Chapter 6./Briefly, the cleaved plasmid 
was incubated with the bridging oligo in a buffer that allows 
reannealing of the plasmid which was denatured by incubation in 
boiling water and then cooled to room temp. E. coli JM83 was 
then transformed with the bridged plasmid and plated on agar 










Digest with Smai and bridge 




.. I Transformation and repair 
T -in E. coli JM83 
Psti BamHI Bsmt EcoRI 
5' --GCTCAGGTCGACGGATCCCCTGCATTCGGG.~TTCACTGGCCGTC--3' 
3'--CGAGTCCAGCTGCCTAGGGGACGTAAGCCCTTAAGTGACCGGCAG--5' 
Figure 2.4 Strategy for insertion of Bsmi site·· into pUC9 to 
produce pSyn synthesis vector. 
a) pUC9 and its· multicloning site. 
b) Production of synthesis vecto:r·. pUC9 is cut with Smai 
oligo-directed break-repair ·performed with linear 
pUC9. This is transformed into JM83 and oligo-
directed repair of the gap in pUC9 inserts the. Bsmi 
site. · 
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The resulting plates contained in excess of 300 colonies each, 
all of which were white, while the control JM83(pUC9) cells 
were all blue. The bridging of the gap created by Smai 
digestion of pUC9 with the 37 mer oligo had given rise to an 
insertion of 7 bases (Bsmi site) into pUC9 ie an insertion of 2 
X 3 bases ( 2 codon equivalents) + 1. Thus the lacz' gene of 
pUC9 had been forced out of frame with its promoter by one base 
pair giving a nonsense 13-galactosidase ex-fragment unable to 
complement with the w-fragment of 13-galactosidase of the 
cloning host, E.coli JM83. This results in colonies with no 13-
galactosidase activity which remain white as they are unable to 
degrade the X-gal in the medium. 
Ten such colonies taken from each of 3 separate platings were 
streaked to single colonies on Luria agar containing lOOpg/ml 
of Ampicillin and 20pg/ml of X-gal (L1Al00x) plates. From 20 of 
these, mini preps of plasmid DNA were made and the resulting 
plasmid DNA tested for the presence cf a Bsmi site. All were 
found to be linearized with Bsmi, while the control pUC9 was 
uncut by this enzyme. This indicated that these 20 plasmids 
each had at least one copy of the Bsmi site. To verify the 
results, the sequence across the multicloning site (mcs) of 2 
of these plasmids was determined by Sanger dideoxy sequencing. 
Both were found to have a single copy of the Bsmi site in an 
otherwise intact pUC9 roes. One of these was selected for 
further work and called pSyn. 
The gene for ETI had been designed to be excised from the 
synthesis vector (pSyn) by EcoRI and BamHI digestion. However, 
as can be seen from Fig 2. 4 the roes of pUC9 and hence pSyn 
73 
contains both an EcoRI and a BamHI site and the final product 
of ETI in pSyn would have appeared as shown below: 
BamHI EcoRI 
1<- 4 bp- >I ETI 
EcoRI 
11 bp -->1 
It can be seen from the above sketch that on attempting to 
remove ETI from pSyn with EcoRI and BamHI, the entire gene 
would be released, carrying pSyn.sequences either~~ or 3 1 to 
itself depending on which enzyme was used first. 
Forced cloning into pBtac1 ( ie EcoRI-BamHI fragment into an 
EcoRI. and BamHI digested vector) would require removal by 
digestion with EcoRI of 4 base pairs of DNA, from the 5 1 end of 
gene when the initial digest had bee.n with BamHI. Similarly, 
the removal of 11 base pairs of pSyn DNA from the 3 1 end of the 
gene with BamHI would be required when EcoRI had been the 
initial cutter. However, the removal of such small pieces of 
DNA by digestion with either of these two enzymes is reportedly 
not reliable (New England Biolabs .J2-atalogue 1990-1991). 
To avoid this problem, the EcoRI site was removed from the roes 
of pSyn. This was achieved by EcoRI digestion, removal of the 
resultant 4 base overhangs with Mung bean nuclease digestion 
followed by blunt end ligation to close the plasmid. The 
resultant plasmid, pSyn.1 had lost 4 bases ie 1 X 3 (or 1 codon 
equivalent) + 1. Thus, the inserted base which put the lacz I 
gene of pSyn out of frame was removed and the lacZ 1 gene of 
pSyn. 1 was put in frame with its promoter. Colonies of JM83 
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transformed with this plasmid were all blue when plated on 
LAA100x plates. The method is outlined in Chapter 6 and shown 
in Figure 2.5 below. 














Figure 2.5 Strategy for removal of the EcoRI site from pSyn 
the modified pUC9 synthesis vector 
2.4 Synthesis and purification of oligonucleotides for 
construction of the synthetic ETI gene 
Synthesis of any large gene requires some form of sequential 
fragment assembly. This is cer~ainly the case with gene 
./ 
synthesis by serial cloning (Hayden and Mandecki, 1988). With 
this methodology it is essential to supply 15-b.ase 
hybridization arms at the 5' and 3' ends of the coding sequence 
to anchor each succesbive oligo fragment_of the gene across the 
gap created by Bsmi digestion of the synthesis plasmid. 
The sequence of ETI was divided int.o 8 portions (see Figure 
2. 2) . The length of each portion was chosen to put the lacZ' 
gene of pSyn .1 alternately out of sequence then back into 
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sequence. Selection for the incorporation of each new insert 
would be based on change of colony colour from blue to white or 
vice versa. Eight oligos having the sequence of each of these 
portions were synthesized (see Figure 2.6). Each of these was 
designed with a 15-base arm at the 5' and 3' ends. 
In oligo 1 the arms are homologous to pSyn.1 on either side of 
the Bsmi cleavage. All the oligos had the same 3' arm for 
homology to pSyn. 1 and for regeneration of the Bsmi site. 
Subsequent oligos had 5' arms complementary to the coding 
strand produced by the 3' end of the preceding insert (see 
Figure 2.7). 
Full length oligos free of truncated sequences (also known as 
failure sequences) is a requirement for successful gene 
synthesis. Truncated sequences arise in even the most efficient 
of synthesis strategies as a result of incomplete coupling of 
nucleoside 3' -phosphoramidi tes with the controlled pore glass 
(CPG) supported 5'-hydroxyl DNA (Horn and Urdea, 1988). These 
authors recommend purifying oligos on phenyl derivatized silica 
syringe columns to separate the hydrophobic 5'-dimethoxytrityl 
( DMT) protected full length product from unprotected failure 
products. 
In addition, shorter fragments can alno arise during removal of 
the oligo from the CPG by treatment with concentrated NH 40H 
which cleaves the DNA at any apurinic sites (Horn and Urdea, 
1988). These sites. arise during synthesis by random 
t 
acid 
hydrolysis of purine bases without affecting the phosphodiester 
OLIG0-1 
51 -GGT CGA CGG ATC CCC GAA TTC ATG CTT CTA GAC GGT AAC GGT GAA GTT GTT 
CAG AAC GGT GGT ACC TAC TAC CTG CTG CCA CAG G TGC ATT CGG GCA CTG-3 1 
Bsmi 
OLIG0-2 
51 -ACC TGC TGC CAC AGG TTT GGG CCC AAG GTG GTG GTG TTC AGC TAG CTA AAA 
CCG GTG AAG AAA CCT GCC CAC TGA CCG TT TGC ATT CGG GCA CTG-3' 
Bsmi 
OLIGI-3 
5'-TGC CCA CTG ACC GTT GTT CAA TCT CCA AAC GAA CTG TCT GAC GGT AAA CCA 
ATC CGG ATC GAA TCT CGT CTG AGA TCT GCT T TGC ATT CGG GCA CTG-3' 
Bsmi 
OLIG0-4 
51 -GTC TGA GAT CTG CTT TCA TTC CGG ACG ACG ACA AAG TAC GTA TCG GTT TCG 
CTT ACG CTC CAA AAT GCG CTC CAT CTC CA TGC ATT CGG GCA CTG-3' 
Bsmi 
OLIG0-5 
51 - TGC GCT CCA TCT CCA TGG TGG ACC GTT GTT GAA GAC. GAA- CAA GAA GGC CTG 
TCT GTT AAG CTT TCT GAA GAC GAA TCT ACC C TGC ATT CGG GCA CTG-3' 
Bsmi 
OLIG0-6 
51 -AAG ACG AAT CTA CCC AAT TCG ACT ACC CAT TCA AAT TCG AAC AAG TTT CTG 
ATC AAC TGC ACT CTT ACA AAC TGC TTT AC TGC ATT CGG GCA CTG-3' 
Bsmi 
OLIG0-7 
51 -TAC AAA CTG CTT TAC TGC GAA GGT AAA CAC GAG AAG TGC GCA TCG ATC GGT 
ATC AAC CGT GAC CAG AAA GGT TAC CGT CGT C TGC ATT CGG GCA ~G-3' 
Bsmi 
OLIGI-8 
51 -AAG GTT ACC GTC GTC TGG TTG TTA CCG AAG ACT ACC CGT TAA CCG TTG TTC 
TGA AGA AGG ACG AGA GCT CTT AAT GCA GGG ATC C TGC ATT CGG GCA CTG-3 1 
Bsmi 
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Figure 2.6. Sequences of the o+i~onucleotides required for 
the synthesis of ETI. 








'-psyn.1 coding strand/~ 
77 
Double strand break repair with oligo 1 a 70 base oligo 
fragment that encodes the EcoRI site and the amino terminal 
region of ETI. Followed by transformation to allow oligo 




Bsmi digestion and double strand break repair with oligo 2 a 65 
base oligo encoding the next portion of ETI 
complementary arm to insert 1 
5-'GATCCC------------- ·=-------------------'TGCATTCGGGCACT-3' 
3'-CTAGG ACGTAAGCCCGTGA-5' 
Transformation, oligo directed 









for serial cloning of 
as described by Hayden and 
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bonds of the backbone. The 5' end of the cleaved product 
carries a 5'-DMT and is purified along with 5'-protected full 
length product. 
However, apurinic sites are susceptible to mildly alkaline 
solutions of amines and were cleaved in the presence of 1M 
lysine pH9 (without removal of other oligos from the CPG) and 
the soluble 5' -DMT truncated fragments were washed away. The 
remaining 3'-bound material was removed from the support with 
NH 40H. As only full length oligos are protected with 5'-DMT, 
these are readily purified away f:z::om the rest of the mix on 
passage through a rapid reverse-ph~se cartridge containing 
phenyl derivatized silica. 
2.5 Synthesis of the ETI encoding gene 
The gene synthesis protocol of Hayden and Mandecki (1988), as 
discussed in Chapter 2.3 and outli~ed in Figure 2.7, was 
followed. Prior to each serial addition of oligonucleotide to 
extend the ETI sequence, the plasmid was linearized by Bsml 
digestion. After each round of bridge mutagenesis up to 20 
colonies of the correct colour, were streaked to single 
colonies on LAAlOOx plates. This was done to ensure their 
stability, by monitoring their maintenance of correct colour on 
X-gal containing medium, and to separat.e them from satellite 
colonies which invariably form around antibiotic resistant 
colonies. 
Of the apparently stable colonies, 12 were chosen for plasmid 
minipreps and digested with the appropriate restriction enzyme 
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that had been introduced on that pcrticular insert. Four 
plasmids that were shown to contain the new site were extracted 
on large scale by plasmid maxipreps, purified twice by CsCl 
ultracentrifugation and sequenced by Sanger dideoxy sequencing. 
After each successful insertion of successive ETI portions the 
' plasmid ... containing the correct sequence was termed pLTl to . 8 
depending_ on the number of the oligo most recently inserted. 
The results of each successive round of insertion are 
summarized in Table 2.2. 
From the insertion of oligo 3 onwards ·the development of blue 
colouration of colonies required about 48 hours to develop (16 
hrs at 37°C, approximately 5 hrs at room temp. and the 
remainder at 4°C), whereas for oligo 1 and 2 this required only 
about 16 hrs at 37°C. Furthermore, the blue that did develop 
was very pale and difficult to discern. Nonetheless, a 
selection was made at this stage and those colonies streaked on 
LAA100x as described earlier. At a second round of growth, 
easily discernible blue colour developed aft~r 12-16 hours. It 
is possible that the initial slow development of colour was due 
to the repair process. 
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Insertion % colour/ 
ETI length Colour Total enzyme Correct 
plasmid (bases) selection colonies site sequence 
(a) (b) (c) (d) (e)/(f) (g) 
pLT1 .70 white 100 38/12 4 
pLT2 65 blue 117 23/10 4 
pLT3 67 white 125 25/11 4 
pLT4 65 blue 130 30/9 3 
.-.. 
pLTS 67 white 152 32/8 2 
pLT6 65 blue 103 20/6 4 
pLT7 67 white 119 22/7 4 
pLT8 70 blue 99 21/9 4 
Table 2.2 Shows summary of results for each successive 
insertion of oligonucleotides in the synthesis 
of an ETI encoding gene. 
(a) pSyn.l with the number of the most recently added insert. 
(b) Number of bases inserted across the gap created by Bsmi 
digestion. 
(c) Selected colour for the number of bases added. 
(d) Total number of colonies produced from 3 plasmid: oligo 
bridgings of 1:10, 1:100 and 1:1000 on 3 separate plates . . 
(e) Percentage of the total number of colonies that on initial 
selection were of the correct colour. 
(f) Of the 12 colonies of correct colour that were chosen for 
mini preps, the number with the :cestriction site of the 
most recent insert. 
(g) The number out of 4 with the correct restriction site that 
had the correct sequence. 
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It can: be seen from Table 2. 2, that from 20-38% of total 
colonies at each insert produced the correct colour. Of those 
selected for minipreps not all could be digested by the newly 
inserted restriction site. This was thought to be as a result 
of incorrect repair of the gap created by the bridging oligo. 
In the case of pLT4, one out of 4 sequenced plasmids and in 
pLT5, two out of 4 sequenced 
plasmids, the unique restriction sites contributed by these 
oligos were left intact while error was introduced elsewhere in 
the new sequence. 
Upon construction of the entire ETI encoding gene in pSyn. 1, 
plasmid pLT8 was purified as before and both strands of the 
synthetic ETI gene were sequenced using 4 primers (see Figure 
2.8). The entire sequence of this gene was found to be free of 















->REV 02 5'-AAGTACGTATCGGTTTC-3' 


















Figure 2.8 The sequence of pLTB 
oligonucleotide primers used 






pSyn.l sequence is sho~~ in bold and arrows show 
direction of sequence. 
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2.6 Discussion 
The strategy adopted for the design of a gene encoding ETI will 
be summarized as a set of general guidelines for future gene 
designs. The .. amino acid sequence was initially translated 
strictly into major codons for E. coli. To make the sequence 
acceptable for possible expression in S. cerevisiae, 2 codons 
(for Pro and Gln) of the sequence were changed such that they 
would still be acceptable to E.c~~i. The sequence was scanned 
for restriction sites and partial restriction sites using a 
large database of enzymes. Restriction sites unique to the 
ETI/pSyn.l vector were introduced into the sequence by change 
of the wobble base of that codon but \vi thout compromising the 
ability of E.coli to utilize the sequence. Two other changes 
were made to the E.coli major codon sequence in order to break 
up two strings of A's but again without compromising the 
intended expression host. A very useful ETI-encoding sequence 
was designed that can be used for investigations beyond this 
work into the inhibitory mechanisms of ETI. The design has made 
allowance for alterations to the amino terminus and the ease by 
which this region is altered will be demonstrated in Chapter 3. 
Furthermore, the carboxy terminus can be altered in the same 
manner and the coding sequence for the amino acids at and 
surrounding the scissile bond can also be altered in the same 
manner with relative ease. 
The decision was made to synthesize the gene by the bridge 
mutagenesis method for three important reasons viz: 
a) The reduction in cost, as only 1.5 times the length of the 
gene was needed in synthetic oligo (taking into account 
the 5'' and 3' 15 base arms regnired on each oligo), as 
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opposed to at least double the length of the gene as is 
requ.i red in a double strand synthesis approach. The 0. 5 
times gene length is contributed by the required arms for 
anchoring each oligo across the gap created by digestion 
with Bsmi. This amount can be reduced somewhat by 
increasing the distance between the arms ie., by 
increasing the size of each oligo. 
b) The accuracy of the repair of the gap in E.coli, which as 
can be seen in Table 2.2 is r~~sonably high~ 
c) The relative ease of the synthesis approach which, after 
oligo synthesis, requires no further chemical 
manipulations for insertion of each new gene segment. 
From Table 2.2 it can be seen that only between 20 and 38% of 
the transformants that were obtained after each bridging step 
were of the required colour. However, it was not established 
how much of this was contributed by either uncut or reclosed 
cut plasmid. Thus the accuracy of the procedure cannot be 
judged from the results obtained at this step. Of a selection 
from the correct colour of transformants, from 50 to 100% were 
found to carry the restriction site coded for on the newly 
inserted oligos. Thereafter, of a sampl9 taken from those with 
the required restriction site, in only two cases, viz pLT4 and 
5, 1 out of 4 and 2 out of 4 respectively, did not have the 
correct sequence coded for by the latest insert. 
Technically, bridge mutagenesis is very simple. However, gene 
synthesis by serial cloning using bridga mutagenesis is time 
consuming because of the cumbersome screening procedure that 
was used for this work. For synthesis and final sequencing of 
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the completed gene required 8 months of normal working days by 
this worker. The time required to complete a similar project 
would be much reduced as the technique has now been established 
and the laboratory well equipped for the work. 
To further expedite a future synthesis project it has been 
suggested by Mandecki (pers. comm.) that the method of gene 
synthesis by the Foki method would be preferable to serial 
cloning. This method was described by Mandecki and Bolling 
(1988) and later used by Mandecki et al. (1990) to synthesize 
an entire plasmid of some 2050 base pairs as was discussed in 
the introduction to this chapter. However, prior to the start 
of this work some experiments were done to determine the 
suitability of the Foki method for this current work. It was 
determined at this stage that the enzyme Foki produced 
unreliable cleavage in the hands of this worker and the 
decision was made to synthesize by serial cloning. However as 
the Foki method is highly recommended by Mandecki and bearing 
in mind their spectacular success in synthesis of an entire 
plasmid, the technique should be ~erfected and established for 
use in this laboratory .. 
In addition, it was also suggested that to expedite screening, 
post-bridging transformants should be screened with a sample of 
end-labeled oligo most recently used for bridging. This method 
was used in parallel with the successful screening approach 
described earlier for selecting transformants after bridging 
with oligos 4, 5 and 6. However, it offered no saving of time 
and no improvement in accuracy to the first screening step. 
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Thus 1 in summary 1 the method of gene synthesis by serial 
cloning using bridge mutagenesis as described by Hayden and 
Mandecki (1988) was used with great success in the synthesis of 
a gene encoding ETI. 
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3.1 Introduction 
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It was shown in Chapter 2 that the gene designed for ETI was 
accurately synthesized. Furthermore, it appears to be stably 
maintained in the synthesis vector pSyn.1 and the host JM83 and 
89 
thus is amenable to be excised and placed in a suitable 
vector/host system for expression or, more desirably, for 
overexpression. 
3.1.1 E.coli as a vehicle for expression of cloned genes 
The decision had been taken earlier to use an E. coli-based 
expression system to produce ETI from this synthetic gene. The 
advantage of this organism is the well established technology 
for DNA manipulation and cell culture, as compared with that of 
other expression systems. In addition, there is a large body of 
knowledge on the genetics and physiology of E.coli which can be 
drawn on to address difficulties in the expression of a 
particular gene. In support of this, there are many genes both 
cloned and synthetic that have.been successfully expressed in 
E.coli (Marston, 1986). 
Nonetheless, E.coli is not suitable for expression of all 
genes. The most important drawbacks to the use of this organism 
for production of proteins are its limited capacity to secrete 
proteins and its inability to perform certain post-
translational modifications of proteins such as acetylation and 
glycosylation (Balbas and Bolivar, 1990). 
ETI requires 
require two 
neither glycosylation nor acetylation but does 
disulphide bridges to stabilize the correct 
structure for activity. In the ·reducing environment of the 
E. coli cytoplasm these disulphide bonds are unlikely to form 
(Goeddel, 1990). ~owever, E.coli expression systems are 
versatile and the problem may be overcome by exporting the 
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protein to an oxidizing environment, either the peri plasm or 
the extracellular medium (Kohno et al., 1990). This strategy 
has been very successful for the expression of a number of 
proteins (Marston, 1986) and will be discussed later. 
Alternatively, Kohno et al. (1990) indicate that disulphide 
bonds can be formed accurately and in high yield in vitro by 
supplying the in vivo redox state of the natural environment of 
the native protein. In doing so, they indicate, the primary 
amino acid sequence will direct the normal folding pathway of 
the protein. 
Despite the high degree of control that current expression 
technology allows over E.coli expression systems, in many 
instances, success is achieved empirically and the practice is 
described by Stader and Silhavy · ( 19 9 0) as an art. This must 
certainly reflect how much is still to be learned about gene 
expression in E.coli. 
The choices of expression vector and host and combinations of 
these for E.coli are numerous. Thus, before attempting 
expression it is appropriate to review briefly, current views 
on the requirements for overexpression of recombinant proteins 
in E.coli. 
3.1.2 Increasing the stability of foreign proteins in E.coli 
Many proteins, both foreign and native are rapidly degraded by 
proteolytic enzymes when expressed in E. coli. Proteolysis in 
bacteria is a very selective and carefully regulated process 
aimed at recycling amino acids and preventing accumulation of 
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nonfunctional or denatured polypeptides that could be toxic to 
the cells (Goldberg and Goff, 1986). 
The reason for the instability of particular recombinant 
proteins is not well understood. Nonetheless, it appears that a 
single degradation system is involved in the breakdown of 
proteins in E.coli. Thus one approach to stabilization of such 
proteins has been the use of strains carrying one or more 
mutations in the genes that control the degradation system to 
decrease intracellular proteolysis (Miller, 1987). However, no 
one protease mutant will stabilize all foreign proteins. 
Therefore, when it has been established that proteolysis is the 
cause of poor protein yield, the correct strain for expression 
must be established empirically. 
Strains of. E. coli with mutations i.n the lon and htpR genes are 
known to lower levels of proteolytic activity and have been 
used successfully for expression of proteins (Miller, 1987). 
3.1.2.1 lon Mutations 
Lon is a protease that seems to be active against unfolded or 
misfolded proteins. Strains with lon mutations degrade such 
proteins more slowly than their lon+ parents (Gottesman, 1990). 
Both deletion and insertion mutations in lon are available and 
can be introduced into other · strain backgrounds by P1 
transduction (Gottesman, 1990). However, lon mutations produce 
two major phenotypes viz mucoidy and UV sensitivity, which may 
make them unsuitable as expression hosts. These phenotypes can 
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be eliminated by appropriate secondary mutations (Gottesman, 
1989). In addition, lon mutations can affect transformation 
efficiency and plasmid stability and may not be suitable for 
selection of transformants after ·ligation (Goldberg and Goff, 
1986). 
Mucoidy phenotype is seen when lon mutants are grown at 
temperatures of 34°C and below and on minimal media, but 
serious problems of mucoidy can be avoided when these strains 
are grown on rich media or at temperatures of 37°C or above. 
Genetic solutions to prevent capsule synthesis by the mucoidy 
phenotype include mutations in the gal operon, cps gene cluster 
or rcsB and rcsA genes (Gottesman, 1990). 
In response to UV damage, lon mutants form long nonseptated 
filaments, which are frequently not viable. In addition, lon 
mutants tend to show some filamentation on rich growth media. 
Filamentation is lethal when cells are transferred from minimal 
to rich media. Filamentation is due to the stabilization of the 
SOS inducible cell division inhibitor sulA. Generally, this 
phenotype is not troublesome enough to require remedies. 
However, mutations inactivating sulA have no deleterious 
effects on cell growth and should eliminate the filamentation 
phenotype (Gottesman, 1990). 
3.1.2.2 htpR Mutations 
The htpR gene codes for ~3 2 , the subunit that confers 
specificity on RNA polymerase for gene promoters required for 
the heat shock response (Grossman et al.,1984). As lon itself 
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is a heat shock protein, strains deficient in this factor are 
generally defective in proteolysis. Strains wi~h lon and htpR 
mutations appear to stabilize foreign proteins better than 
either one alone (Miller, 1987). 
However, the most commonly used htpR allele is an amber 
mutation in the gene, used in strains that provide conditional 
suppression of the mutation, for example, sup temperature 
sensitive hosts. Such hosts allow for good growth at 32°C, poor 
growth at 37°C and no growth above this temperature (Gottesman, 
1990). 
3.1.2.3 Other protease mutants 
Mutations in another heat shock gene dnaJ have been used for 
stabilizing foreign proteins in E. coli (Gottesman, 1990). In 
addition, clp mutations enhance stability of proteins in 
strains with defective lon protease (Goldberg and Goff, 1986). 
Proteases located in the periplasm may degrade foreign proteins 
that have been exported to this region. In particular, 
mutations in ompT inactivate an outer membrane-localized 
protease that has been implicated in protein degradation in 
extracts from E.coli (Sedgwick, 1989; Grodberg and Dunn, 1988). 
Mutations in degP inactivate a· periplasmic protease which can 
cleave phoA fusions to release the phosphatase portion. This 
protease may degrade periplasmic proteins and thus inactivating 
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it may help to stabilize some exported proteins (Strauch et 
al., 1989). 
3.1.3 General characteristics of expression plasmids 
The minimal elements that are required of an expression plasmid 
vector are as follows: 
1) Well characterized origin of replication. · 
2) A gene encoding a selection marker for plasmid propagation 
and maintenance. 
3) A multicloning region into which the gene of ~nterest can 
be cloned under control of a strong regulatable promoter 
and in frame with _the coding sequence for a st~ong 
ribosome binding site. 
3.1.3.1 Plasmid replication 
The primary function of naturally occurring plasmids · is· self 
replication. The region _on a plasmid that controls this 
function as well as the plasmid copy number (number of plasmids 
per cell) is found at the ori9in of replication. Relaxed 
replicating plasmids, such as pBR322 and its derivatives have 
been preferentially used for expression systems ( Balbas and 
Bolivar, 1990). 
Of particular importance to the expression of ETI ·is that in 
relaxed plasmids , copy nuniber i_s inversely l?roportional to the- _ 
_ growth rate. Thus at high growth ·rates the number of -plasmids. 
per cell is low. This, coupled with defective partitioning of 
plasmid DNA between cells during cell division, invariably 
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leads to segregational instability (Klotsky and Schwartz, 
1987). The plasmid can be gradually lost from the growing 
population by segregational instability unless a gene for 
selection, usually an antibiotic resistance gene, is carried by 
the plasmid. When the concentration of the selective antibiotic 
in the growth medium is reduced by the action of the resistance 
gene product, sensitive cells (those with few or no copies of 
the plasmid) are allowed to grow. Such plasmid-deficient cells 
may outcompete high-dose plasmid-containing cells as the latter 
suffer 'metabolic drag' induced by diversion of metabolic 
energy to their plasmids. Multiple additions of antibiotic to 
cultures appears to be the only solution currently available 
(Balbas and Bolivar, 1990). 
A more insidious form of plasmid instability is that of 
structural instability resulting from some physical change (eg. 
deletion, insertion or rearrangement), usually to the DNA of 
interest, while the remainder of the plasmid including the 
selectable gene is unchanged. No method is yet available for 
accurate prediction of such instabilLty. Nonetheless, the 
problem can be controlled by alternative strategies for gene 
cloning or by use of RecA- strains (Balbas and Bolivar, 1990). 
3.1.3.2 Gene expression at the transcription level 
As discussed in Chapter 2, for overexpression of a gene, the 
mRNA derived from it must become the major mRNA species in the 
cell. To achieve this, the gene must be placed under the 
control of a strong promoter. 
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Gene transcription or mRNA synthesis is catalyzed by RNA 
polymerase. The core enzyme of this polymerase, when combined 
with a dissociable subunit called sigma ( cr) , which confers 
specificity to the interaction between RNA polymerase and 
binding sites on the DNA called promoters, is known as a 
holoenzyme (Losick and Pero, 1981·). E. coli has multiple forms 
of RNA polymerase which differ only in their cr subunits 
(Grossman et al., 1984). Each holoenzyme form transcribes a 
family of genes controlled by its cognate promoter. Recombinant 
genes in E.coli are usually placed under the control of 
promoters recognized by holoenzyme Ecr 70. In general the core 
promoter is that DNA region that is critically important for 
complex formation with holoenzyme in the absence of other 
factors (Gralla, 1990). 
The core DNA promoter elements for Ecr 70 lie in an approximately 
29 base pair region between positions -7 and -36 with respect 
to the start point of transcription. The region is bounded by 
two hexanucleotide consensus sequences near position -10, viz 
5'-TATAAT-3' and position -35, viz 5'-TTGACA-3'. These two 
sequences are separated by a spacer region of 17 ± 1 base 
pairs. Polymerases containing other cr factors recognize other 
promoter sequences (McClure, 1985). These core DNA promoter 
elements were identified by both functional and statistical 
analyses. Most importantly, they have been extensively 
mutagenized and the damaged elements were shown to be 
associated with defective transcription (Gralla, 1990) . 
. Transcription is a multistep process which can conveniently be 
divided into initiation, elongation and termination events. 
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Firstly, holoenzyme scans the DNA and encounters a promoter. 
The bases in the -35 and -10 regions form molecular contacts 
with the holoenzyme and may hold it long enough for a 
holoenzyme/DNA complex to form and DNA melting to occur. The 
strength of the promoter influences the stability of this 
complex and hence whether initiations will occur (Gralla, 
1990). It is thought that the simultaneous binding of 
polymerase to the two conserved regions of core promoter 
induces conformational changes in the DNA. This leads to 
melting of the DNA in the promoter and formation of an open 
complex or transcription bubble. 
In the final open complex the polymerase extends from position 
-45 to +20. Thus DNA sequences both upstream and downstream 
from the core promoter can have an important influence on 
expression, for example the upstxeam activator regions which 
are usually binding sites for re.gulatory proteins (Kuhnke et 
al., 1987). It has also been suggested that non core DNA 
sequences can influence promoter function by causing bending or 
allowing melting. E. coli cr 7 0 promoters are in general quite 
rich in AT pairs and the sequences near -45 show some tendency 
toward being conserved (Hawley and McClure, 1983; Boroweic and 
Gralla, 1986). 
Within the open complex RNA polymerase synthesizes a short 
primer strand which is paired with the template strand. If this 
template is allowed to grow to about 10 nucleotides, at which 
point it is strongly bound to .the template, initiation is 
completed successfully. However, the enzyme frequently aborts 
initiation and the short primer cannot bind to the template. 
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The enzyme repeatedly produces and releases short initiation 
products while being held firmly at the promoter in a cycling 
pathway. This cycling slows down transcription initiation and 
can limit expression (Carpousis et al., 1982). The phenomenon 
is more pronounced with some promoters than with others, giving 
rise to the term slow start ( eg. lacUV5 promoter) and rapid 
start (eg. T7 promoter) promoters. At slow start promoters RNA 
polymerase seems to have difficulty in escaping the forces that 
positioned it for initiation in the first place. In rapid start 
promoters the non transcribed regions of the promoter may 
assist in polymerase escape and promoter clearance (Gralla, 
1990). In addition, there is some evidence to suggest that the 
initial transcribed region plays a role in setting the rate of 
polymerase escape and promoter clearance (Deuschle et al., 
1986; Carpousis et al., 1982). Thus a cloned sequence itself 
may influence the level of e~pression from a particular 
promoter and hence the perceived .strength of the promoter. As 
there are currently no rules for prediction of the influence a 
cloned gene will have on its promoter, the correct vector for 
expression must be determined empirically. 
Once holoenzyme has synthesized a short, stable RNA initiation 
primer, ~ factor is released and the core enzyme, which is no 
longer complexed to the promoter, elongates the RNA chain. The 
properties of elongating core polymerase can be altered by 
factors that associate with it. For example, NusA protein binds 
to core RNA polymerase, preventin_g ~ from binding and may, to 
some extent, alter patterns of pa~sing and termination (Gralla, 
1990). 
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3.1.3.2.1 Transcription termination 
Elongation of mRNA continues until transcription is terminated, 
at which point, the mRNA/RNA polymerase/DNA complex 
dissociates. In bacteria, termination is achieved either by the 
action of a protein termination fc;1ctor called rho or by factor 
independent methods (Balbas and Bolivar, 1990). Both methods 
utilize a site on the DNA which causes pausing of the 
elongation complex at the end of a coding sequence to achieve 
termination. Factor independent termination is usually used in 
expression systems and makes use of two GC rich segments that 
in the transcript have the potential to form a stem-loop 
structure. Following this is a downstream run of 4-8 A 
residues. It is believed that the GC rich segments cause 
pausing of polymerase. The nascent transcript forms a hairpin 
structure at this region displacing it from the template. 
Transcribing the A rich segment then completes the 
destabilization of the transcription complex and termination is 
achieved. 
These termination regulatory elements are not indispensable in 
an expression plasmid vector but their presence at the end of a 
highly expressed gene is advantageous as transcription 
terminators act as barriers to elongation. Thus they minimize 
sequestering of RNA polymerase that may be engaged in 
unnecessary transcription. They also restrict the mRNA length 
to the minimum, thus limiting energy expense. Furthermore, as 
strong transcription may interfere with plasmid replication, 
transcription terminators may isolate the origin of replication 
and allow plasmid copy number to be maintained ( Balbas and 
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Bolivar, 1990). In addition, it is believed that the presence 
of strong terminators at the end of a gene can greatly increase 
the message half life (Schmeissner et al.,1984). 
However, the gene to be expressed may itself contain one or 
more sequences that lead to termination. A general solution to 
such a problem is offered by vectors that utilize the ,\ 
anti termination system to override transcription stop signals 
(Das, 1990; Gottesman, 1980). This is achieved by cocloning of 
the A NutL site which produces the AN gene product. This binds 
E.coli NusA protein which is complexed with RNA polymerase core 
enzyme and alters the response of elongation complex to 
transcription terminators (Salstrom and Szybalski, 1978). 
3.1.3.2.2 Transcription control 
A common feature of bacteria is. their ability to adapt readily 
to changes in their environment.· For example, the genes for 
lactose utilization are activated once E.coli cells sense the 
presence of lactose or a similar compound and the lactose 
utilizing enzymes are induced. Many other genes are similarly 
kept in a turned-off state until their products are needed. 
Still other genes, concerned primarily with anabolism, are kept 
in a turned-on state unless the product of the anabolic 
sequence is present, and then the genes are repressed or turned 
off. 
Both enzyme induction and repression are achieved through 
control of transcription, primarily at the initiation step. An 
example of gene regulation at the level of transcription, that 
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soluble form. In general 3 steps are followed to achieve this 
purpose: 
Firstly, the forces holding the inclusion bodies together must 
be broken and the proteins solubilized. Solubilization agents 
include: 
a) 5-8M guanidine chloride. 
b) 6-8M urea. 
c) Detergents. 
d) Alkaline pH ( >9) . 
e) Organic solvents. 
Shoemaker et al. ( 1985) discovered a small amount of monomer 
with disulphide bridges on cytoplasmic expression of 
prochymosin in E.coli. However, it is known that the cytoplasm 
of E. coli is kept in a reduced state (Fahey, 1977). It was 
presumed that this disulphide bonding occurred on exposure to 
air, during cell lysis or in an oxidizing environment in the 
inclusion bodies. It is reasoned that any disulphide bridging 
that occurs under such conditions ~s likely to be incorrect and 
most protocols include thiol reagents such as mercaptoethanol 
to disrupt these. 
Secondly, the protein can be purified by a number of strategies 
including ion exchange or gel chromatography, centrifugation or 
by extraction of proteins into iso-butanol or methylbutanol. 
The choices here depend on the protein in question and the 
denaturant used (Marston, 1987). 
112 
Thirdly, the disrupted proteins must be slowly introduced to 
the appropriate conditions to allow the correct intramolecular 
interactions including disulphide bonds to form. Generally, 
dialysis is employed to remove denaturant, dilute and introduce 
the denatured protein to an environment conducive to folding 
(Marston, 1987). 
Clearly there are a large variety of expression systems for 
E.coli from which to choose. While the choice is to some extent 
empirical, at least a general understanding of expression 





3.2 Expression in pbtac1T.M vector 
3.2.1 The pBtac1TM expression vector 
As discussed in Chapter 2 the synthetic gene for ETI was 
provided with restriction sites for cloning into the expression 
vector pBtac1. The pBtac expression vectors were obtained from 
Boehringer Mannheim and supply the strong tac promoter which is 
regulated by the repressor of the lacz gene, the lacz ribosome 
binding site, strong rrnB ribosomal RNA transcription 
terminators, which have been inserted downstream of the 
multicloning site of pUC8 and a gene for ampicillin resistance 
(see Figure 3.1). 
The tac promoter is a hybrid promoter consisting of the -35 
region of the trp promoter and the -10 region of the 1acUV5 
promoter (De Boer et al., 1983). The 1acUV5 promoter was 
derived from a UV induced mutation of the lacz promoter. This 
mutation changed the lac -10 region from 5 1 - TATGTT-3 1 to the 
consensus 5 1 -TATAAT-3 1 -10 sequence (Carposius et al., 1982). 
However, 1acUV5 has a non-consensus 5 1 -:-TTTACA-3 1 -35 region. 
Conversely, the trp promoter has a consensus 5 1 -TTGACA-3 1 -35 
region but a non-consensus 5 1 -TTAACT-3 1 -10 region. In 
addition, the 1acUV5 promoter supplies a good S-D sequence, viz 
5 1 -AGGA-3 1 in the ribosome binding site, while the trp promoter 
has a less than ideal 5 1 -GGTA-3 1 S-D sequence. The fusion of 
these two pieces of DNA, one containing the -35 region of the 
trp promoter and the other containing the -10 region 
of the 1acUV5 promoter, its lac operator and its 
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a) 




b) -35 16bp -10 1 S-0 EcoRI Bam/11 
5'-GAGCTGTTGACAATTAATCAT CGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACA~CCGGGGATCC-3'ptac 
-35 18bp -10 1 S-0 
5 ' -CCAGGCTTT ACACTTT ATGCTTCCGGCTCGTAT AATGTGTGGAA TTGTGAGCGGA TAACAA TTTCACAC.B§§..AAACAGAATTCTATG-3' p lacUVS 
-35 17bp -10 1 S-0 
5'-GAGCTGTTGACAATTAATCATCGAACTAGTTAACTAGTACGCAAGTTCACGTAAAAAGGGTATCTAGAATTCTATG-3' •••••••••••••••• ptrp 
Figure 3.1 Plasmid pBtacl and the origin of the tac promoter. 
a) Map of pBtac1 (not to scale). Size is indicated in 
base pair (bp) .. The tac promoter ·and ampicillin 
resistance gene with its promoter are indicated by 
arro-v1s. 
b) Shows the tac promoter (ptac) and other control 
elements which are deri;ved from the trp and lacUV5 
promoters (ptrp and p1acUV5). The -35, -10, Shine-
Dalgarno (S-D) sequence and restriction sites are 
indicated by underlining. The transcription start 
sites are indicated by 1. The lac operator is 
indicated for tac and lacUV5 by italicized sequence. 
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ribosome binding site (see Figure 3.1) has given rise to a 
promoter that conforms with the consensus sequence for 
promoters and is far more efficient than either of the parental 
promoters (De Boer et al., 1983). 
The tac promoter is repressed in lac.Tl strains of E. coli, eg 
JM105 which has resident the F' episome carrying, inter alia, 
the lac.Tl mutant form of the laci gene, allowing for 
overexpression of the lac repressor (Yannish-Perron et al., 
1985). In such a host the tac promoter is induced by IPTG. This 
promoter has been used to give high yields of expressed product 
from certain recombinant genes. For example, De Boer et al. 
( 1983) found the tac promoter to be 5-10 times- more efficient 
than the lacUVS promoter for the production of hGH. Interferon 
was produced to high levels by Amman et al. (1983) and in 
addition, they produced the ci repressor of bacteriophage A to 
30% of total cell protein using the tac promoter. More 
recently, Smith et al. (1990) Eecovered, correctly folded and 
active, the eukaryotic protein, ·horseradish peroxidase 
isoenzyme C (HRP C), at a yield of 2-3% of total cell protein. 
In this example, HRP C was produced from a synthetic gene 
driven by the tac promoter. Thus the t4c promoter was 
considered to be ideal for cytoplasmic expression of synthetic 
ETI. 
3.2.2 Construction of pTETI expression vector 
The expression vector pTETI was constructed by directional 
cloning of the synthetic gene for ETI into pBtac1. The gene for 
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ETI was removed from pLT8 by digesting firstly with the unique 
EcoRI site in pLT8 (see Chapter 2.3) to linearize the plasmid. 
Linearized plasmid was purified, precipitated and digested 
further with BamHI releasing the synthetic ETI gene. _The gene-
bearing DNA fragment was gel-purified from the rest of the 
plasmid. 
To receive ETI, pBtac1 was digested firstly with BamHI, 
purified, and precipitated. Linearized plasmid was digested 
with an excess of EcoRI to allow some cleavage at the EcoRI 
site which was located 4 base pairs from the end of the 
linearized DNA. The large fragment was gel-purified as before. 
The two pieces of DNA were ligated and used to transform JM105 
to ampicillin resistance. Transformants were selected at 
random, DNA was extracted by the miniprep method discussed in 
Chapter 6 and digested with the appropriate restriction enzymes 
to verify single insert and orientation. DNA was extracted from 
promising transformants by the maxiprep method and sequenced by 
Sanger dideoxy-sequencing using the Fow-02 and Rev-02 primers 
shown in Chapter 2.5. 
3.2.3 Expression of ETI from pTETI 
E.coli JM105(pTETI) was grown in LB (Luria broth) containing 
100 pg/ml of ampicillin to late log phase (A600 0.6-0.8), the 
tac promoter controlling the SYnthetic ETI gene was then 
induced by addition of IPTG to 1 IDM. The cells were allowed to 
grow for a further 3 hrs under inducing conditions. As a 
control JM105 (pBtac1) was subjected to the same conditions of 
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growth and induction as JM105(pTETI). Samples were taken prior 
to induction and after 3 hrs of post-induction growth. 
Figure 3.2 shows an SDS-PAGE g~l after staining and destaining 
of samples run as described above·. From this it is clear that 
there is no difference in banding pattern between the three 
samples and no accumulation of any band after induction of 
pTETI in particular of ETI size range (approximately 20 kDa). 
Thus the synthetic gene for ETI was not expressed at detectable 
levels in this vector/host system. 
It was established in Chapter 3.1 that current understanding of 
gene expression requires that the optimal expression system for 
any gene be chosen empirically. Thus no further ·work was 
performed to establish the reason for failure of the 
JM105(pTETI) system to express :ETI and this can only be 
speculated upon at this point. Such reasons may include: the 
ribosome binding site being caught up in secondary structure, 
degradation of mRNA prior to translation or degradation of 
newly synthesized ETI in the cytoplasm before it can accumulate 
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PAGE gel of samples from the attempt to express 
the synthetic ETI gene of JM105 (pTETI). 
ETI purified from seeds of Erythrina caffra and 
kindly supplied by Serevac South Africa 
JM105(pTETI) just prior to induction 
JM105(pTETI) 3 hrs after induction 
JM105(pBtacl) 3 hrs after induction 
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3.3 Exprassion from pMALTM-c expression vector 
3.3.1 The pMAL expression vector 
The pMAL expression vectors are supplied by New England Biolabs 
(NEB) and provide a single system for expression of genes and 
purification of the resultant proteins (see Figure 3.3). These 
expression vectors supply the malE gene (which codes for 
maltose binding protein or MBP) fused through a po1ylinker 
region to the lacz~ gene. Transcription of the fusion complex 
is controlled by the tac promoter and strong rrnB ribosomal RNA 
transcription terminators have been cloned downstream of the 
lacz~ gene to prevent transcription from ptac from interfering 
with plasmid functions. The promoter is kept in a switched off 
or repressed state by lac repressor, the product of the laci 
gene, which is also carried by the pMAL vectors. Cloning of a 
coding sequence (which contains a stop codon such as TAA) into 
the polylinker and derepression of the promoter by IPTG 
interrupts the malE-lacz~ fusion. This changes colony colour 
from blue to white on X-gal in an ~-complementing E.coli host 
such as TB1. Furthermore, cloning into this region gives rise 
to a fusion protein consisting of MBP and the target protein. 
To separate the two domains after purification, a sequence 
coding for the cleavage site of blood coagulation factor X a 
protease has been inserted between the malE gene and the 
polycloning site. This provides a mechanism for cleavage of the 






b) Sacl Stui EcoRI 
malE ••• TCG AGC TCG GTA CCC GGC CGG GGA TCC ATC GAG GGT AGG CCT GAA TTC AGT AAA ACC CTC GAT GGA TCC TCT 
Ile Glu Gly Arg 
' h 
I 
Factor Xa cleavage site 
Hindi! I 
AGA GTC GAC CTG CAG GCA AGC TTG ••• laclA 
Figure 3.3 The pMAL-c vector 
a) Map of pMAL-c. This contains the inducible ptac 
promoter positioned to "transcribe a malE-lacZcx gene 
fusion. The laci gene encodes the lac repressor, 
which turns off transcription from ptac until IPTG is 
added. The rrnB terminators prevent transcription 
from interfering with plasmid functions. 
b) The poly linker provides several restriction 
endonuclease sites to insert the gene of interest, 
fusing it to the malE gene~ 
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MBP is an E. coli K-12 perip1asmic protein of 370 amino acids 
( 4 2 kDa) that is invo1 ved in the transport of maltose and 
maltodextrins across the bacterial envelope, as well as in the 
chemotaxis towards these sugars (Kellerman and Ferenci, 1982; 
Duplay et al., 1984). MBP is fused with target protein in pMAL 
vectors to facilitate purification and offers the following 
advantages: firstly, MBP binds with high affinity to cross-
linked amylose matrix, and is released from the matrix by 10 mM 
maltose. Thus high yield and purity can be achieved in a single 
affinity chromatography step. Secondly, the purification takes 
place under physiological conditions and denaturation is 
unlikely to occur during these steps. Thirdly, the fused 
protein can be directed to the periplasm by incorporation of a 
malE export signal sequence, as ·is the case with the pMAL-p 
vector. The periplasm offers an environment conducive to 
disulphide bond formation and MBP does not contain any cysteine 
residues that could interfere with disulphide bond formation 
within the target protein (Guan et al., 1988). In addition to 
the advantages discussed above, formation of a fusion protein 
can afford protection to the mRNA and to the protein itself. A 
fusion may overcome the inability of ptac of pBtac1 to express 
ETI. 
Factor Xa (FXa) is a serine protease involved in blood 
coagulation. It is derived from cleavage of a specific bond of 
factor X (FX) which is a plasma glycoprotein of 55 kDa composed 
of a heavy chain of 38 kDa and a light chain of 17 kDa. A 
number of non-physiological mechanisms for the activation of FX 
have been described, for example, a protein present in 
Russell 1 s viper venom. Action of Russell 1 s viper venom on FX 
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results in the release of a glycopeptide of 11 kDa from the 
amino terminal end of the heavy chain (Fujikawa et al., 1972). 
This gives rise to FXa, a protein·of 44 kDa that recognizes the 
tetrapeptide Ile-Glu-Gly-Arg and cleaves at the carboxy-
terminal side of Arg, between it and any amino acid that 
follows. As a result it can be used to produce a protein with 
any desired N-terminal amino acid (Maina et al., 1988). In 
mammalian blood, FXa converts prothrombin to thrombin during 
the coagulation process (Jackson, 1985). 
Nagai and Thogersen ( 1984) and Nagai et al. ( 1985) used a 
construct containing a FXa cleavage site to generate 13-globin 
for which they required a native N-terminus. ·To achieve this, 
and to prevent secondary structure formation of the rnRNA in the 
region of the S-D sequence, they inserted the sequence for FXa 
between the 31 N-terminal amino acids of A cii protein and Val 
1 of human 13-globin and produced'this hybrid in high yield in 
E.coli. They then cleaved the hybrid specifically at the single 
Arg and liberated the authentic 13-globin chain. 
The strategy for expression and purification of proteins using 
the pMAL system is shown schematically in Figure 3.4. It 
involves cloning into the multicloning site of a pMAL vector, 
preferably into the Stui site to avoid vector derived amino 
acids after cleavage with FXa. Ef{pression is started as with 
pBtacl by induction with IPTG and allowing synthesis to 
continue for an optimal period that has been established 
empirically. Cells are then lysed, cell debris is centrifuged 
out and the remaining solution is passed over an amylose resin 
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Figure 3.4 Expression and purification with the pMAL vectors. 
a) Schematic representation of a portion of a pMAL 
vector showing the malE gene, the coding region for 
factor Xa and a hypothetical gene cloned into the 
poly linker and the protein that results from 
expression of this gene. 
b) Schematic representation of the synthesis and 
purification of MBP fusion protein with a 
hypothetical protein. FXa indicates the recognition 
site for factor Xa. ·The cleared lysate of induced 
cells · is run through a: crosslinked amylose column. 
After washing, the fusion protein is eluted with a 
dilute maltose solution. The purified fusion protein 
is cleaved with factor Xa and the target protein 
purified away from the MBP domain by repassage 


















remaining proteins to flow through the column. Purified hybrid 
is eluted from the column with 10 mM maltose and after removal 
of maltose, target protein is re~eased by digestion with FXa· 
MBP is then removed from solution.by passing it again over the 
amylose column. This strategy was used successfully to express 
both a bacterial ~-galactosidase and an invertebrate paramyosin 
gene and to purify the resultant proteins (Maina et al., 1988). 
3.3.2 Alteration of the N-terminus of synthetic ETI 
As the pMAL expression system has the potential to produce an 
N-terminus of choice, it was decided to alter the synthetic 
ETI gene to produce a Val-Leu-Leu amino terminus as occurs in 
natural ETI rather than the Met-Leu-Leu which was designed for 
expression in pBtac1. 
A unique Xbai (TCTGAG) site had been placed near the 5' end of 
the gene. Cutting at this site separated the Met-Leu-Leu coding 
sequence and a C from the coding strand of the synthetic ETI 
gene (see below). 
Met Leu Leu Asp Gly 
... GAATTC ATG CTT CTA GAC GGT .. . 
... CTTAAG TAC GAA GAT CTG CCA .. . 
I Xbai digestion 
.... 
. .. GAATTC ATG CTT CTA GAC GGT ... 
... CTTAAG TAC GAA GAT C TG CCA .•. 
The gap created was bridged by an. oligonucleotide carrying the 
sequence for an Xhoi restriction endonuclease site, the amino 
acids Val, Leu, Leu and a G to replace the G of the GAC codon 
for Asp which would otherwise be lost in the bridging: 
15 base 5'-arm Xhoi Val Leu Leu 15 base 3'-arm 
5'-AATTCATGCTTCTAG CTCGA GTT CTG CTG G ACGGTAACGGTGAAG-3' 
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.. GGGCTTAAGTACGAAGATC TGCCATTGCCACTTCAACA 
The altered plasmid, pLT8 .1 was screened for the unique Xhoi 
site introduced by bridge mutagenesis and the modified ETI gene 
sequenced as described earlier. 
The Xhoi site was introduced 5' to the ETI gene in pLT8.1 as it 
was absent in pLT8. In addition, the Xhoi site ends in a G 
which is the 1st base of the codon for Val and when the 
overhang after Xhoi digestion is removed, this leaves a coding 
sequence that begins with the codon for Val. These properties 
were utilized to remove ETI from pLT8.1 and to prepare it for 
insertion into pMAL-c. 
3.3.3 Construction of pMeti the pMAL-c/ETI fusion 
Plasmid pLT8.1 was digested firstly with Xhoi to linearize it 
and then with BamHI as there are two of these sites in pLT8.1 
(as discussed in Chapter 2.3). This releases an approximately 
550 base pair (bp) fragment which was gel purified and the 5' 
overhangs at each end of the gene-bearing fragment were removed 
by digestion with mung bean nuclease. This gave rise to a 
blunted DNA fragment bearing the gene for ETI. 
Xhoi Val Leu Leu Asp BamHI 
... TAGCTCGA GTT CTG CTG GAC .. ETI ... CAGGGATCCTGCATT .. . 
... ATCGAGCT CAA GAC GAC CTG .. ETI ... GTCCCTAGGACGTAA .. . 
I Xho! digestion 
T BamBI digestion 
... TAGC TCGAGTT CTG CTG GAC ... ·ETI ... CAGG GATCCTGCATT .. 
... ATCGAGCT CAA GAC GAC CTG ... ETI ... GTCCCTAG GACGTAA .. 
I Gel purification 
T Digest overhangs 
GTT CTG CTG GAC ... ETI ... CAGG 
CAA GAC GAC CAG ... ETI ... GTCC 
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The pMAL vectors have been designed with a Stui site which 
gives blunt ends and allows for cloning directly 3' to the 
sequence coding for FXa such that on cleavage with factor Xa no 
vector derived sequence is carried with the target protein. 
This site was used for cloning the blunt fragment carrying the 
ETI gene. As the fragment can be'cloned in either orientation 
or in more than one copy, to: characterize plasmids were 
digested with BstEII which has a single site in the vector and 
one in the ETI-coding sequence. The expected fragments of 
BstEII digestion are shown in Figure 3.5 
Clones selected by the initial BstEII screen were sequenced, 
using the ETI primers shown in Chapter 2.5 to ensure that the 
gene had remained intact. The clone selected was called pMETI 
and used for subsequent expression work. 
3.3.4 Expression of the fusion protein coded for by pMETI 
The plasmid pMETI was introduced into E. coli strain TBl by 
transformation and the stability of the plasmid in this host 
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(ii) :::>EETI'~E+i- ~~ 
l-----t>530 bp---j 
BstEII BstEII 
(iii) :::>Bwi~ffi~-m ~~ 
t-----'ooobp 1 
BstEII BstEII 
(iv) :::>8er1'~~-a.& ~~ 
Diagram showing possible band sizes · (sizes in 
base pairs) from BstEII digestion of putative 
clones of ETI in pMAL-c 
Predicted sizes of bands that would be removed 
from pMAL-c bearing a single copy of ETI. 
i) ETI in correct orientation for expression 
from the tac promoter removes a ± 2 500 
base pair band leaving a ± 4 100 bp band. 
ii) Incorrect o~ientation of ETI produces two 
bands of ± 2000 and 4 600 bp each. 
b) In addition to the above bands, the presence of 
one or more of the four bands shown here was 
used as an indicator of multiple ETI bands. 
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manner, a suitable transformant, TB1(pMETI), was selected for 
production of ETI. 
Expression was induced, as discussed in Chapter 6, by addition 
of IPTG to a mid log phase culture and incubating further to 
allow for accumulation of the fusion protein. Samples taken 
prior to induction and 3 hrs thereafter, were run with suitable 
controls on a 15% polyacrylamide gel and shown in Figure 3.6. 
The controls show no apparent accumulation of any protein in 
the host E. coli TB1 after induction (lanes 5, 6 and 7) . In 
addition, there appears to be no accumulation of any protein in 
TB1 ( pMETI) prior to induction (lane 2) as compared with the 
host lanes. This indicates that there is no apparent fusion 
protein synthesis from pMETI in TB1 prior to induction and that 
the repressor protein coded for py pMAL-c prevents detectable 
levels of expression from the t.ac promoter. However, 3 hrs 
after induction, TB1(pMAL-c), shown in lane 4, produced a heavy 
band which appeared to be slightly larger than the 45 kDa 
marker protein band of lane 1. Pure MBP, shown very faintly in 
lane 8, is a 42 kDa protein (Duplay et al., 1984) thus it was 
concluded that the large band of lane 4 was a fusion of MBP and 
the oc-fragment of 13-galactosidase. Lane 3 shows TB1 ( pMETI) 3 
hrs after induction, and here a dominant band has appeared 
which migrates slightly ahead of the 66 kDa marker band seen in 
lane 1. As MBP is a 42 kDa protein and ETI is approximately 20 
kDa, a fusion of these two woU:ld be expected to yield an 
approximately 62 kDa band on gel. electrophoresis. An MBP-ETI 
fusion would not be expected to include oc-fragment as the stop 
codon of ETI would prevent its inclusion during translation. 
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Figure 3.6 Expression of ETI-MBP fusion protein 
Lane 1) Protein molecular weight markers (kDa) 
2) TBl(pMETI) u~induced time Ohrs 
3) TB1(pMETI) induced time 3hrs 
4) TB1(pMAL-c) induced time 3hrs 
5) TB1 uninduced time Ohrs 
6) TB1 induced time 1hr 
7) TB1 induced time 3hrs 
8) ETI(natural) + MBP 
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represents about 25% of the total protein produced by this 
expression system. 
As was discussed previously, overproduction of a protein in 
E. coli often results in its being sequestered in inclusion 
bodies. Thus, before purification could be attempted, it was 
necessary to determine the state of the expressed fusion 
protein in the cytoplasm, ie to determine if it was soluble in 
the cytoplasm or if it had been sequestered in inclusion 
bodies. To do this the pellet was resuspended in a lysis buffer 
(see Chapter 6) containing tween and ~-mercaptoethanol and 
lysed by freeze-thawing and sonication. The cell debris was 
removed by centrifugation and a sample from the supernatant and 
the pellet was removed for analysis. The results are shown in 
Figure 3.7 from which it can be seen in lane 5 that under the 
conditions of cell lysis used for this work the fusion protein 
is soluble and located in the · supernatant. The insoluble 
fraction contains an insignificant amount of the fusion protein 
and is shown in lanes 6 and 7, and could be as a result of 
supernatant remaining with the pellet after cell lysis. 
A 1 litre culture of TB1 ( pMETI) was induced, lysed and the 
lysate purified on a column of cross-linked amylose and the 
eluate collected in 10 fractions. Aliquots from each fraction 
were pooled and a sample from each pool run on a gel. From 
Figure 3.8 it can be seen that pools 5 and 6 (lanes 6 and 7) 
appear to have the highest concentrations and purity of the 
fusion protein and it was decided to use the fractions from 
which these pools were derived. In addition to the fusion 
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Determination of location of the ETI-MBP 
fusionprotein after cell lysis 
Protein molecular weight markers (kDa) 
TB1(pMETI) induced time 3hrs 
TB1(pMETI) uninduced time Ohrs 
TB1(pMETI) induced time 3hrs 
TB1(pMETI) induced time 3hrs supernatant of 
lysed cells 
TB1(pMETI) induced time 3hrs solubilized 
pellet of lysed cells 
TB1(pMETI) induce.d time 3hrs pellet remaining 
from lane 6 
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Pooled eluates after affinity chromatography of 
partially purified TBl(pMETI) cell lysate 







TB1(pMETI) induced time 3hrs 
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believed that this band is a MBP-p-galactosidase-cx-fragment 
fusion produced by a subpopulation of the TB1 (pMETI)population 
that had lost the ETI gene. This band is also seen in the 
results presented by Maina et al.(1988). 
The selected fractions were 10 mM in maltose which had to be 
removed so that after cleavage with FXa, free ETI could be 
separated from free MBP by loading again on the cross-linked 
maltose resin. It was decided to remove the maltose from the 
pooled fractions by dialysis. Experiments with fluorescent 
spectroscopy have shown that the rate of dissociation of 
complex between maltose and MBP is high (Silhavy et al.,1975). 
Nonetheless, to ensure diffusion of maltose from the dialysis 
bag, it is essential to make the solution very dilute in MBP, 
thus the pooled fractions were diluted to 400ml with 10 mM Tris 
(pH 8), 100 mM NaCl giving a concentration of about 80 pg/ml. 
This was dialyzed against 40L of 10 mM Tris (pH 8), 100 mM NaCl 
with 6 changes over 24hrs at 4°C.The dialysate was concentrated 
to 15 ml with a millipore immersible CX-30 ultrafilter. The 
concentrate was dialysed against 1 L of FXa buffer for 24hrs 
with 3 changes of buffer at 4°C. A 50 pl sample was taken and 
incubated at a constant 22°C for 24 hrs with 2.5 pl of 200pg/ml 
FXa (ie in this instance FXa was used at a w/w ratio of 1% the 
amount of fusion protein). Samples were taken for 
electrophoresis and shown in Figure 3.9. However it was 
apparent from this gel that incubation with FXa even for 24hrs 
(lanes 3-6) did not cleave the E.TI-MBP fusion protein at the 
FXa recognition site to release .a band that comigrated with 
ETI(natural) in lane 2. Nonetheless, some cleavage had occurred 
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Attempt to cleave ETI-MBP fusion protein with 
factor Xa 
























after 4 hrs of digestion and had migrated slightly ahead of the 
± 45 kDa MBP-/3-galactosidase-oc-fragment band. After 8 hrs of 
digestion (lane 5) this band had increased in intensity and 
another faint band appeared at approximately 50 kDa, between 
the above mentioned ± 45 kDa band and the fusion protein and 
these increased further in intens~ty in the 24 hr sample (lane 
6). In addition, the 24 hr sample gave rise to an extremely 
faint band that migrated at about 14 kDa. 
It was postulated that the MBP-p-galactosidase-oc-fragment 
fusion protein was cleaved slowly, freeing MBP ( 42 kDa) and 
gave rise to the band that migrated slightly ahead of 45 kDa. 
The smaller p-galactosidase-oc-fragment was believed to either 
have run off this gel or to be too dilute to be discerned under 
the conditions in which this gel was run. 
The appearance of the ± 50 kDa protein after 8 hrs of digestion 
and the appearance of the approximately 14 kDa band in the 24 
hr sample suggest that some cleavage of the MBP-ETI fusion 
protein had occurred. MBP does not contain the sequence Ile-
Glu-Gly-Arg required for FXa cleavage (Maina et ,al., 1988; 
Duplay et al., 1984). However, Lauritzen et al. (in press, from 
the abstract) produced bovine pancreatic trypsin inhibitor 
(BPTI) extended at the N-terminus by 6 amino acids, N-Gly-Ser-
Ile-Glu-Gly-Arg after expression from a pMAL vector and 
cleavage . with FXa. This indicated that FXa had recognized an 
alternative site at the C-terminus of MBP, possibly under the 
influence of the cloned sequence. Such a cleavage was not 
suspected in this case however, as it would have given rise to 
cleavage products of which one would be larger but closer in 
I 
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size to ETI than any band produced in this digest. Thus, it was 
concluded that cleavage was taking place in the ETI domain of 
the fusion protein. 
That no ETI sized fragment was produced even after 24hrs of 
digestion indicated that, for .this fusion protein, FXa could 
not recognize or contact its recognition site between the MBP 
and ETI domains. There were two possible explanations for the 
inability of FXa to separate the two domains: 
1) The fusion had adopted a secondary structure that obscured 
the FXa recognition site from this enzyme. Furthermore, 
the structure adopted left exposed an ETI sequence Ile-
Glu-Ser-Arg that·starts at residue 58 (see Figure 2.1) and 
could offer a cleavage site for FXa. Further examination 
of the sequence of ETI revealed that cleavage at this 
putative FXa site within the ETI domain of the MBP-ETI 
fusion would give a product of approximately 14 kDa 
leaving a fragment of about 50 kDa. At the time of choice 
of this expression vector it was believed that the true 
Fxa cleavage site supplied by pMAL-c would be used in 
preference to the partial site within ETI. 
2) As discussed earlier, FXa is a serine protease and ETI is 
an inhibitor of serine proteases, known to inhibit 
trypsin, chymotrypsin and plasminogen activator. 
Furthermore, in many cases the inhibitor functions as a 
substrate for the enzyme and under appropriate conditions 
of time, pH and relative concentrations of inhibitor and 
enzyme, inhibitor can be cleaved at a single scissile bond 
situated at its reactive site. For ETI, the scissile bond 




this bond in the MBP-ETI fusion will also produce two 
bands of about 14 and 50 kDa each. However, in order to 
inhibit FXa in this way, ETI must have folded into a 
structure approximating that of natural ETI. When choosing 
this expression vector it was reasoned that being part of 
a fusion protein of which it represents one third would 
prevent ETI from folding into its correct structure. In 
addition, the choice of the cytoplasm (rather than the 
periplasm) as the site of accumulation of the expressed 
protein was made to limit the ability of the protein to 
form disulphide bridges and further prevent it from 
inhibiting FXa. 
Examining the first possibility required that the fusion 
protein be denatured in an effort to expose the FXa recognition 
site. To this end, samples of the purified fusion were 
dialysed, as suggested by NEB, ag~inst 100 volumes of 20mM Tris 
(pH 8), 6M guanidine hydrochloride or against 6M urea for 4 hrs 
at room temperature. To remove denaturant and prepare for 
digestion they were then dialysed against 2X 100 volumes of FXa 
buffer for 4 hrs each. Thereafter, the samples were digested 
using FXa at 1% and at 3% of the total protein conc,fantration. 
The results for guanidine hydrochloride as denaturant are shown 
in Figure 3.10, from which it can be seen that at all time 
intervals sampled, 3% FXa has given increased digestion over 
that produced by the 1% FXa recommended by NEB. In addition, 
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Further attempt to cleave ETI-MBP fusion protein 
after denaturation with guanidine hydrochloride 
ETI-MBP fusion protein after affinity 
purification and concentration + ETI 
ETI-MBP digested with FXa (3%) for 4hrs 
ETI-MBP digested with FXa (1%) for 4hrs 
ETI-MBP digested with FXa (3%) for 8hrs 
ETI-MBP digested with FXa (1%) for 8hrs 
ETI-MBP digested with FXa (3%) for 24hrs 
ETI-MBP digested with FXa (1%) for 24hrs 
ETI-MBP control with no FXa for 24hrs 
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FXa. This increased markedly after 24 hrs by which time an 
extremely faint band that comigrated with ETI appeared. From 
this it seemed, that upon dialysis against FXa buffer, most of 
the protein had regained the structure that shielded FXa from 
its recognition site and allowed for the formation of the ±14 
kDa fragment. 
The next step was to determine whether ETI was cleaved on 
interaction with FXa and by implication that it inhibits also 
this protease. The approach used was to incubate purified 
natural ETI with FXa at 3% of the total protein and under the 
same conditions that had been used in the attempt to cleave the 
fusion protease. A sample of this was used for electrophoresis 
and is shown in Figure 3.11 . In lane 2 of this gel, digested 
ETI had produced a band of much the same size as seen on 
digestion of the fusion protein. The remainder of the reaction 
mix was then used to determine tbe sequence of the N-terminus 
of ETI and any cleavage products . of ETI in the solution. The 
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Determination of effect of FXa on ETI(natural) 
Protein molecular weight markers + ETI (natural) 










cycle PTH YIELD 
amino acid (pmoles) 
1 Val 104 
2 Leu 171 
3 Leu 184 
4 Asp 48 
5 Gly 90 
b) 
cycle PTH YIELD 
amino acid (pmoles) 
1 Ser 47 
2 Ala 117 
3 Phe 94 
4 Ile 31 
5 Pro 95 
Table 3.1 Results of automatic sequencing of the products of 
FXa digestion of purified natural ETI. The amino acid 
residues that produce·the two largest peaks and their 
yields are reported. 
a) The sequence that could be aligned with the 
known sequence for ETI. 
b) The second sequence which appeared concomitantly 
with that shown in a. 
As ETI was seen in Figure 3.11 to be cleaved on reaction with 
FXa two N-terminii were expected in the sequence. As these had 
not been purified from each other, each sequencing cycle had to 
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produce pheny1-thio-hydantoin (PTH) derivatives of sequential 
amino acids of each chain. Thus, for each cycle, the two 
highest yielding residues were recorded and one matched with 
the known N-terminal sequence of ETI. The second sequence was 
aligned with a sequence within ETI (see Figure 2.1). In this 
way it was found that the second sequence started at what was 
residue 64 in the sequence of ETI. This indicates that ETI has 
been cleaved at the scissile bond between Arg63 and Ser64 of 
ETI and hence that ETI is an inhibitor of FXa and suggests that 
conditions of pH and inhibitor:enzyme ratio in the digest are 
conducive to cleavage of the inhibitor. 
To understand the varying yields of the PTH-amino acids shown 
in Tables 3.1 a) and b), it is necessary to describe briefly 
the stepwise degradation of proteins by the method of Edman 
which was used in this sequencing reaction. To prepare the N-
terminal amino acid for removal from the protein, phenyl-iso-
thio-cyanate (PITC) is coupled to its ~-amino group to produce 
a phenyl-thio-carbamyl-peptide (FTC-peptide) . The PTC peptide 
bond is cleaved by causing the N-terminal PTC-amino acid to 
cyclize under acid conditions producing an anilino-thiazolinone 
(ATZ) derivative of the amino acid. The ATZ-amino acids are 
unstable and are converted to PTH-amino acids usually by 
heating to 80°C. It is at the stage of conversion of ATZ-amino 
acids to PTH-amino acids where much of the problem arises; some 
PTH-amino acids tend to decompose during the conversion and 
decrease the yield of those amino acids (Han et al., 1985). 
3.3.5 Discussion 143 
The need ~o produce forms of ETI with specified N-termini has 
been discussed but it is clear that this requires a specialized 
expression system. It was primarily for this reason that the 
pMAL expression system was chosen to express the ETI-encoding 
gene. The system provides a leader sequence in the form of MBP 
which it was reasoned would protect the expressed ETI from 
degradation. 
A drawback to the use of this system is that FXa is used to 
separate ETI from MBP to which it is fused. FXa is a serine 
protease much like trypsin and tPA and could be inhibited by 
ETI. In addition, ETI has a sequence of residues 58 to 62 that 
is remarkably similar to the FXa recognition site. It was 
reasoned that if both sites were equally available to FXa it 
would be more likely to utilize its precise recognition site in 
preference to the partial site in ETI. Furthermore, it was 
reasoned that as ETI contributed only about one third of the 
mass of the fusion protein it would not fold to the correct 
conformation to inhibit FXa. If on the other hand it did fold 
correctly the MBP at the N-terminus of ETI was predicted to 
prevent it from binding to arid inhibiting FXa. Finally, 
Lauritzen et al. (1991) had been able to produce active bovine 
trypsin inhibitor (BTI), although with an altered N-terminus, 
using the pMAL expression and purification system. Considering 
the fact that BTI is also a serine protease inhibitor, it was 
considered that this would be an ideal system for the 
expression and facile purification of ETI. 
While it was shown that good expression levels of the fusion 
protein were achieved, FXa was unable to cleave at its 
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recognition site and free ETI from the fusion. Possible reasons 
for this were that FXa could not reach its recognition site 
because of the structure adopted by the fusion protein or that 
ETI was in fact inhibiting FXa. To examine the first 
possibility, the fusion protein was denatured and incubated 
with FXa but no ETI sized cleavage product was produced. All 
attempts to cleave the fusion produced amongst others a ± 14 
kDa fragment.- A band of the same size was seen when purified 
natural ETI was incubated with FXa which indicated that ETI 
does inhibit FXa. This was confirmed on sequencing the amino-
terminii of the products of incubation of pure natural ETI with 
FXa. 
Thus the evidence indicated that the ETI domain of the ETI-MBP 
fusion protein was able to inhibit FXa. Taking into account 
that ETI has MBP attached to its N-terminus indicates that the 
kinetics of interaction in this case are different from that of 
ETI with trypsin or tPA. 
That ETI could have attained the structure required for 
activity after being expressed in the cytoplasm where 
disulphide bridges are reputed t_o be unable to form can be 
explained by the methods used for purification. In addition to 
extensive exposure to air, the fusion was exposed to lysis 
buffer containing /3-mercaptoethanol and tween and at a later 
stage after other purification steps it was diluted several-
fold and dialysed against a buffer which was conducive to 
folding. 
3.4 Expression of two forms of synthetic ETI in the pET 
expression system 
3.4.1 The pET expression system 
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The pET expression system developed by Tabor and Richardson 
( 1985) and Studier and Moffatt ( 1986) involves a number of 
vectors into one of which the target gene for expression is 
cloned under control of a promoter of bacteriophage T7 . RNA 
polymerase of T7 in turn is supplied in a controlled manner by 
one of a number of E.coli hosts developed for this purpose. 
There are 17 known promoters in the genome of bacteriophage T7 
and these have a highly conserved sequence of 23 continuous 
base pairs starting from -17 to +6 relative to the start site 
of the RNA chain (Dunn and Studier, 1983). Individual promoters 
are identified by a ¢ followed by the number of the gene first 
transcribed from the promoter, except for ¢0L and ¢0L, which 
are thought to be parts of the replication origins loc~ted near 
the left and right ends of the DNA (Dunn and Studier, 1981). 
Assays of these promoters in vivo and in vitro show that all 17 
are utilized by T7 polymerase . to. a greater or lesser degree 
(Golomb and Chamberlin, 1974). ·One of these promoters ¢10 
(shown in Figure 3.12) is utilized in all of the pET expression 





¢3.8 promoter CGTGGATAAT.TAATTGAACTCACTAAAGGGAGA CC 
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Figure 3.12 Promoters ¢10, used in the pET expression 
system, ¢3.8, an example of a classii promoter 
and the 23 base pair conserved sequence (from 
Dunn and Studier, 1983) . Within the conserved 
sequence, bold type indicates nucleotides that 
are unchanged in the conserved region of all 17 
promoters. Within the ¢3. 8 sequence, bold type 
indicates nucleotides that are different from 
the conserved · sequence. In all sequences, + 1, 
the first nucleotide of the RNA chain, is 
underlined. In addition, spaces separate the 
conserved region from the rest of the sequence. 
The promoters for T7 RNA pol~erase in T7 DNA have been 
classified into three groups viz, .class II, III and replication 
promoters based on their location, utilization and nucleotide 
sequence (Dunn and Studier, 1983). The five class III promoters 
to which ¢10 belongs, appear to be the strongest in vitro and 
in vivo and all have the same 23 base pair conserved sequence 
located at positions -17 to +6 (Golomb and Chamberlin, 1974). 
The class II promoters, all of which appear to be weaker than 
class III promoters, are different at a number of positions in 
the -17 to +6 region from class III promoters (Saito et al., 
1980). 
The conserved sequence required to make a T7 promoter is of 
sufficient length to make unlikely its occurrence by chance in 
any DNA unrelated to T7 DNA. Furthermore, no such promoters are 
known to exist in the DNA of E. coli, the natural host of 
bacteriophage T7, which favours transcription of viral rather 
than host genes during infection (Studier and Moffatt, 1986). 
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The RNA polymerase of bacterioph~ge T7, the product of viral 
gene 1, is a single subunit ·pr~tein of 10.7 kDa molecular 
weight and it exhibits in vivo and in vitro, almost absolute 
specificity for T7 promoters. In addition, T7 RNA polymerase 
initiates RNA chains efficiently and is a very active enzyme 
which elongates chains about five times faster than does E.coli 
RNA polymerase (Golomb and Chamberlin, 1974; Davanloo et al., 
1984). Furthermore, its progress along a DNA strand appears to 
be stopped, albeit inefficiently, by the only T7 terminator, ~T 
and its progress appears to be unhindered by the factors that 
cause termination of transcription by E. coli RNA polymerase 
(Carteret al., 1981). Therefore, T7 RNA polymerase should be 
able to produce complete transcripts from almost any DNA that 
is linked to a T7 promoter (Studier and Moffatt, 1986). 
3.4.1.1 The pET expression vectors 
These vectors contain the strong ~10 promoter and the efficient 
translation initiation signals for gene 10 inserted into the 
/ 
BamHI site of the multicopy plasmid pBR322 oriented such that 
the bla gene is expressed from the T7 promoter along with the 
target gene (Tabor and Richardson, 1985). There are a number of 
differences between the various pET expression vectors. The one 
chosen for this work, specifically for its ability to direct 
export of the expressed protein to the periplasm, was pET12a 
(Fig 3.13). 
Each of the three pET12 vectors has a unique BamHI in a 
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BamHI Sal I start BgiiJ 
omp T leader Initiation 
pET 12a 
4674 bp 
Map of pET 12a. 
This contains the .T7 q,lO promoter, translation 
initiation signals of T7 gene 10 inserted into 
pBR322 such that a,mpicillin resistance gene is 
expressed . from the T7 promoter. Downstream of 
the T7 casette is cloned a T7 DNA fragment 
bearing the Tq, terminator. 
The ompT peptide starts with Met and ends with 
the Ala at the Sali site. The leader peptide is 
cleaved on transport to the periplasm between 
this Ala and the Ser which follows. 
149 
suffix a, b, or c indicates whether the GGA, GAT or ATC triplet 
of the BamHI site is in the open reading frame. These vectors 
produce a fusion protein consisting of 22 amino acids of the 
outer membrane protein specified by ompT of E.coli attached to 
the N-terminus of the target protein. The ompT leader peptide 
directs transport of the protein into the periplasm and is 
itself removed in the process. In addition, these vectors 
contain the T¢ transcription terminator of T7 (Rosenberg et 
al., 1987; Grodberg et al., 1988). 
3.4.1.2 Hosts for expression from pET vectors 
The two hosts commonly used for pET expression are the E.coli 
K12 strain HMS174 (F- recA r-k 12in+ kl 2 RifR) and the B strain 
BL21 (F- ompr r-Bm-B). BL21 is deficient in the lon and the 
ompT proteases that can degrade proteins during purification 
and for this reason was chosen as the host for production of 
ETI (Studier et al., 1990). 
To deliver T7 RNA polymerase to the cell, Studier and Moffatt 
(1986) established a DE3 lysogen in the host. Bacteriophage DE3 
is a ~ derivative that carries inter alia the laci gene, the 
lacuv5 promoter, the beginning of the lacz gene and the gene 
for T7 RNA polymerase. Once the lysogen is formed, T7 RNA 
polymerase is transcribed from· the lacUVS promoter which 
requires IPTG induction because :of the presence of the laci 
gene. In the resulting mRNA, T7 polymerase has its own 
transcription start site and hence is not produced as a fusion 
with the product of the beginning of the lacz gene. Thus, 










HMS174(DE3) induces the T7 RNA polymerase, which in turn 
transcribes the target DNA in the plasmid . 
. 
However, the basal level of T7 RNA polymerase activity promotes 
some transcription of the target gene in the uninduced cell. As 
a result, some genes whose products . are sufficiently toxic 
cannot be established in BL21(DE3) or HMS174(DE3). A method of 
reducing the basal activity of the polymerase is to supply the 
cell with T7 lysozyme a natural inhibitor of T7 RNA polymerase 
(Moffatt and Studier, 1987). 
T7 lysozyme binds to T7 RNA polymerase and prevents 
transcription. However, it also degrades the peptidoglycan 
layer of the E. coli cell wall ·but appears unable to pass 
through the cell membrane to reach this layer. Lysozyme is 
provided to the cell from a clone of the T7 lysozyme gene in 
the plasmid pACYC184. A plasmid having this gene oriented to be 
expressed from the tet promoter of pACYC184 is referred to as 
pLysE; cells carrying this plasmid accumulate substantial 
levels of lysozyme. When the gene is in the opposite 
orientation it is known as pLysS and cells carrying this 
plasmid accumulate much lower levels of lysozyme. Neither 
lysozyme plasmid interferes with transformation of pET vectors 
in cells that carry it. Nonetheless, they do slow the growth 
rate of their host cells, pLysE to a much greater extent than 
pLysS but their presence is necessary to increase tolerance to 
toxic gene products and to stabilize unstable plasmids (Studier 
et al., 1990). 
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The pET expression system has been successfully used by a 
number of workers to express a variety of genes. For example, 
Freedman et al. (1988) produced a·150 amino acid glucocorticoid 
receptor fragment in E. coli using· the T7 system. Their yield, 
after purification, was 2 mg/L of starting material. 
Wheat high molecular weight (WHM) glutenin was expressed in 
BL21(DE3)pLysS from pET3a at high yields (no data supplied), 
where other expression systems had yielded no WHM glutenin due 
to the toxicity of this protein to E.coli cells (Galili, 1989). 
A further example of expression of toxic gene products was 
described by Sano and Cantor (1990), where they expressed the 
extremely lethal streptavidin gene in BL21 (DE3 )pLysE with a 
yield of 39-65 mg/L of culture .. In contrast, procathepsin D 
which is not toxic to E.coli, was .produced from pET3a using the 
basal level activity of T7 RNA polymerase in BL21(DE3) (Conner 
and Udey, 1990). Thus it was decided to use the pET e~pression 
system to produce forms of ETI that could be further 
manipulated to achieve a desired N-terminus. 
3.4.1.3 Proposed reconstruction of the synthetic gene for ETI 
It has been established that ETI has a structured N-terminal 
region stabilized by hydrogen and hydrophobic interactions. The 
N-terminal region lies in close p~oximity to the protease when 
E'l'I is in complex with trypsin ·or. tPA. Ideally it was required 
that the expressed ETI have the same sequence, including the N-
terminal Val, as natural ETI in order to produce a protein with 
the same activity as natural ETI. 
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STI is v~ry similar to ETI in its sequence and structure (as 
described in Chapter 1) and has an N-terminal region structured 
much like that of ETI. One diffe~ence between the two regions 
is that STI has an Asp N-terminal residue. It has been 
hypothesized that because of the sequence homology of ETI and 
STI and the hydrophilic nature of Asp it is not incorporated 
into the structure of the STI N-terminus. This leaves the 
residue free to form an ion pair with Lys60 of trypsin but 
interferes with the interaction of STI and tPA. One of the aims 
of this work was to add an Asp residue to the N-terminus of ETI 
to make it like STI in this region to investigate the 
abovementioned hypothesis. Thus there was a need to produce two 
forms of ETI differing in only their N-terminal residues. 
Direct expression (ie. with no leader sequence) of the ETI-
encoding gene was shown to be unsuccessful (Chapter 3. 2). It 
was then attempted to express the gene as part of a fusion 
protein with MBP which produced good yields . However, FXa 
appears to be inhibited by ETI and cannot cleave the MBP-ETI 
fusion (Chapter 3.3). Nonetheless, this exercise indicated the 
need for a leader sequence to assist in the expression of the 
ETI-encoding gene. It also showed that ETI may inhibit other 
serine proteases that would cleave it from leader sequences to 
which it could be fused. The pET12 series of vectors supply a 
leader sequence in the form of a signal sequence for export to 
the periplasm but the signal sequence cleavage system of E.coli 
leaves these proteins with anN-terminal Ser (Rosenberg et al., 
1987; Studier et al., 1990). While this may have been suitable 
to make ETI that functions as the natural form of the protein 
it could not be used to produce ETI with an Asp N-terminal 
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residue. As ETI has no internal Met, it was decided to modify 
the 5' end of the synthetic gene to generate ETI with an N-Ser-
Met-Val ... N-terminal region which can be cleaved in 70% formic 
acid, by CNBr, between Met and Val leaving ETI with the natural 
Val N-terminus (Gross, 1967; Boyot et al., 1990). 
To add an Asp residue to the N-terminus of ETI, the same 
approach was used and the 5' end of the synthetic gene modified 
to produce Asp between Met and Val in the sequence above. The 
resultant protein could be cleaved with CNBr to produce a 
variant ETI possessing an Asp residue at its N-terminus. 
3.4.2 Reconstruction of the 5' end of the synthetic ETI gene 
The plasmid pLT8 was cleaved with Xbai and the gap bridged (in 
the manner discussed in Chapter 2.3.2) with one of twb 
oligonucleotides: oligo- Val which introduces an Mlui 
restriction site and amino acid residues Ser, Met and Val in 
that order, or oligo-Asp which introduces an Asp residue 
between Met and Val to the above order. The resultant plasmids', 
called pLT8.val and pLT8.asp, respectively were each digested 
firstly with Mlui to linearize the plasmid and then with BamHI 
to remove the ETI gene. 
The ETI gene-bearing fragment was gel purified and the 
overhangs resulting from the Mlui and BamHI digests were 
removed by digestion with mung bean nuclease. This gave rise to 
two blunt ended fragments carrying the gene for ETI both of 
which start at their 5' ends with the codon for Ser.Success in 







determined by initially establishing the presence of the Mlui 
site and then by sequencing. 
3.4.3 Construction of pET 12a/ETI fusions 
Plasmid pET12a was digested with Sali which cuts between Ala 
and Ser codons at the end of the ompT coding sequence shown in 
f 
Figure 3.13. The Sal! overhangs were removed from ~the 
linearized plasmid with mung bean nuclease to produce a 
linearized blunt ended plasmid which had lost the coding 
sequence for Ser required by signal peptidase to cleave off the 
ompT leader peptide on export to the periplasm. To this was 
ligated one of the blunt ended ETI-carrying fragments described 
above. In the correct orientation, the ETI fragment supplied 
the Ser codon lost on blunt ending linearized pET12a. Initially 
the ligation of a single insert and its orientation was 
determined by restriction digests and this was confirmed by 
sequencing the selected clones. Sequencing primers used to 
prime outside the ETI sequence were synthesized for the purpose 
and called pET12a.F01 of sequence: 5'-CCTAGGAATAGTCCTG-3' which 
primes ± 30 base pairs 3' of the Sal! site in pET12a and 
pET12a. RO 1 of sequence: 5 1 -GCTCAGCGGTGGCAGC-3 1 which primes 
about 50 base pairs 5 1 of the Sal I site in pET12a. Internal 
primers used for this sequencing are those used for sequencing 
ETI as discussed previously. The two clones of confirmed 
sequence were called pPETI .1 fro~ oligo-Val ( ie the sequence 
required to produce natural ETI. sequence) and pPETI. 2 from 










3.4.4 Determination of the appropriate strain for expression 
To test for toxicity of the expression product of pPETI.l and 
2, pET expression host strains were transformed with equivalent 
amounts of the two plasmids. The results are shown in Table 
3. 1. If one or both forms of ETI. were innocuous to the hosts 
all seven strains would transform with equal frequency. At some 
level of toxicity, the DE3 lysogens (where the basal level of 
T7 lysogen is highest) would fail to be transformed while the 
lysogen containing pLysS would transform at the same frequency 
as the parental host. At higher levels of toxicity, even pLysS 
lysogens would not transform and pLysE lysogens may be needed. 
# Transformants per 
PLASMID * 
STRAIN pPETI.1 pPETI.2 
HMS174 200 155 
HMS174(DE3) 0 5 
HMS174(DE3)pLysS 195 150 
HMS174(DE3)pLysE 198 154 
BL21 201 156 
BL21(DE3) 1 0 
BL2l(DE3)pLysS 200 160 
Table 3.1 Numbers of transformants per pET expression strain 
for ETI plasmids pPETI . 1 and pPETI. 2 in order to 
determine stability of the plasmids in these strains. 
* Numbers reported above are the average for three 
transformations. 
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The results shown in Table 3.1 indicate that the product of 
both plasmids was somewhat toxic to the E. coli hosts as both 
plasmids failed to transform DE3 lysogens. It may be that it is 
not ETI itself but the large volume of mRNA or expressed 
product that is harmful to the cells. However, it was clear 
that T7 lysozyme would be required to dampen the basal activity 
of T7 polymerase and that a pLysS lysogen could be used as 
these gave equivalent numbers of transformants to pLysE 
lysogens. Nonetheless, there was no clear indication from these 
results as to which strain, E.coli HMS174 or BL21 would be best 
for this work. To answer this question, HMS174(DE3)pLysS, pLysE 
and BL21(DE3)pLysS were transformed with pPETI.1 and grown in 
20 ml liquid cultures and induced at the appropriate time. 
Samples taken just prior to and 3 hrs after induction were 
lysed and subjected to electrophoresis and the results shown in 
Figure 3.14. 
Examination of lanes 2, 3 arid . 4 of Figure 3.14 shows an 
accumulation of two bands in each of these' in comparison with 
lane 5, the uninduced BL21(DE3)pLysS. The lower of the two 
bands comigrates with natural ETI and it was concluded that 
this represents full length ETI from which the signal sequence 
had been cleaved. The slower of the two bands was. believed to 
be ETI plus the secretion signal sequence. In lanes 2 and 4 
this upper band is the heavier of the two which indicates that 
the cell's export machinery is unable to cope with the rate of 
production of the protein. Similar sample volumes were 
collected for the three cultures ~hown in Figure 3.14 and each 
was treated in the same manner and similar volumes added to 







2 3 4 5 
Determination of stability of pPETI.1 in 
different hosts. 
Purified natural ETI 
E.coli HMS174(DE3)pLysS(pPETI.l) 









contains a greater amount of both forms of ETI than either of 
the other two lanes indicated that BL21(DE3)pLysS is the most 
suitable host for expression of the ETI gene of pPETI.1. 
To confirm the ability of this host to express the ETI-
encoding gene of pPETI.2 a culture of BL21(DE3)pLysS(pPETI.2) 
was grown and induced along · with the pPETI.1 containing 
BL21(DE3)pLysS strain described above. Samples were taken and 
processed as described before and electrophoresed, the results 
of this are shown in Figure 3.15. From lane 3 of this gel it is 
clear that asp-ETI, the product of the ETI gene of pPETI.2 is 
produced to much the same level as val-ETI, the product of 
pPETI.1 (lane 5). No asp-ETI or val-ETI is produced prior to 
induction as can be seen in lanes 2 and 4. In addition, both 
forms of asp-ETI (lane 3) migrate slightly ahead of the two 
val-ETI bands (lane 5) and was accredited to the increased 
negative charge of asp-ETI which is contributed by the Asp 
residue. 
3.4.5 Expression, cleavage and purification of ETI from 
pPETI.l and pPETI.2 
Large scale cultures (1 litre) of pPETI.1, pPETI.2 and pET 12a 
containing strains were grown, the cells harvested and 
sphaeroplasted to release the periplasmic proteins which were 
collected in a final volume of 240 ml of sphaeroplasting 
solution. The pET12a containing strain was included as a 
control for background inhibitor activity. To concentrate the 
periplasmic proteins, the solution was 80% saturated with 
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centrifugation. The pellet was resuspended in sterile distilled 
water ( sddw) and the ( NH4 ) 2so4 removed by dialysis. A light 
precipitate was formed after about 24 hrs of dialysis and was 
removed by centrifugation for later examination. The cleared 
dialysate was freeze-dried and resuspended in 3 ml of saline 
from which samples were taken for PAGE electrophoresis The 
results of this are shown in Figure 3.16. 
Figure 3.16 shows that ETI has been recovered and is to be 
found in the cleared dialysate (lanes 3 and 5). There is very 
little of either form of ETI found in the precipitate that 
forms on extended dialysis. From the samples of this 
precipitate that were run (lanes 2, ~and 6), it is clear that 
a number of contaminating proteins have been removed from the 
solution when comparing these with samples of the cleared 
dialysate (lanes 3, 5 and 7). 
Cleared dialysate derived from ·pPETI.1, pPETI.2 and pET12a 
carrying strains as described ab<;>ve, was incubated with CNBr 
under the appropriate conditions to induce cleavage at the 
carboxy-side of Met residues. After the required period for 
cleavage, the solution was diluted, freeze-dried and 
redissolved in 4 ml of 100 mM Tris pHS. Each was loaded onto a 
Sephadex GSO column and eluted with 100mM Tris pHS. Fractions 
were collected and the presence of the respective ETI 
established by PAGE and these were pooled (equivalent fractions 
of the control were also pooled), freeze-dried and redissolved 
in 100mM Tris at approximately 4 mg/ml in a total of 250 pl for 
ETI solutions and 50 pl for the · control. From more accurate 
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Examination of the fractions collected during 
precipitation and dialysis of periplasmic 
proteins of BL2l(DE3)pLysS(pPETI.l and .2). 
Purified natural ETI 
Pellet of precipitate formed on dialysis 
pPETI.2 strain 
Cleared dialysate - pPETI.2 carrying strain 
Pellet of precipitate formed on dialysis 
pPETI.l strain 
Cleared dialysate - pPETI.l carrying strain 
Pellet of precipitate formed on dialysis 
BL2l(DE3)pLysS(pET 12a) control 
Cleared dialysate . - BL2l(DE3)pLysS(pET 12a) 
control 
Purified natural ETI 
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that the concentration of protein in val-ETI, asp-ETI and 
control solutions was 3.64, 4.32 and 4.4 mg/ml respectively. A 
1pl sample of asp-ETI, a 1.5 pl sample of val-ETI and 15 pl of 
control was run on the gel shown in Figure 3.17. 
Lanes 5 and 7 of this gel suggest that the upper bands seen in 
the uncleaved supernatant material (lanes 4 and 6) have been 
removed. This may be as result of . CNBr cleavage having reduced 
them to a small enough size to be separated from ETI on gel 
exclusion chromatography. Lane 3 was loaded with cleaved and 
treated control and appears to have lost most bands seen in 
lane 2, the untreated control material. This indicates that a 
great deal of contaminating host and vector proteins that have 
coprecipitated with ETI appear to be removed by CNBr cleavage 
followed by gel exclusion chromatography. 
In addition, there is no apparent difference in migration 
between cleaved and uncleaved ETI of both forms to be seen in 
Figure 3.17, even though CNBr cleavage removes two amino acids 
from the protein. This was to be expected as 15% PAGE will not 
show such a small difference in size and this can be seen in 
the closeness of the bands produced by ETI with and without its 
signal sequence as seen in Figures 3.14 and 3.15. 
In an effort to confirm that the bands seen in Figures 3.14 and 
3 .15 were correctly identified as ETI and ETI with signal 
sequence , western blots were performed. These compared natural 
ETI, total lysates of BL21(DE3)pLysS(pPETI.l and .2) and 
cleaved product of cleared dialysates of pPETI.l, .2 and pET12a 
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Examination of products of CNBr cleavage of 
proteins expressed from pPETI.l and .2 carrying 
BL21(DE3)pLysS. 
Purified natural ETI 
Cleared dialysate BL21(DE3)pLysS(pET12a) 
control 
Cleaved product of BL21(DE3)pLysS(pET12a) 
cleared dialysate 
Cleared dialysate - pPETI.2 carrying strain 
Cleaved product of pPETI.2 cleared dialysate 
Cleared dialysate - pPETI.1 carrying strain 
Cleaved product of .pPETI.1 cleared dialysate 
Purified natural . ETI 
a) 
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1) Purified natural ETI 
2) Total lysate of BL21(DE3)pLysS(pPETI.2) 
3) Cleaved product of cleared dialysate of pPETI.2 stra· 
4) ---------------- do ------------------ control strain 
1) Purified natural ETI 
2) Total lysate of BL2l(DE3)pLysS(pPETI.1) 
3) Cleaved product of cleared dialysate of pPETI.l strain 




anti-ETI antibodies raised against purified natural ETI 
(Figures 3.18a and b) which cross react with purified natural 
ETI to produce a single band in lane 1. In addition, these 
antibodies reacted with total lysate of BL21(DE3)pLysS(pPETI.1 
and .2) in lane 2 of both gels to produce two main bands. The 
upper band of this doublet in both gels appears in the same 
position relative to the lower as seen in PAGE (Figures 3.14 
and 3.15) and its cross reactivity with these antibodies 
confirms it to be ETI with the· 20 amino acid ompT signal 
sequence. Lanes 2 also carry two faint high molecular weight 
bands which are believed to be doublets of the two lower bands. 
Lane 3 of both gels a and b contains asp-ETI and val-ET! 
respectively and a faint single high molecular weight band that 
comigrates with the lower of the faint doublet of lanes 2 and 
is believed to be a doublet of the respective ETI form. 
Finally, lane 4 contains cleared dialysate of the control which 
can be seen to contain no proteins that cross react with the 
antibodies. 
To ensure that CNBr cleavage had produced the required N-
terminus of both ETI species, a sample of each ( 5 .ul) was 
partially sequenced to determine the first five residues of the 





cycle PTH YIELD 
amino acid (pmoles) 
1 Val 173 
2 Leu 148 
3 Leu 145 
4 Asp 73 
5 Gly 103 
b) 
cycle PTH .YIELD 
amino acid . (pmoles) 
1 Asp 149 
2 Val 147 
3 Leu 148 
4 Leu 125 
5 Asp 93 
Table 3.3 Results of automatic sequencing of a) val-ETI and b) 
asp-ETI. Tables show amino acid residue that produces 
the largest peak in each cycle and the yield for that 
peak. 
The partial amino acid sequence of cleaved product of cleared 
dialysate of BL21(DE3)pLysS(pPETI.1) and BL21(DE3)pLysS 
(pPETI.2) is shown in Table 3.3 a and b respectively. The amino 
acid residue with the highest yield in each cycle was accepted 
as the residue to be found at that position, with respect to 
the N-terminus, of the particular ETI under investigation. The 
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of the two forms of ETI isolated· from the periplasm. In both 
sequences, yield of Ser in cycle 1 is low (<1 pmole for val-ETI 
and 18 pmole for asp-ETI) This indicates that most of the ETI 
in each preparation has been cleaved at its unique Met residue 
by the CNBr. 
3.4.6 Discussion 
The pET expression system chosen for this work has proven to be 
a prolific producer of ETI. It was seen that the cell's export 
machinery was unable to keep up with production and the 
majority of the expressed protein :has remained in the cytoplasm 
of BL21(DE3)pLysS. As it was essential to show that active ETI 
with natural sequence could be produced from the synthetic ETI 
gene, the most cautious approach was adopted and only 
periplasmic material was used for further work. The logic here 
was that on export to the periplasm, the protein would be able 
to fold according to the dictates of its primary sequence and 
form correct disulphide bridges. CNBr cleavage, under the 
conditions used, it was reasoned, would cause only denaturation 
of the protein but not reduction of the disulphide bridges. 
Hence on removal of CNBr and formic acid, refolding would be 
quick and efficient. The same re~soning and approach was used 
to produce the altered form of ETI. 
The N-terminus of the final product of both forms of ETI were 
sequenced and the results interpreted as showing that the 
proteins had been correctly cleaved and purified. The final 
















ETI and its altered forin is the: assaying of these proteins. 
This will be discussed in Chapter 4. 
Success of this approach may lead to the requirement for large 
amounts of either form of ETI or of some other form of the 
protein. In this eventuality, consideration should be given to 
recovery of the ETI plus signal peptide form of the protein 
from the cytoplasm. The signal peptide should be removed by 
CNBr with the same degree of success as were the Ser and Met in 
this work, even though the signal peptide has an N-terminal 
Met. Furthermore, cleaved ETI in the appropriate environment 
will fold into the correct form for activity which is the 
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4.1 Introduction 
In Chapter 3, the expression of two forms of a synthetic gene 
for ETI viz, pPETI.l and pPETI.2 were discussed. CNBr cleavage 
of the resultant proteins, and purification of the products 
gave rise to a natural form of ETI (val-ETI) and ETI with an 
Asp residue beyond Val at theN-terminus (asp-ETI). 
It was necessary to assay first, the level of affinity of val-
ETI for both trypsin and t-PA and compare these results with 
those obtained for natural ETI prepared from E. caffra seeds. 
Results comparable to that of natural ETI would indicate that 
conditions had been met for efficient and correct folding and 
disulphide bridge formation especially after the harsh 
conditions .required for CNBr. cleavage. Furthermore, such 
results would allow comparisons to be made between the 
activities of val-ET!, natural ETI and asp-ETI and conclusions 
could be drawn on the effect of adding an Asp at the N-terminus 
of ETI. 
To obtain this information an established assay for ETI against 
2-chain t-PA was used as described by Heussen-schemmer and 
Dowdle (in Press). In this report they have shown that the 
inhibition of t-PA by ETI at 25°C is slow and a steady state 
velocity in the presence of inhibitors is only attained after 
15 minutes, whether the enzyme is preincubated with the 
inhibitor before the assay or not.· Under both assay conditions·, 
the steady state velocity of the reaction was the same, showing 
that ETI is a freely reversible inhibitor of 2-chain t-PA. 
Furthermore, in their examination of complex formation of ETI 
with 2-chain t-PA, Heussen-Schemmer and Dowdle (in press) found 
that with a t-PA:ETI molar ratio as high as 17:1, only 27% of 
the inhibitor was complexed with this enzyme, indicating that 
the complex between t-PA and ETI is relatively loose. Thus, ETI 
could be described by the classification of Cha ( 1980) as a 
semi-tight binding inhibitor. However, in the absence of 
inhibitor, these same authors have found that the steady state 
of the t-PA catalyzed reaction was reached so rapidly that the 
pre-steady state range was undetectable. Thus they reasoned 
that for the defini tlon of the mechanism of the reaction and 
for the determination of Ki, the specific velocity equation 








































However, ETI was found to behaye differently against trypsin. 
Preincubation of the enzyme with ·inhibitor, gave a much lower 
rate of product release than when enzyme was added last. This 
is typical of an irreversible, tight-binding reaction (Heussen-
Schemmer and Dowdle, in press). 
Enzyme inhibitor assays essentially determine the decrease in 
activity of the enzyme against which the inhibitor is active. 
One of the prerequisites for a successful assay system is that 
the reaction being catalyzed should be capable of being 
accurately monitored. Thus Heussen-Schemmer and Dowdle (in 
press) have utilized the substrate methylsulphonyl-D-
cyclohexyltyrosyl-glycyl-arginine :paranitroanilide which is a 
direct chromogenic substrate for t-PA standardization described 
by Magnotti (1988). The action of t-PA .on this substrate 
releases nitroanilide, the accumulation of which can be 
monitored at an excitation wavelength of 405mm and an emission 
absorbance wavelength of 680nm. 
The specific velocity plot of Baici (1981) was derived using 
the basic model shown in Figure 4.1. In addition, to derive the 
equation, it was assumed that the inhibitor binds in a rapid 
equilibrium fashion and that· the catalytic step is 
irreversible. 
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EI + s <--> ESI <--> EI + p 
ocK
5 13~ 
Figure 4.1 Basic Model from which specific velocity plot of 
Baici (1981) was derived. 
E = enzyme, S = substrate, I = inhibitor, 
P = product, Kp = catalytic constant 
E ] [ I ] I [ EI ] 
E ] [ S ] I · [ ES ] 
ocKi = K'i = [ ES ] ·[ I ] I [ ESI ] 
For these conditions, the following equation called the 




[ I ] ( 1 IK' i - 1 IKi ) 
1 + 13 (I]IK'i 
cr 
(l+cr) 
where cr = [S]I~ (Baici, 1981) 
+ 
1 + (I]IKi 
1 + 13[I]IK'i 
( 1) 
Measurement of the rate of steady state release of nitroanilide 
as a function of substrate conc.entration in the absence of 
inhibitor (Vo) allowed Heussen-Schemmer and Dowdle (in press) 
to calculate a ~ of 0.14 mM for 2-chain t-PA. Similar 
measurements of the reaction rates (Vi) of t-PA with different 
concentrations of ETI as a function of substrate concentration, 
was made. The combined data were used to construct a specific 
velocity plot which gave a family of curves that intersect at 
VoiVi = 1 and crl1+cr = 1 indicating that ETI functions as a 
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purely competitive inhibitor of. ~-PA (Heussen-Schemmer and 
Dowdle, in press). 
In the case of pure competitive inhibition, cx=()l) and f3=0 and 
under these conditions the specific velocity equation (1) 
becomes: 
Vo/Vi = - [I] ~ I Ki (1+~) + 1 + (I]/Ki (2) 





Ki (1 + [S]/Km) 
+ 1 ( 3) 
Using equation ( 3) and plotting Vo/Vi as a function of [I], 
Heussen-Schemmer and Dowdle (in press) obtained an average Ki 
of 2.88 X 10-8M for 2-chain t-PA with pure ETI. 
The reaction velocities Vo and Vi are determined by the slope, 
between 15 and 30 minutes, of the A405/A680 vs time plot and as 
the ratio of these velocities is used in equation ( 3), the 
reaction product concentration in molar terms are not required 
for the calculations. Furthermore, as can be seen from equation 
(3), knowledge of initial enzyme concentration is not required 
for the calculations. Nonetheless, an approximate initial 
enzyme concentration is required to provide conditions 
appropriate for analysis of the steady state kinetic data by 
the method of Baici ( 1981). These are reported by Heussen-
Schemmer and Dowdle (in press) to be: 
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a) initial inhibitor concentration must be > tenfold larger 
than initial enzyme concentr~tion; 
b) substrate concentration must be large enough to ensure 
that less than 10% of it is hydrolysed during the 
reaction. 
For the calculation of Ki from equation (3), accurate 
concentrations of substrate and inhibitor are required. 
Substrate is obtained in a high purity form and accurate 
concentrations can be made of this. However, to determine the 
Ki of ETI against t-PA (ie. the affinity of the inhibitor for 
t-PA) it is necessary to establish accurately, the 
concentration of active inhibitor. Concentration of active 
inhibitor will invariably be lower than that for total protein 
concentration (as determined for example by biuret reaction) 
which can be attributed to the presence in the sample of 
inactive inhibitor and other protein impurities. 
In the case of ETI, it has been shown that for inhibitory 
activity, the overall tertiary structure is required to confer 
a suitable conformation on the active site loop (Heussen-
Schemmer et al., 1991). Any enzyme or inhibitor protein 
preparation will invariably be contaminated with both protein 
of correct sequence which is incorrectly folded and hence is 
inactive, and other proteins unrelated to the one of interest 
( Kezdy and Kaiser, 19 7 0) . This is a very important 
consideration when assaying val-ETI and asp-ETI both of which 
have been denatured by 70% formic acid and CNBr treatment and 
then purified. Prior to CNBr cleavage, ETI had been allowed to 
form disulphide bridges on export to the peri plasm. It was 
reasoned that these bonds should remain intact in redistilled 
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formic acid and pure CNBr while the rest of the protein 
denatured. Under renaturing conditions the folding would be 
assisted by the disulphide bridge's and provided these were of 
correct sequence, the protein would be likely to fold to give 
the tertiary structure that allows for the inhibiting activity 
of ETI. Nonetheless, it was expected that a percentage would 
not refold correctly and that in addition, unrelated 
contaminating protein could be expected. 
Thus it was decided to determine the amount of active inhibitor 
in val-ETI, asp-ETI, a sample of purified natural ETI, a sample 
of pure STI and a control sample, by titrating active sites 
with trypsin. Active site ti tr.:ations were suggested by Kezdy 
and Kaiser ( 1970) as a method of· determining the molarity of 
active sites in a preparation of .an active protein 
independently of the purity of the sample. The inhibitor active 
site concentration determined by titration against trypsin can 
be used reliably to determine the inhibitor's Ki for t-PA for 
the following reasons: 
a) ETI reacts with trypsin in an irreversible, tight-binding 
manner and on a 1:1 molar ratio (Heussen-Schemmer and 
Dowdle, in press); 
b) interaction of ETI with t-PA is dependent to a large 
extent on the integrity of the trypsin reactive site 
(Heussen-Schemmer et al., 1991), ie. ETI molecules active 
against trypsin are likely to be active against t-PA. 
As with inhibitor assays, titrations of inhibitor active sites 
require determination of decrease of enzyme activity. In 
choosing a substrate for trypsin active site titrations, 
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advantage was taken of the facts that serine proteases, of 
which trypsin is an example, c_an hydrolyze a wide variety of 
esters and in doing so form a covalent intermediate, the acyl 
enzyme (Chase and Shaw, 1970). Thus, p-nitrophenol-guanidino 
benzoate ( pNPGB) , an ester of p-ni trophenol and guanidino-
benzoic acid, which on cleavage by trypsin releases the light 
absorbing or chromogenic alcohol viz p-nitrophenol, according 
to the scheme in Figure 4.2, is the substrate of choice for 
trypsin active site titrations (Chase and Shaw, 1970). 
Figure 4.2 






---> E + acid 
Scheme for reaction of trypsin with ester 
substrate such as pNPGB (from Chase and Shaw, 
1970). E=enzyme, S=substrate (pNPGB), ES=enzyme 
substrate complex, ES'=acyl enzyme. 
However, it can be shown that the active enzyme concentration 
is equal to the observed burst of p-nitrophenol only if k 2 >> 
k 3 and the titrant concentration is greater than the apparent 
Michaelis constants. Chase and Shaw ( 1970) have observed in 
their work that no effect of pNPGB on burst size is observed 
down to [pNPGB] = 2 X lo-6 M with trypsin. 
Using pNPGB as a substrate for active site titrations of 
trypsin has a number of advantages. First, p-nitrophenol is an 
excellent leaving group and its esters, which are stable in 
aqueous solutions at neutral pH and room temperature, have high 
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values of K2/K3 . In addition, in its ionized form (pKa = 7.04), 
p-nitrophenol has high absorbance·at 410 nm and can be detected 
at 10-6 M with < 2% error while its ester (pNPGB in this case) 
has negligibly small e410. Furthermore, pNPGB has sufficiently 
high affinity for trypsin. to allow active site determinations 
to be independent of substrate concentration provided it is 
supplied in excess over [E] (Kezdy and Kaiser, 1970). 
Thus it was decided to use the method described by Chase and 
Shaw (1970) for active site titrations of trypsin using pNPGB. 
The method requires that enzyme and inhibitor or enzyme alone, 
be incubated in a cuvette for 10 minutes at room temperature. 
Substrate is added to the cuvette, mixed rapidly and placed 
immediately in a spectrophotomet~r for absorbance at 410 nm 
(A410) to be recorded every 60 seconds for 5. 5 minutes • After 
deduction of values obtained in a similar manner for a 
reference cuvette the A410 valves were plotted against Time. 
Extrapolation of this plot to Time=O gives the maximum A410 of 
the pre-steady state or burst portion of the reaction. 
Subtraction of inhibited from uninhibited burst A410 and 
dividing this valve by e410 for p-nitrophenol viz 16595, gives 
the molarity of the original ETI solution, from which can be 
deduced the specific activity of that solution. 
The initial burst of product (p-nitrophenol) can be explained 
by the stoichiometric reaction of enzyme active sites with 
pNPGB to produce the acyl intermediate ES' shown in Figure 4.2. 
This is followed by a slow further production of p-nitrophenol 
due to the following factors: 
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1) Hydrolysis of the acyl enzyme and reaction of the freed 
enzyme with a second molecule of pNPGB ie. turnover (this 
is small in trypsin because ~3 of Figure 4.2 is very small 
relative to K2 ). 
2) Nonspecific hydrolysis of pNGPB by other nucleophilic 
groups of the enzyme or buffer ( ie. non-specific 
hydrolysis) which is small in the case of trypsin (Chase 
and Shaw, 1970). Nonspecific hydrolysis produced by the 
buffer is blanked out by addition of pNPGB to the 
reference cuvette and following the reaction as for the 
sample cuvette. However, any inequalities in addition of 
pNPGB will result in an erroneous rate of postburst 
nitrophenol production. 
In addition, Chase and Shaw (1970) emphasize a number of 
important considerations regarding their titration technique 
which was utilized in this work (see Chapter 6) . These are 
listed and discussed below. 
1) The titration is carried out at pH of 8. 3. This pH was 
selected as a compromise between the instability of both 
trypsin and pNPGB at higher pH and the rapid change of 
extinction coefficient of p-nitrophenol at lower pH. 
Furthermore, at pH 8.3 p-nitrophenol is approximately 92% 
ionized and sensitivity i~ near maximal. Under such 
conditions, only small errqrs are introduced by small 
changes of pH (± 0.2 units) caused by the buffering effect 
of a buffered sample. 
2) Verona! was selected as titration buffer because of the 
lower rate of non-enzymatic hydrolysis of pNPGB in it than 
in other buffers of useful capacity at this pH. 
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4.2 Results and Discussion. 
4.2.1 Titration of inhibitor active sites with trypsin 
The concentration of trypsin active sites was determined for 
known inhibitors: purified natural ETI and STI and for putative 
inhibitors: val-ETI, asp-ETI and expression control as 
described in Chapter 6.15.1. Release of p-nitrophenol was 
measured by recording the absorbance of the reaction solution 
at 410nm at 60 second intervals between 30 seconds and 5. 5 
minutes. After correction for non-active site background 
release of p-nitrophenol at equiv~lent time intervals from the 
start of the reaction, the A410 values were plotted as a 
function of Time and shown in Figure 4.3. 
The plots were extrapolated to Time=O to obtain the pre-steady 
state or burst A410 value. Difference between burst A410 for 
the pure trypsin solution and that for trypsin incubated with 
each inhibitor was used to calculate the concentration of 















100 150 200 
Time (seconds) 
250 300 350 
Titration of trypsin alone and trypsin in the 
presence of inhibitors or putative inhibitors 
• - Trypsin alone 
X - expression control 
0 - STI 
* - val-ETI 
..._ - asp-ETI 
+ - Natural ETI 
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rActive sitel [Total Ac.si 
Sample Burst pmol/L mg/ml prot] Activ. % 
A410 a a b c d 
Trypsin 0 0 675 406.69 9.76 11.06 36.77 88.25 
Control 0.673 1.21 -- 4.4 0.275 --
STI 0.423 151.83 3.05 3.56 42.65 85.67 
Natural ETI 0.414 157.25 3.15 3.80 41.38 82.90 
val-ETI 0.477 119.30 2.39 3.64 32.78 65.66 
asp-ETI 0.425 150.63 3.01 4.32 34.87 69.68 
Table 4.1 Active site concentrations determined as 
discussed in the text. 
a. -Titratable active site concentrations. 
b. Total protein concentration determined in biuret 
reaction in mg/ml. 
c. Activity in pmole/g 
d. Active site concentration as a % of the total 
protein concentration. 
The activity. values shown in Table 4.1 of each test sample 
indicates the concentration of active protein in pmole of 
active protein/g of total pro~ein (determined in biuret 
reaction) . A sample of pure ETI should have an activity of 
approximately 50 pmole/g ie when 100% of the sample is active 
protein. However, as discussed previously, some preparations of 
active proteins contain contaminants and inactive protein and 
will have less than 100% of their total as active protein. This 
can be seen in Table 4.1 with the pure sample of natural ETI 
titrated in this work in which only ± 83% of the total is 
active. The expressed forms of ETI had been subjected to 
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denaturing conditions during CNBr cleavage followed by only 
partial purification. Thus the concentration of active protein 
in these preparations was expected to be lower than that for 
purified natural ETI. The specific activity of val-ETI · was 
found to be about 33 pmole/g (about 66% active) while that for 
asp-ETI was 35 pmole/g (about 70% active). 
From these results it can be concluded that while approximately 
30% of the preparation, in the case of asp-ETI and 34% in the 
case of val-ETI, is inactive protein, these two forms of ETI 
expressed from synthetic genes do inhibit trypsin. Furthermore, 
considering the parallel expression, treatment and purification 
of val-ETI and asp-ETI, the results indicate that there is 
little difference between the two in their ability to bind to 
and inhibit trypsin. This was predicted by molecular modelling 
studies . 
It can be seen from Table 4.1, that there is a small measure of 
background inhibition contributed by components of the 
preparation other than the expressed ETI. Nonetheless, its 
contribution was considered to be negligible for the purposes 
of this titration. 
4.2.2 Assays of ETI preparations for tissue plasminogen 
activator inhibiting activity. 
Concentration of active proteins in each preparation to be 
assayed against t-PA had been determined (Chapter 4.2.1). 
Steady state release of nitroanilide was followed by recording 
A405/A6BO of the reaction. Reaction velocities were determined 
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from the slope of plots of A408iA680 as a function of time. 
These were determined in the absence of inhibitor (Vo) and in 
the presence of various concentrations of inhibitor (Vi). 
The rate Vo/Vi was determined for each dilution of the various 
samples and plotted as a function of active inhibitor 
concentration, [I]. The data were fitted by linear regression 
to the equation (3): Vo [I] 
= + 1 
Vi Ki (1+[5]/~) 
The slope of the resulting straight lines were determined, from 
which the Ki and specific activity of the assayed samples were 
calculated. These are shown in Table 4.2. The specific velocity 
plots are shown in Figure 4.4 while the data for these plots is 
tabulated in Appendix A. The necessary calculations to derive 
Ki and specific activity are described in Chapter 6 .15. 2 and 
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Figure 4.4 Determination of inhibition constants. Data are 
fitted to the simplified forms of the specific 
velocity equations (see text). 
x - control 
.A. - asp-ETI 
D - STI 
3t-; - val-ETI 
+ - Natural ETI. 
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Specific 
Ki Ki activity 
Sample pg/ml moles/L units/mmole 
Control 97.967 ---- ----
val-ET! 0.677 3.386 X 1o-8 1. 701 X 10 9 
asp-ETI 56.405 2.820 X 10-6 2.040 X 10 7 
Natural ETI 0.594 2.970 ·x 10-8 1.939 X 109 
SBTI 66.549 3. 311 ·X 10-6 1. 740 X 10 7 
Table 4.2 Ki's and specific inhibitory activity for expressed 
ETI's and controls against t-PA. One inhibitor unit 
is the amount of inhibitor that will inhibit one unit 
of enzyme activity by 50%. One unit of enzyme 
activity is equal to 10 pmol of substrate hydrolyzed 
per minute. 
A sample of purified natural ETI, should have Ki of 2.88 X 10-8 
M and specific activity of 2 X 10 9 units/mmole (Heussen-
Schemmer and Dowdle, in Press). This may reflect differences in 
titration and assay applications. Results obtained in this work 
indicate that 1.14 times more of the val-ET! preparation than 
natural ETI was required to inhibit the same amount of t-PA. In 
this case there may be substances in the preparation that 
interfere with the ability of t-PA to interact with ETI but do 
not affect t-PA's ability to cleave Spectozyme-tPA. Nonetheless 
these imply that val-ET! is very much like natural ETI in its 
ability to inhibit t-PA. 
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On the other hand, about 111.4 and 94.95 times more active STI 
and asp-ETI respectively are required than natural ETI to 
reduce, by 50%, the activity of t-PA in this assay. Thus, 
adding an Asp to the N-terminus of ETI as in asp-ETI, appears 
to greatly decrease its ability to inhibit t-PA. In fact, the 
added Asp residue has made asp-ETI very STI-like in their 
abilities to inhibit tPA. 
In the case of the expression control preparation, Ki and 
specific activity are reported although it shows negligible 
inhibitory activity to trypsin. The purpose here is to show 
that this preparation also displays negligible inhibitory 
activity to t-PA and the constants for val-ETI and asp-ETI were 
thus determined with confidence, using the active site 




An ETI-encoding gene was designed using the published amino 
acid sequence. The gene was synthesized by serial additions of 
8 oligonucleotides into a synthesis vector designed for the 
purpose. It was ascertained from the literature that the 
correct system for expression of a gene is, in most cases, 
largely empirically determined. In this case the synthetic ETI 
gene was originally designed to be placed under the control of 
a strong promoter in a simple . expression vector, pBtacl. Met 
was designed to be the N-terminal ·amino acid in place of Val as 
E.coli requires a Met codon for initiation and it was reasoned 
that this amino acid could act in the same capacity as Val at 
this position. However, no detectable levels of expressed 
protein was detected from this expression system. It was 
suspected at this stage that a leader sequence was required to 
assist expression by opening the mRNA to contact with the 
ribosomes, or to protect against degradation of either the mRNA 
or the expressed protein. This was confirmed when the gene 
failed to express from the expression vector, pET lla which 
also supplies no leader sequence.· These results have not been 
presented in this work as they offe.red no more illumination 
, 
than the results gained from expression of pBtacl. 
In the MBP expression system, the target protein is expressed, 
fused at its N-terminus to MBP. This system was used very 
successfully to express and purify an ETI-MBP fusion protein. 
In this context MBP acted as a leader peptide and high levels 
of expression were achieved from the synthetic ETI gene. 
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Apparently the presence of a 5 '- leader sequence of E. coli 
origin has provided protection to ETI and allowed it to 
accumulate to high levels in the cell. However, even as part of 
a fusion protein, ETI was able to fold into a fo~ enabling it 
to inhibit the serine protease which was to free it from MBP. 
At this point it was decided to use the secretion vector pET12a 
to produce ETI with ompT, the periplasmic secretion signal 
peptide, at its N-terminus. The aim here was primarily to allow 
expression of the synthetic gene ~nd secondly to promote export 
to an environment conducive t·o .disulphide bridging. As the 
signal peptidase of E. coli would only cleave off the ompT 
peptide to leave ETI with a Ser N-terminus, a Met was 
engineered between Ser and the natural Val which had been 
inserted into its correct position. The Ser and Met were 
removed by CNBr cleavage to leave ETI with the same amino acid 
sequence as found in the natural protein isolated from 
Erythrina caffra. This was confirmed by sequencing the amino 
terminal region of this protein and by assaying its activity 
against trypsin and t-PA. However most of the expressed ETI 
with ~he signal sequence attached, was left in the cytoplasm as 
the cell's export machinery could not keep up with the level of 
expression. It was suggested that, because of the apparent 
ability of ETI isolated from the cytoplasm to fold correctly 
and form disulphide bridges, as was seen with the MBP system, 
. the cytoplasmic ETI + signal sequence be isolated, cleaved and 
purified for an even greater yield of functional ETI. 
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The expressed ETI was called va],.-ETI and was incubated with 
trypsin, one of the proteases against which ETI is active and 
to which it binds irreversibly in a 1:1 molar ratio, to 
determine the concentration of active molecules in the sample. 
From this, the amount of active ETI as a percentage of the 
total protein was determined. An amount of 66% of val-ETI was 
found to be active protein compared to 83% in natural ETI. This 
was considered to be ·a comparable activity as val-ETI had 
undergone relatively harsh treatment and some loss of activity 
was expected. The concentration of active protein determined in 
this way was used in determining the inhibition constant of 
val-ETI against t-PA. At the same time, purified natural ETI 
(which had been donated by Seravac) was also assayed against t-
PA. The Ki determined for val-ETI was found to be very similar 
to that determined for natural ETI. In essence. this was the 
culmination of the synthesis of val-ETI, a project that had 
started at the translation of the published amino acid sequence 
to a DNA sequence. At the start there was some apprehension as 
to whether E. coli would be able to synthesize this eukaryotic 
protein, although it is a relatively simple one requiring only 
two disulphide bridges in a single chain protein. Nonetheless, 
as a form of insurance, the gene was designed to be utilized by 
S. cerevisiae as well. After engineering into the design a 
number of unique restriction sites, theoretical structures that 
the resultant mRNA could adopt were looked at. The most stable 
of these turned out to be a complex structure with extensive 
double stranded regions. This was acceptable from the point of 
view of protecting the mRNA from degradation. However, there 
was the danger of any ribosome binding site that was attached 
to this mRNA being caught up in the stable secondary structure 
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and being unavailable to the ribosomes for translation. This, 
of course would halt expression at this point and may have been 
the explanation for unsuccessful expression from pBtacl and 
pETlla. Both of these vectors are for the direct expression of 
proteins in the _cytoplasm of E.coli. 
The remedy was cloning the synthetic gene at the 3' end of a 
leader sequence which allowed good levels of expression. In 
these cases it is believed that the leader sequence has made 
the sequence more available to the ribosomes. 
It was suggested that a very useful ETI-encoding gene had been 
designed. In addition to being able to produce ETI almost 
indistinguishable from the natural protein, changes can easily 
be made to the sequence to produce altered forms of the protein 
as a way to investigate its function in relation to its 
structure. This was put to the test in altering the sequence to 
allow insertion in pET12a. Then an altered form of the protein 
was produced to address a question on the role of the Asp N-
terminus of STI in its inability to inhibit t-PA. 
STI is an inhibitor of trypsin ~ut not of t-PA. ETI and STI 
bear a great deal of similar~ty in their sequence and 
structure. However, they differ firstly in the scissile bond 
which is the point of contact of the protein with its 
substrate, trypsin. This bond, between Arg63 and Ser64 in ETI 
and between Arg63 and Ile64 in STI is cleaved under the right 
circumstances. The other point of difference between the two 
proteins relates to their N-termini ETI has been shown to 
have a structured N-terminal region which does not interefere 
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with the interaction of the prote~n with trypsin or tPA. STI is 
believed to have a similar structure to its N-terminal region, 
by virtue of sequence homology with ETI and three-dimensional 
structure overlay. STI has an N-terminal Asp residue which, 
because of its hydrophilic nature does not participate in the 
structure of the N-terminal region. Furthermore, while this Asp 
residue participates in STI: trypsin complex formation by ion 
pairing with the side chain of Lys60 of trypsin, it interferes 
with the interaction of STI and tPA either sterically or 
possibly by charge repulsion. 
For this reason, the N-terminus of val-ETI was extended by an 
Asp to produce asp-ETI. This new form of ETI was seen to have 
activity towards trypsin similar to that of val-ETI but to have 
very little activity against t-PA as compared with val-ETI. 
This result supports the hypothesis, based on computer modeling 
that the Asp residue of STI prevents docking of this protein 
with tPA, thereby thwarting inhibitor:protease complex 
formation. 
Another inhibitor, WTI was discussed briefly and seen to be 
more like ETI in its primary structure than STI but no crystal 
structure has been determined for this protein. As with STI, 
WTI is an inhibitor of trypsin but not of tPA. Based on 
sequence homology with ETI and STI, WTI appears to have the 
same N-terminal structure as that of STI. The implication from 
this is that its N-terminal Glu is responsible for the 
inability of this protein to inhibit tPA. 
However more work is required to understand the unique ability 
of ETI to inhibit t-PA. For example, the scissile bond of val-
ET! could be altered to resemble that of STI and the effect on 
its activity assayed. The synthetic ETI gene was designed with 
such a use in mind and as an ETI very .similar in activity to 
natural ETI was produced, such changes can be made and their 
effects on activity compared reliably with those of val-ETI. 
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6.1 Extraction and purification of plasmid DNA 
The method used in this work was adapted from the alkaline 
lysis method of Sambrook et al. (1989). 
6.1.1 ~mall scale preparations (Miniprep) 
a) A single colony of the plasmid containing culture was 
grown overnight in 8ml of Luria broth (LB) (Appendix B) in 
a sterile McCartney bottle with the appropriate 
antibiotic(s). 
b) Five 1 ml aliquots of this culture was centrifuged in a 1 
ml microfuge tube and resuspended in 100 pl of ice cold 
Solution 1 (Appendix B) by vortexing and pipetting 
vigorously. 
c) To this was added 200 pl of. room temperature Solution 2 
(Appendix B) and mixed thoroughly by hand until cleared 
then stood on ice for 5 minutes. 
d) 150 pl of ice cold Solution 3 (Appendix B) was added and 
vortexed vigorously whereupon a white flaky precipitate 
was produced. 
e) This was centrifuged in a microfuge for 5 minutes at room 
temp. and the supernatant transfered to a fresh tube 
f) To the supernatant was added 450 pl of equilibrated phenol 
(Appendix B), vortexed thoroughly and centrifuged for 2 
minutes and the upper aqueou~ phase recovered. 
g) This was repeated with a 1:1 mix of phenol and chloroform, 
chloroform and 900 pl of ether. The aqueous phase after 




Plasmid was precipitated by addition of 500 pl of absolute 
ethanol (-20°C), centrifuged for 2 min. and the pellet 
washed with 1 ml 70 % ethanol then left to air dry briefly 
and dissolved in 15 pl TE (~ppendix B) with RNAse A (50 
pg/ml) (Appendix B). 
6.1.2 Large scale lysis by alkali 
a) A single colony of the required plasmid containing strain 
was grown overnight in 500 ml of LB in a 2 L flask with 
the appropriate antibiotics and vigorous shaking. 
b) The cells were harvested by centrifugation at 7000 rpm in 
a JA10 rotor of a Beckman J2-21 centrifuge for 10 minutes 
at 4°C and the pellet resuspended in 3.6 ml of Solution 1 
as in 6.1.1. 
c) 8 ml Solution 2 was added ·and mixed gently but thoroughly 
. until clear then stood on ice for 5 min. 
d) To this was added 4 ml of solution 3 and mixed vigorously. 
The solution was cleared of precipitate by centrifugation 
at 17 000 rpm in a JA20 rotor for 20 min. 
e) The plasmid was precipitated, centrifuged, air dried 
briefly and dissolved in 4 ml TE. 4.5 g of CsCl was added 
and dissolved and 150 pl of EtBr 10 mg/ml added. 
f) The preparation was centrifuged at 55 000 rpm at 20°C for 
16 hrs. The resultant plasmid band was extracted, 
redissolved and centrifuged for a second time. 
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6.2 Plasmid digests 
High, medium and low salt buffers supplied by Boehringer 
Mannheim as a 10 x stock were used for most digests except for 
Bsm I which was supplied, by New England Biolabs with a 10 x 
stock buffer. Between 1 and 2 pg of plasmid DNA were digested 
in volume of 20 - 30 pl with 1 -3 U of enzyme per pg of DNA. 
Digests were performed at the optimal temperature for the 
particular enzyme for 5 hrs in the case of Bsm I and for 2 hrs 
for all others. The reaction tube was incubated in a heating 
block set at the required temperature and incubated in oven, 
set at the same temp., to prevent condensation .from forming on 
those parts of the reaction tube not in direct contact with the 
heating block. 
In the case of double digests, .a sample of the digest mix was 
electrophoresed to determine complete digestion, in which case 
the digest was treated with phenol, phenol/CHC1 3 , CHC13 and 
ether and precipitated with LiCl as before. The resultant 
digested plasmid pellet was dissolved in a 1 x strength buffer 
required for the 2nd enzyme and digested as before. 
6.3 Gel electrophoresis 
6.3.1 Agarose 
DNA preparations were routinely analysed by agarose gel 
electrophoresis, using a flatbed·apparatus and 1% agarose in 
TBE buffer (Appendix B), pH 8 containing ethidium bromide 
(EtBr) at 0.5 pg/ml. The running buffer (TBE) in which the gel 
198 
was submerged also contained EtBr at the same concentration. 
Gel loading buffer containing sucrose and bromophenol blue as a 
tracking dye was added to samples before loading and 
electrophoresis was carried out at 4-8 volts/em for 1-2 hrs. 
6.3.2 SDS Polyacrylamide gel electrophoresis (SDS PAGE) 
All cell extracts and purified proteins were electrophoresed on 
15 % acrylamide SDS PAGE (for recipes see Appendix B). 14 em 
long gels were run consisting of a ± 2 em stacking gel and 12cm 
of separating gel. Samples were dissolved by boiling for 2 min. 
in the case of pure samples and 5 min. for cell lysates, in an 
appropriate volume of SDS sample buffer containing 20 pl/ml of 
2-mercaptoethanol. For cell lysates, cell were first harvested 
then dissolved in the lysis buffer. Gels were run at 10 rnA 
until the bromophenol blue of .the loading buffer had entered 
the stacking gel .then current increased to 15 mA.and run until 
the bromophenol had just run off the bottom of the gel. 
Gels were submerged in Page Blue 83 stain (45% methanol, 45% 
H2o, 10% acetic acid, 0.2% Page Blue) for 1 hr at 37°C with 
gentle shaking and destained in 20% acetic ac.i,.d until the 
background had cleared. 
6.4 Purification of digested DNA fragments from agarose gels 
There are many good methods available for this purpose, the one 
found best for this work was : the Freeze squeeze method 
described by Antoniw (1985). 
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a) The digest reaction mix was loaded into a preparative well 
of a 1% agarose gel with no EtBr in the gel or the running 
buffer and electrophoresed as before. 
b) The gel was stained in 0.5 pg/ml EtBr in water for 10 min. 
in the dark. DNA bands were observed with long wavelength 
(302 nm) UV and cut out of the gel. 
c) Gel slices were incubated in ± 500 pl of Freeze squeeze 
buffer in the dark for 30 min. with occasional inverting. 
d) Small ( 0. 5 ml) polypropylene microfuge tubes each had a 
hole pierced at the bottom with a wide gauge needle. The 
hole was plugged with a small amount of siliconized glass 
wool and the gel slice placed on this and the tube closed. 
e) The tube with its gel slice was dropped into liquid N2 and 
left for ± 5 min. then placed inside and hanging on the 
lip of a 1 ml microfuge tube from which the lid had been 
cut. 
f) This was centrifuged in a mi¢rofuge for 5 min. at 4°C then 
the· gel refrozen and respun. 
g) The eluate was vortexed with an equal volume of phenol, 
then phenol/CHC1 3 , CHC1 3 alone and two volumes of ether. 
h) DNA was precipitated with two volumes of absolute ethanol 
after addition of 1/10th final volume of 4 M LiCl, washed 





a) Ligation of cohesive termini ( according to Sambrook et 
al., 1989). 0.1 pg of digest~d and phosphatased vector DNA 
was added to eguimolar, 2 x eguimolar, 3 x eguimolar and 4 
x eguimolar insert DNA. Water was added to.7 pl and the 
solution warmed to 45°C for 5 min to melt any cohesive 
termini that have reannea1ed, then incubated on ice until 
the start of the reaction. To this was added 1 pl each of 
10 x bacteriophage T4 DNA ligase buffer, 5 mM ATP and 
bacteriophage T4 DNA ligase at 1 U/ pl. The reaction was 
incubated at 16°C for 1 - 4 hrs or at 14°C for 16 hrs. 2 
pl of this was used to transform competent E.coli. 
b) Ligation of blunt-ended DNA (adapted from Sambrook et al., 
1989). Higher concentrations .of both vector and insert DNA 
were required for successful ligation. 100 pg of 
phosphatase treated vector and an eguimolar amount of 
insert were mixed on ice with water and 1.5 pl of 10 x 
ligase buffer, 2.5pl of 5mM ATP. To this was added 5 pl of 
60% PEG 6000 at room temp. and 1 pl of T4 DNA ligase at 15 
U/pl and incubated at 20°C for 16 hrs. This was used to 
transform competent E.coli. 
6. 5. 2 Phosphatase treatment of vector DNA ( Sambrook et al. , 
1989). 
Digested or mung bean nuclease . treated plasmid was phenol 
treated and precipitated as described above and dissolved in 
calf intestinal phosphatase or CIP buffer (Boehringer 
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Mannheim). The DNA was treated with CIP at 2 units per pmole of 
termini. For 5' overhangs, the reaction was incubated at 37°C 
for 3 0 min. then a further aliquot of CIP was added and 
incubated for a further 30 min. For blunted DNA, after the 30 
min. incubation the reaction was. incubated for a further 45 
min. at 55°C 
6 . 5 . 3 Mung bean nuclease removal of overhangs from digested 
DNA (New England Biolabs 1988-1989 catalogue). 
The digested DNA was phenol treated and precipitated as before 
and dissolved in mung bean nuclease MBN buffer at a 
concentration of 1 pg of DNA per 10 pl of buffer. To this was 
added 0.5 units of MBN per pg of DNA and incubated at 30°C for 
30 min after which it was made 0.2 Min NaCl. 
6.5.4 Transformation 
a) Competence induction. Fresh overnight culture in LB with 
the appropriate antibotics ( 25 pg/ml of chloramphenicol 
for BL21(DE3)pLysS) from single colony off a fresh plate 
was grown. 1 ml of this was added to 100 ml of . LB + 
antibotic if necessary and groWn to A550 of ± 0.6. Cells 
incubated on ice for 15 min. 40 ml of this was centrifuged 
at 5000 rpm in JA20 rotor of a Beckman J2-21 centrifuge at 
4°C for 5 min and immediately dissolved in 8 ml of 0.1 M 
MgC1 2 at 4°C. This was recentrifuged as above and 
resuspended in 8 ml 0.1 M Ca~12 at 4°C and kept on ice for 
1 hr then harvested as before and redissolved in 1. 6 ml 
CaC1 2 at 4°C then kept on ice. 
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b) Transformation. Ligation solution was made up to 100 pl 
with water and incubated on ice in polypropylene microfuge 
tube. To this was added 200 pl of competent cells and 
stood on ice for 15 min. after which transferred directly 
to a waterbath at 42°C for 3 min. then back to ice for 5 
min. To this was added o.s· ml of LB and incubated at 37°C 
with shaking for 1 hr. Cells were spun down and 
resuspended in 200 pl of LB of which all or dilutions 
thereof were plated on appropriate plates which had been 
dried in an incubator and after plating the plates were 
dried for 10 min. without lids in the incubator. 
6.6 DNA sequencing 
DNA was sequenced using a SEQUENASE TM sequencing kit supplied 
by United States Biochemical according to the manufactures 
instructions. In all cases double stranded DNA was used as 
template. 10 pg of template DNA ·( 2 x CsCl gradient purified) 
was diluted to 18 pl with sterile double distilled water and 2 
pl of 2 M NaOH added. This was incubated at 37°C for 5 min. The 
solution was neutralized and the DNA precipitated by addition 
of 150 pl of absolute ethanol and 4 pl of 3 M Na-acetate and 
centrifuged in a microfuge for 20 min. The resultant pellet was 
washed with 70% ethanol then air dried. The DNA was then ready 
for priming for which the manufacturers protocol was followed. 
203 
6.7 Photographic techmiques 
SDS PAGE gels stained with Page blue - 83 were photographed on 
a light box with Ilford Pan - F film and a red filter. Film was 
developed U:sing Agfa Rodinal according to the manufacturers 
instructions. 
6.7 Oligonucleotide synthesis 




These and other reagents 
Synthesis was performed 
for synthesis 
on a model 
were from Biosearch. 
6500 AutogenTM DNA 
synthesizer in a glass column containing 1 pmole (for the long 
synthesis oligos) and 0.2 pmole (for short oligos eg. primers) 
of an appropriate 5 1 -0-dimethoxytri tyl deoxynucleoside-3 1 -0-
succinyl-derivatized 1000 Angs4rom control pore glass support 
at a loading of 18 pmol/g. 
b) Purification (Horn and Urdea, 1988). 
i) After synthesis, the resin was dried, transfered to a 
microfuge tube and washed with 1 ml CH3CN then air dried. 
ii) Resin was incubated for 1 hr at room temp. in 1 ml tri 
-butylamine/pyridine (1:9 v/v). 
iii) Tri - butylamine/pyridine was removed and the resin 
washed 5 x with CH3CN then air dried. 
i v) 1 ml of lysine pH 9 was added to the resin and 
incubated at 60°C for 1~ hrs: 
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v) Lysine was removed and the resin washed 2 x with distilled 
water and 3 x with CH3CN. 
vi) Resin was transfered to a glass vial, air dried and 1 
ml concentrated NH40H added, vial closed immediately and 
incubated for 1 hr at room temp. then at 60°C for 24 hrs. 
vii) Solution was cooled, ~mmonia allowed to evaporate and 
the solution added to 1 ml 0•1 M Tris pH 9.5 and 8 ml TNE 
(Appendix B) in glass scintillation vial. 
viii) A disposable rapid reverse phase phenyl silica 
cartridge (Baker 10 SPE TM Baker Chemical Co., 
Phillipsburg,NJ) was equilibrated with 10 ml methanol, 
followed by 10 ml 50% v/v methanol/100mM TEAA followed by 
10 ml of 20 mM TEAA. 
ix) The oligo. containing solution was loaded onto the 
equilibrated column and washed with 5 ml of 20 mM TEAA 
followed by 10 ml of 30% v/v methanol/lOOmM TEAA. 
x) The oligo was eluted in· 4 ml 75% v/v methanol/100mM 
TEAA and evaporated to dryness. 
xi) The residue was dissolved in 100 pl of 80% aqueous 
acetic acid in which it was incubated for 30 min. then 
evaporated to dryness, dissolved in 1 ml of 5 x TE pH 7.4 
and centrifuged to remove any precipitate. The 
concentration was determined from the A260 value. 
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6.8 Gene synthesis 
The gene for ETI was synthesised by the method of 
oligonucleotide-directed double-strand break repair established 
by Mandecki (1986). Three aliquots of 50 ng of plasmid 
linearized with Bsm I restriction enzyme was mixed with 
complementary oligonucleotide at ·. 10 fold, 100 fold and 1000 
fold molar excesses. To this was added 3 pl of 10 x 
concentrated denaturation buffer (Appendix B) and the solution 
made up to 30 pl with water. The mixture was boiled for 3 min. 
and allowed to cool for 5 min at room temp. on a polystyrene 
block. The cooled mixture was centrifuged to collect condensate 
and placed on ice. To this was added 200 pl of competent E.coli 
JM83 [ara, c::,.(lac-pro), strA, thi,!280d lacz 6Ml5]. Transformed 
cells were plated on LB containing 100 pg/ml of ampicillin and 
20 pg/ml of 5-bromo-4-chloro-3-indolyl ~-galactoside (X-gal). 
Transformants were selected according to the appropriate change 
in colour from that of the parent~l on the same medium. 
6.9 Gene expression 
All strains containing a gene to be expressed were grown at 
37°C with shaking to A550 of 0. 6 0. 8 in LB with the 
appropriate antibiotic(s). Cells were harvested at 5000 rpm in 
a JA20 rotor under sterile conditions and resuspended in fresh, 
sterile LB at 37°c, containing antibiotic then induced by 
making the culture 0.4mM in isopropyl-~-D-thiogalactoside 
(IPTG) and shaking for a further.3 hrs at 37°C. In all cases 
ampicillin was required in the. culture medium and futher 
aliquots of this were added, in addition to the initial 100 
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pg/ml, every hour after the start of growth and after 
induction. This practice and that of harvesting and 
resuspension of cells was adopted in an effort to prevent 
plasmidless cells from outgrowing plasmid containig cells in a 
medium depleted of ampicillin by secreted ~-lactamase. 
6.10 The Maltose binding protein ·purification system 
Two 500ml cultures of E.coli TBl (pMETI) were grown to mid log 
phase and induced with IPTG. After 3 hrs of growth, the cells 
were harvested and lysed as described earlier. The supernatant 
of the lysate was found to be about 20 mg/ml in total protein 
and was diluted to about 2.5 mg/ml. Cross-linked amylose resin 
(1.5 g) supplied by NEB, was swollen in 50 ml of column buffer 
and packed into a 50 ml syringe to act as a column. Diluted 
supernatant was loaded onto the amylose resin which was then 
washed with 50 ml of column buffe~ + 0.25% tween and then with 
80 ml of column buffer with no. tween. Bound MBP-ETI fusion 
protein was eluted in about 300 ml of column buffer containing 
10 mM maltose and collected in approximately 10 ml fractions. 
Samples of the fractions (20 pl) were pooled 5 at a time and a 
10 pl sample from each pool run on a polyacrylamide gel. 
6.11 Detection of expressed ETI with anti - ETI antibodies 
a) Production of antisera. Purified natural ETI (a donation 
from Serevac) was dissolved at 200 pg/ml in phosphate 
buffered saline (PBS - see A~pendix B) and emulsified with 
an equal volume of Freunds _incomplete adjuvant. Rabbits 
were primed with three intramuscular injections of 1 ml at 
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1 week intervals and boosted thereafter at 4 - 6 weeks 
over several months. Rabbits were bled from a marginal ear 
vein at weekly intervals starting 3 weeks after the first 
injection. The serum or primary antibody fractions (10 -
20 ml) were stored separately at - 20°C and titred to 
determined which had the highest anti-ETI antibody 
concentration. Dilutions ( 10 times from 10-1 - 10-8 in 
Tris buffered saline with 0.1% Tween 20) were made of each 
primary antibody fraction, and incubated with ETI (diluted 
in PBS) in an ELISA plate reaction. Reaction with the non 
antigenic molecules in the antigen solution was blocked 
with 3% BSA in TBS/Tween. Anti-ETI antiboby remaining 
bound to ETI in the wells was detected with goat-anti-
rabbit alkaline phosphatase conjugate. The reaction was 
developed with 1 mg/ml of nitrophenylphosphate in 10% 
diethanolamine, pH 9.8. 
b) Western blots. Gels run as described before and transfered 
electrophoretically to HyboD:d™ as described in Ausubel 
(1987). The nitrocellulose was blocked in 5% milk powder 
buffer and was incubated, 1hr at room temperature, with 
antibody diluted 10-5 in TBS/Tween at 100 pl/cm2 of 
nitrocellulose. This was washed 2 x 10 min each in 
TBS/Tween. The washed nitrocellulose was incubated further 
with diluted (1/1000) goat-anti-rabbit alkaline 
phosphatase conjugate (made in the Department of 
Biochemistry, UCT) at 100 pl conjugate/cm2 at room temp. 
for 30 min. Nitrocellulose was washed in TBS/Tween and 
then in Developing buffer (Appendix B). The reaction was 
developed in BCIP, NBT developing solution until the 
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solution took on a purple tinge or until the background 
became dark in colour then washed in TBS/Tween. 
6.12 Sphaeroplasting E.coli BL21(DE3)pLysS (pPETI.l or.2) cells 
to release periplasmic proteins 
The method of Marston ( 1987) was adapted and used to release 
periplasmic proteins separate from cytoplasmic proteins. 
a) Cells were harvested from two 500 ml cultures 3 hours 
after induction by centrifugation at 5000 rpm in a JAlO 
rotor for 5 minutes in a Beckman J2-21 centrifuge. 
b) The entire pellet from each 500 ml culture was resuspended 
in 20 ml Tris pH 8 then pool both of these. 
c) Immediately added 40 ml 200mM Tris pH 8 , 1M sucrose and 
mixed very gently. 
d) As soon as -possible 40 ml of lOOmM EDTA was added and 
mixed very gently. 
e) To this 120 pl of 10 mg/ml lysozyme was added in 200mM 
Tris pH 8 and mixed very gently again. 
f) Immediately after added 120 ml sterile double distilled 
water (sddw) and mixed gently. 
g) 20 pl sample was taken, added to 980 pl sddw and the 
absorbance at 450 nm monitored, sphaeroplasting was seen 
to be complete as A450 ceased to decrease. This took about 
22 minutes. 
h) Mg2+ was added 20 mM ie 20 ml . of 1 M MgC1 2 . 6H2o, to 
stabilize sphaeroplasts. 
i) Sphaeroplasts were harvested at 4000 rpm for 5 minutes in 
a JA20 rotor at room temp .. 
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j) Supernatant at final volume of 240 ml, which contained 
periplasmic proteins, was poured off and stored on ice. 
6.13 Concentration of periplasmic proteins released by 
sphaeroplasting 
The expressed ETI' s were dissolved in a volume of 240ml and 
hence too dilute to for further work. It was thus decieded to 
concentrate the periplasmic proteins by precipitation with 
(NH4 ) 2so4 . It was previously established that 80% saturation of 
samples of the harvested peri plasmic solution precipitated a 
fraction of proteins that appeared to contain all of the 
expressed ETI's. The precipitation was performed as follows: 
a) The solution was made up to 250ml in a 500ml beaker with 
sddw and cooled on ice. 
b) 145g of (NH4 )so4 was added and stirred on ice until all 
salt had dissolved. 
c) Precipitated protein was collected by centrifugation at 
lOOOOrpm in a JAlO rotor in a Beckman J2-21 centrifuge for 
15 minutes at 0°C. 
d) The pellet was resuspended in 8ml of sddw and dialysed 
against running water for about 24hrs. 
e) The light precipitate which formed at about 24hrs of 
dialysis was removed by centrifugation at 15 OOOrpm in a 
JA20 rotor at 4°C for 15 minutes. 
f) Freeze dried the supernatant and resuspended in 3ml of 
saline. 
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6.14 Cyanogen bromide cleavage of proteins extracted from the 
peri plasm 
a) To 2. 6 ml of each solution of concentrated peri plasmic 
proteins, in a 20 ml McCartney bottle, was added 0.4 ml of 
sterile distilled water ( sddw) and 7 ml of redistilled 
formic acid. 
b) To this was added 6 0 mg of ·.recondensed CNBr and a small 
magnetic stirrer bar. 
c) · N2 was blown across the top of the solution to displace 
the air as best possible, the bottle capped tightly, 
sealed with parafilm and wrapped in foil to exclude light. 
d) This was stirred on a magnetic stirrer for 12 hrs at room 
temperature, after which a further 60 mg of CNBr was added 
and the above procedure in c above repeated. The solution 
was then stirred for a further 12 hrs. 
e) After the required incubation period the solution was 
diluted 15 times with sddw, 50 ml aliquoted per freeze dry 
flask and freeze dried. Th~ freeze dried material was 
weighed out and dissolved at 4 mg/ml in 100 mM Tris pH 8. 
6.15 Inhibitor assays 
6.15.1 Active site titratiion 
Reagents: 
a) Trypsin (type XIII from bovine pancreas, 
supplied by Sigma) was dissolved in 
approximately 10 mg/ml. 
TPCK treated, 
1 mM HCl at 
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b) A 0 . 1 M, pH 8 . 3 sol uti on of verona! ( Na barbital) was 
prepared containing 0.02 M CaC1 2 . 
c) p-Nitrophenol guanidinobenzoate (NPGB) was dissolved in 
dimethyl formamide at 16.8 mg/ml to give a 0.05 M 
solution. This was diluted by addition of 4 volumes of 
acetonitrile to give a 0.01 M solution. 
d) Inhibitor (purified natural ETI and soybean trypsin 
inhibitor (STI)) and putative inhibitor (expression 
control, syn-ETI and asp-ETI) were dissolved at 
approximately 4 mg/ml in Tris-HCl pH 8. 
Procedure. Cuvettes were prepared as shown in Table 6.1: 
Volume (ml)/cuvette 
Reagent A B A' B' 
Trypsin 10 mg/ml 0.2 0.2 - -
HCl 1mM - - 0.2 0.2 
Verona! buffer 0.69 0.69 0.69 0.69 
Tris-HCl 0.1M, pH 8 - 0.1 - 0.1 
Inhibitor solution 0.1 - 0.1 -
Table 6.1 Plan showing the preparation of cuvettes for 
titration of trypsin active sites. Where in the table above, B 
and B' represent the titration of trypsin active sites and its 
reference reaction respectively. A and A' represent titration 
of trypsin active sites remaining after incubation with an 
inhibitor solution and the related reference reaction 
respectively. 
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To each reaction being followed, 10 .ul of NPGB solution was 
added and rapidly mixed by capping the top of the cuvette and 
inverting twice. As fast as possible, the cuvette was placed in 
the spectrophotometer and the absorbance at 410 nm (A410) 
recorded at 30 seconds after addition of the titrant. The A410 
values were recorded at 60 second intervals thereafter up to 
5.5 minutes. 
As a single-beam spectrophotome~er was utilized for these 
titrations, each reaction was followed separately of its 
reference reaction. The recorded values for the reference 
reaction were deducted from the appropriate reaction values. 
Corrected A410 values were plotted as a function of time. The 
resultant curve from each set of data was extrapolated to Time 
= 0 to determine 6A (ie the burst A410 for trypsin) and 6B (ie 
the burst A410 for the remaining trypsin active sites after 
incubation with the inhibitor in question). 
The molarity of the original ETI solution was calculated from 
the following formula: [ETI in moies/L] = [(D.B- CJ.A) * 10 
16595 
ie the difference between trypsin active site concentration and 
concentration of active sites remaining after incubation, 
corrected for 10 times dilution, divided by e410 for p-
nitrophenol (16 595 M-1 cm-1). 
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6.15.2 Assays of inhibitory activity for tissue plasminogen 
activator 
Reagents: 
a) Tris-imidazole buffer stock solution (according to 
American Diagnostica) was made as described below. 
Solution A: 3.03 g Tris, 1.7 g imidazole, 50 ml HCl (1M) 
was made up to 100 ml with distilled water. 
Solution B: 4.04 g Tris, 2.27 g imidazole, 1.95 g NaCl was 
made up to 100 ml with distilled water. 
Solutions A and B were mixed to give 200 ml of solution of 
pH 8.4 at 25°C 
To the 200 ml of the solution above was added 23.4 g of 
NaCl to obtain a concentrated solution of ionic strength = 
3.0. Aliquots were stored at -20°C. 
b) Tris-Triton-Imidazole (TTI) buffer: 10 ml of Tris-
imidazole stock was mixed with 0.2 ml of 10% Triton X-100 
and made up to 100 ml with distilled water. 
c) Substrate: Spectrozyme t-PA was supplied at 10 pmol/vial. 
The contents of one vial was dissolved in 0. 5 ml of 
distilled. water. To this was ·added 4 ml of TTI to obtain a 
4 mM solution. 
d) t-PA: t-PA was dissolved in O.lM Tris pH 8.1 containing 1% 
Triton X-100. One chain t-PA was converted to 2-chain t-PA 
by treatment with plasmin linked to Sepharose CL-4b. This 
was assayed and diluted to ± 500 I.U./ml. 
e) Inhibitors: Inhibitor and putative inhibitor samples taken 
from stock solutions of which active site concentrations 
had been determined. 
-I.. 
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Procedure: Inhibitors were diluted 200, 300, 400, 500, 600, and 
800 times with TTI buffer. 100 pl a1iquots of each dilution or 
TTI were added to the 1st and 2nd rows of a 96-well flat 
bottomed polystyrene plate (Greiner). To each of these was 
added 50 pl of the substrate Spectrozyme t-PA this was 
incubated at 25°C for 5 minutes. The reaction in each well was 
started simultaneously by the addition, with a multipipette, of 
50 pl of the t-PA solution or TTI to the wells. This is shown 
in Table 6.2 below. 
Well of row 1 a11d 2 of Greiner plate 
Reagent 
A B c D E F G H 
Inhibitor 1/500 TTI 1/200 1/300 1/400 1/500 1/600 1/800 
Substrate s s s s s s s s 
Incubate 
Enzyme TTI t-PA t-PA t-PA t-PA t-PA t-PA t-PA 
Table 6.2 Plan showing position of each reaction in each well 
of the reaction plate. Where s = Substrate 
A Titertek Multiskan MCC/340 microplate reader was used to 
measure absorbance of the released nitroanilide at 405/680 nm. 
Readings were taken after 15 minutes of incubation at 25°C just 
prior to which, at 14.5 minutes~ the machine was zeroed on 
column A of the reaction plate. Subsequent readings were taken 
every 4 minutes up to 43 minutes. 
215 
Calculations: 
Plots of A405/A680 as a function of time were made for each 
reaction well and the slope between 15 and 30 minutes 
determined for each plot and an average slope calculated from 
the duplicate of each reaction. 
The reaction in ·well B is uninhibited t-PA incubated with 
substrate and the average slope = V 0 while the slope of the 
remaining wells (C-H) =Vi. 
For each inhibitor, v 0/vi was calculated and this was plotted 
as a function of [I] (the concentration of inhibitor active 
sites as determined by titration, ·.in ,ug/ml. 
The data was fitted by linear regression to the equation: 
V0/Vi = 1/Kiapp * [I] + 1 
and the slope of this line determined • The apparent Ki was 
calculated as the reciprocal of the slope. This is the 
inhibitor concentration in ,ug/ml that inhibits t-PA by 50%. As 
Kiapp = Ki ( 1 + [ s] /~) where [ s] is the concentration of 
substrate in each well which in this case ~s 1 mM and ~ for 2-
chain t-PA has been determined by Heussen-Schemmer and Dowdle 
(in press) as 0.14 mM with Spectrozyme t-PA 
The specific activity of pure ETI is defined by the above 
mentioned workers as 1 inhibitory uni t/.ug which has a Ki of 
0.576 ,ug/ml (= 2.88*10-8 M). One inhibitory unit of inhibitor 
activity is that amount of inhibitor that will inhibit one 
chromogenic unit of . enzyme activity by 50% and one unit of 
enzyme activity is equal to 10·pmol of substrate hydrolysed per 
minute. 
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Thus, the specific activity of an· unknown sample is calculated 
by dividing 0 . 57 6 by the Ki . Furthermore, as pure ETI has 
specific activity of 100 000 units/mg in the flourometric 
assay, 1 unit determined by chromogenic assay is equal to 
approximately 100 fluorometric units. In order to compare 
specific activities determined by fluorometric assays which 
appear in the earlier literature with results derived in this 
work, all specific activities for inhibition of t-PA were 
reported in terms of the old units. 
6.16 Amino acid sequence analysis 
Sequence analysis was performed on a gas-liquid solid phase 
sequencer constructed as outlined by Hewick et al. (1981) and 
slightly modified as described by Brandt et al. ( 1984) The 
reagents, solvents and degradation cycle used have been 
published in the above references. The converted PTH amino 
acids were identified by isocratic HPLC system on 3 x 250 mm 3 




ASSAY VALUES, REGRESSION DATA AND CALCULATIONS 
I Table of observed values for_titration of inhibitor with 
trypsin 
A410 values at time (T) in seconds 
Sample T=O 30 90 150 210 270 330 
Trypsin 0.675 0.711 0.785 0.828 0.852 0.873 0.891 
natural ETI 0.414 0.443 0.502 0.554 0.580 0.600 0.617 
val-ETI 0.477 0.518 0.602 0.647 0.668 0.690 0.704 
asp-ETI 0.425 0.461 0.534 0.578 0.600 0.623 0.641 
STI 0.423 0.457 0.527 0.567 0.591 0.611 0.628 
Control 0.673 0.707 0.778 0.814 0.834 0.859 0.871 
Table A.l Absorbance at -410 nm at the time intervals shown . . -
Experimental conditions as described in Chapters 4.1, 
4. 2 and 6 .15. The T=.O column shows the values where 
the extrapolated graph intersects the A410 axis as 
shown in Figure 4.3. 
II Observed values and regression data for titration of 
inhibitors, putative inhibitors and controls against t-PA 
Table A 2 See next four pages. Observed absorbance values from 
chromogenic assays of dilutiorts of inhibitors, putative 
inhibitors and controls against t..:_PA taken every 4 minutes from 
15 to 43 minutes. Alongside the absorption vs time data from 
dilutions of each sample is shown :the regression analysis 











































































Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.01267 
Std Err of Coef. 0.000217 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.006235 
Std Err of Coef~ 7.17E-05 
Regression Output: 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 






X Coefficient(s) 0.007687 
Std Err of Coef. 0.000188 
Regression 
Constant 
Std ·Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.008229 
Std Err of Coef. 0.000149 
Regression 
Constant 
Std .Err of Y Est 
R Squared 
No. of Observations 








Std Err.of Coef. 8.62E-05 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.009875 
Std Err of Coef. 0.000168 
Regression 
Constant 
Std Err.of Y Est 
R squared 
No. of Observations 







X Coefficient(s) 0.010414 










































































































































Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.012926 
Std Err of Coef. 0.000197 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.012741 
Std Err.of Coef. 7.19E-05 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.01278 
Std Err of Coef. 0.000117 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.012824 
Std Err of Coef. 0.000102 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.012854 
Std Err of Coef. 4.61E-05 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.012869 
Std Err qf Coef. 2.21E-05 
Regression 
Constant· 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s} 0.012893 






0.186 15 Regression Output: 
0.239 19 Constant -0.01728 
0.286 23 Std Err of Y Est 0.002796 
0.34 27 R Squared 0.999609 
0.397 31 No. of Observations 8 
0.45 35 Degrees of Freedom 6 
0.505 39 
0.559 43 X Coefficient(s) 0. 013363 
Std Err of Coef. 0.000108 
1/200 
A405/A680 Time Regression Output: 
0.119 15 Constant 0.045095 
0.139 19 Std Err of Y Est 0.002214 
0.159 23 R Squared 0.998244 
0. 18 27 No. of Observations 8 
0.204 31 Degrees of Freedom 6 
0.221 35 
0. 239 39 X Coefficient(s) 0.004988 
0.257 43 Std Err of Coef. 8.54E-05 
1/300 
A405/AG80 Time Regression Output: 
0.137 15 Constant 0.037223 
0.161 19 Std Err of Y Est o. 002137 
0.19 23 R Squared 0.99908 
0.218 27 No. of Observations 8 
0.247 31 Degrees.of Freedom 6 
0.271 35 
0.296 39 X Coefficient(s) 0.006652 
0.321 43 Std Err of Coef •. 8.24E-05 
1/400 
A405/A680 Time 
0. 146 15 Regression Output: 
0.18 19 Constant 0.033458 
0. 211 23 Std Err of Y Est 0.002672 
0.243 27 R Squared 0.998928 
0.277 31 No. of Observations 8 
0.304 35 Degrees of Freedom 6 
0.333 39 
0.362 43 X Coefficient(s) 0.007708 
?td Err of Coef. 0.000103 
1/500 
A405/A680 Time 
0.15 15 Regression Output: 
0.183 19 Constant 0.028988 
0. 214 23 Std Err of Y Est 0.001889 
0 .· 24 7 27 R Squared 0.999514 
0.284 31 No. of Observations 8 
0.312 35 Degrees of Freedom 6 
0.343 39 
0. 377 43 X Coefficient(s) 0.008095 
Std Err of Coef. 7.29E-05 
1/600 
A405/A680 Time Regression Output: 
0.161 15 Constant 0.031307 
0.198 19 Std Err of Y Est 0.009964 
0.227 23 R Squ·ared 0.987837 
0.261 27 No. of .Observations 8 
0.272 31 Degrees 6f Freedom 6 
0.332 35 
0.367 39 X Coefficient(s) 0.008485 
0.401 43 Std Err of Coef. 0.000384 
'• 
1/800 
A405/A680 Time Regression Output: 
0.17 15 Constant 0.029753 
0.205 19 Std Err of Y Est 0.002194 
0.243 23 R Squared 0.999502 
0.278 27 No. of Observations 8 
0.322 31 Degrees of Freedom 6 
0.355 35 
0.392 39 X Coefficient(s) 0.009289 









































































































































Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.013265 
Std Err of Coef. 0.000437 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.013101 
Std Err of Coef. 0.000101 
Regressio~ 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.013125 
Std Err of Coef. 0.000124 
Regression 
Constant 
Std Err'of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.013134 
Std Err of Coef. 0.000136 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.013199 
Std Err of Coef. 0.000162 
Regression 
Constant 
Std Err of Y Est 
R Squared 
No. of Observations 







X Coefficient(s) 0.013205 
Std Err of Coef. 0.000128 
Regression Output: 
Constant. -0.01059 
Std Err of Y Est 0.003415 
R Squared 
No. of Observations 
Degrees of Freedom 
X Coefficient(s) 0.013244 






From each regression analysis is required the slope of the line 
that fits the data by linear regression. The slopes are 
reported as X Coefficient(s). These represent Vo for the 
uninhibited enzyme and Vi for the same amount of enzyme 
inhibited by increasing dilutions of inhibitor, putative 
inhibitor or control. A summary OI the slopes derived for each 
sample is presented in Table A 3. ·. 
Amount or. Slopes of fitted line to each set of data 
dilution of 
inhibitor control val-ETI asp-ETI nat-ETI STI 
0 0.013229 0.01267 0.012926 0.013363 0.013893 
1/200 0.013092 0.006235 0.012741 0.004988 0.013021 
1/300 0.013167 0.007687 0.012780 0.006652 0.013024 
1/400 0.013205 0.008229 0.012824 0.007708 0.013125 
1/500 0.013214 0.009119 0.012854 0.008095 0.013199 
1/600 0.013217 0.009875 0.012869 0.008485 0.013205 
1/800 0.013223 0.010414 0.012893 0.009289 0.013384 
Table A 3 A summary of the slopes derived from the fitted data 
shown in Table A 2. 
The ratio of the rate of uninhibited enzyme (Vo) to the rate of 
inhibited enzyme (Vi), at each concentration of inhibitor, was 
determined. This was plotted against the concentration of 
inhibitor ( [ I] ) , corresponding to each Vi, according to the 
equation: Vo/Vi = [I]/Kiapp + 1 (the specific velocity 
equation described in Chapter 4.1~ in this equation Kiapp = Ki 
( 1 + [s]/~ ) and for this reaction [S] = 1mM and Km = 0.14mM 
(see Chapter 6 .15) ie Kiapp = 8 .14. Ki. A straight li·ne was 
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fitted to each set of data by linear regression. The sets of 
data with their regression analyses are shown in Table A 4. In 
addition, Table A 4 has a two extra columns labeled X and Y in 
which the corresponding Y axis (Vo/Vi) values are displayed for 
X axis ([I]) values of 1 and 11 to facilitate the plotting of 
all the graphs on one set of axes ·(Figure 4.4). 
The specific activity of each sample was calculated from the 
slope of the fitted graph (the X coefficient(s) values of the 
regression outputs) of Vo/Vi vs [I]. The calculation was 
performed as shown below using the data from natural ETI as an 
example: the slope = 1/Kiapp or 1/slope = Kiapp in the case of 
ETI slope = 0.206823 thus Kiapp = 4.835. As described above Ki 
= Kiapp/8.14 thus in the case of natural ETI Ki = 0.594 pg/ml. 
In Chapter 4.1 it was shown that pure ETI has a. specific 
activity of 1 unit/pg and that has a Ki = 0.576 pg/ml. 
Therefore, the specific activity of the natural ETI sample used 
in this work was calculated as 0.576/0.594 ie 0.9696969 
units/pg or 96969.69 old units/mg which is equal to 1.94 X 109 
units/mmole. The Ki and specific activity of each sample is 
presented in Table 4.3. 
Table A 4 Displayed on following page. Shows the Vo/Vi ratios 
with the corresponding inhibitor concentration ([I]) 
in pg /ml, the corresponding [I] values for Vo/Vi 
values of 1 and 11 (shown under the headings of X and 
Y), and the regression qutput for each set of data. 
224 
Control 
Vo/Vi (I J X y Regression Output: 
1.0105 11 1 0.997263 Constant 0.996009 
1. 004 7 7.33 11 1.009801 Std Err of Y Est 0. 00091 
1.0018 5.5 R Squared 0.955528 
1. 0011 4.4 No. of Observations 6 
1. 0009 3.67 Degrees of Freedom 4 
1.0005 2.75 
X Coefficient(s) 0.001254 
Std Err of Coef. 0.000135 
val-E'l'I 
Vo/Vi [I J X y Regression Output: 
2.032 5.98 1 1.13022 Constant 0.948809 
1.648 3.98 11 2.944325 Std Err of Y Est 0.02991 
1.539 2.99 R Squared 0.991951 
1. 389 2.39 No. of.Observations 6 
1.283 1. 99 Degrees of Freedom 4 
1.216 1. 49 
X Coefficient(s) 0.181411 
Std Err of Coef. 0.008171 
asp-ETI 
Vo/Vi [I J X y Regression Output: 
1.015 7.53 1 1.001404 Constant 0.999226 
1. 011 5.02 11 1.023185 Std Err of Y Est 0~00072 
1.008 3.76 R Squared 0.979861 
1. 006 3.01 No. of Observations 6 
1.004 2.51 Degrees of Freedom 4 
1.003 1. 88 
X Coefficient(s) 0.002178 
Std.Err of Coef. 0.000156 
Natural ETI 
Vo/Vi [ I J X y Regression Output: 
2.679 7.88 1 1.199098 Constant 0.992275 
2.009 5.25 11 3.267329 Std Err of Y Est 0.064168 
1.734 3.94 R Squared 0.983695 
1. 651 3.15 No. of Observations 6 
1.575 2.63 Degrees of Freedom 4 
1. 439 1. 97 
X Coefficient(s) 0.206823 
Std Err of Coef. 0. 013314 
STI 
Vo/Vi [I) ·x y Regression Output: 
1.0125 7.63 1 1.001838 Constant 0.999991 
1.0107 5.08. 11 1.020303 Std Err of Y Est 0.002074 
1. 01 3.81 R Squared 0.811915 
1.005 3.05 No. of Oqservations 6 
1.0045 2.54 Degrees of Freedom 4 
1.0016 1. 91 
X Coefficient(s) 0.001846 
Std Err of Coef. 0.000444 
l ~ \, 
APPENDIX B 
RECIPES 
B. I DNA techniques 
1) Broth 
Luria Broth (Ausubel et al., 1987) 
per litre Tryptone lOg 
Yeast extract 5g 
NaCl 5g 
NaOH (1M) lml 
2) Alkaline lysis buffers (Maniatis et al., 1982) 
Solution I: Glucose 
EDTA 




This is autoclave and kept in the :fridge. 




Kept at room temp. 





60 ml of 5M solution 
1. 5 ml 
28.5 
3 Phenol preparation (Ausubel et al., 1987) 
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To 500 ml of redistilled phenol 0. 5g of hydroxyquinoline was 
added and dissolved. SOOml of 50rnM Tris base (pH 10) was added 
and stirred for 10 min., then stood at room temp. to allow / 
phases to separate. The aqueous phase was removed and replaced 
with the same amount of 50rnM Tris (pH 8) and the process 
repeated twice. The equilibrated phenol was stored, at 4°C 
under 50rnM Tris (pH 8). 
4 DNAse free RNAse A preparation: 
RNAse A was dissolved at 20mg/ml in 0.3M Na acetate (pH 5.5). 
This was aliquoted into polypropylene eppendorf tubes and in 
these incubated in boiling water for lOmin and stored up to 3 
months at 4°C. 
5 TE (Tris-EDTA) 




6 TBE (Tris-Borate-EDTA) 10 times concentrated 







7 DNA loading buffer 
Dissolve sucrose to 40% in TE (pH 8) and add a tiny amount of 
Bromophenol on the very tip of a spatula. 
8 Denaturation solution for bridge mutagenesis 
(10 times concentrated) 








9 TNE buffer (used in oligonucleotide purification) 






10 Freeze squeeze buffer (extraction of DNA from agarose) 
NaOAc (pH 7) 
EDTA 
11 Mung bean nuclease buffer 








12 Ligation buffer for bacteriophage T4 ligase 
(10 times concentrated) 






B II Western blots and protein detection 
1 Phosphate buffered saline (PBS)" 
Dissolve in 800ml of double distilled water 
NaCl 8g 
KCl 0.2g 
Na 2HP04 1.44g 
KH~P04 1.2g 
Ma e up to 1L with water pH 
2 SDS running buffer (10 times cone.) 
. . 
is 7.2 
For transfer of proteins from PAGE gels to nitrocellulose. 







water and made up to 1L 
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3 Transfer buffer For transfer of proteins to nitrocellulose 
4 TBS tween 









5 Blocking buffer for nitrocellulose 


















Adjust pH to 





Bromo chloro indolyl phosphate (BCIP) @ 50 mg/ml in 100% DMF 
Nitroblue tetrazolium (NBT) @ 75 mg/ml in 70% DMF 
To develop blot after incubation with goat-anti-rabbit 
conjugate and washing in 
2
developing buffer. Incubate in 
developing buffer @ 50 pl/cm and to this add 4.4 pl BCIP and 
3.3 pl NBT per ml of developing buffer. 
B III Protein gels 
1 SDS sample buffer (2x concentrated) 








Add bromophenol for colour and dissolve in 40 ml of water, 
adjust pH to 6.8 and make up to-100 ml. 
Just prior to use add 20 pl/ml of :2-mercaptoethanol. 
2 Stacking gel buffer (4x concentrated) 




Filter through 0.45 pm filter and store at 4°C. 
I 
3 Running gel buffer (4x concentrated) 




Filter through a 4.5pm filter and·store at 4°C · 





Filter and store as before. 
5 Stacking gel 
30% acrylamide stock 
4x stacking gel buffer 
Water 
10% Ammonium persulphate 
TEMED 
6 Separating gel 
30% Acrylamide stock 
4x stacking gel buffer 
Water 












7 SDS electrophoresis buffer (Sx ·concentrated) 
For running SDS PAGE gels 







Make up to 1L with water. Do not alter pH as this is 8.3 after 
dilution to 1x. 
229 
REFERENCES 
Adams, S . E . , I . D. 
Kingsman and R. M. 
4298. 
Johnson, M. Braddock, A.J. Kingsman, S.M. 
Edwards (1988). Nucl. Acid. Res. '16:4287-
Alessi, M.C., P.J. Declerk, M. De Mol, L. Nelles and D. Collen 
(1988). Eur. J. Biochem. 175:531-540. 
Amann, E., J. Brosius and M. Ptashne (1983). Gene. 25:167-178 
Andersson, S.G.E. and e.G. Kurland (1990). 54:198-210. 
Andreasen, P.A., A. Riccio, K.G. Welinder, R. Douglas, R. 
Sartorio, L.S. Nielsen, C. Oppenheimer, F. Blasi and K. Dane 
(1986). FEBS Lett. 209:213-218. 
Antoniw, J.F. (1985). Anal.Biochem. 132:14-19. 
Ausubel. F.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. 
Seidman, J.A. Smith and K. Struhl (1987). Current Protocols in 
Molecular Biology. John Wiley and Sons, New York. 
Baici, A. (1981). Eur. J. Biochem. 119:9-14. 
Baici, A. and M. Gyger-Marazzi (1982). Eur. J. Biochem. 129:33-
41. 
Bakhit, C., D. Lewis, R. Billings and B. Malfroy (1987). J. 
Biol. Chern. 262:8716-8720. 
Balbas, P. and F. Bolivar (1990). Meth. Enzymol. 185:14-37. 
Banyai, L., A. Varady and L. Patthy (1983). FEBS Lett.163:37-
41. 
Barrett, A.J. and P.M. Starkey (1973). Biochem. J. 133:709-724. 
Beers, W.H. (1975). Cell 6:379-386. 
Bennett, W.F., N.F. Paoni, B.A. Keyt, D. Botstein, A.J.S. 
Jones, L. Presta, F.M. Wurm and M.J. Zoller (1991). J. Biol. 
Chern. 266:5191-5201. 
Bennetzen, J.L. and B.D.Hall (1982). J.Biol.Chem. 257:3026-
3031. 
Blow, D.M., J. Janin and R.M. Sweet (1974). Nature 249:54-57. 
Blundell, M., E. Craig and D. Kenell (1972). Nature. 238:46-48. 
Bode, w. and R. Huber (1992). Eur. J. Biochem. 204:433-451. 
Bode, W., I. Mayer, U. Baumann, R. Huber, S.R. Stone and J. 
Hofsteege (1988). EMBO J. 8:3467-3475. 
Bond, J.S. and P.E. Butler (1987). Ann. Rev. Biochem. 56:333-
364. 
I 230 
Borowiec, J.A. and J.D. Gralla (1986). Biochemi~try. 25:5051 
Boyot, P., L. Pillet, F. Ducanel, J. Boulain, 0. Tremeau and A. 
Menez (1990). FEBS. 266:87-90. 
Brandt, W.F., H. Alk, M. Chauhan and C. von Holt (1984). FEBS 
Lett., 174:228-232. 
Brommer, E.J.P. (1984). Thromb. Res. 34:109-115. 
Brosius, J. (1984). Gene. 27:161-172 
Bruch, M., V. Weiss and J. Engel (1988). J. Biol. Chern. ·' 
263:16626-16630. 
Carpousis, A.J., J.E. Stefano and J.D. Gralla (1982). J. Mol. 
Biol. 157:619-621. 
Carrell, R. and J. Travis (1985). Trends Biochem. Sci. 10:20-
24. 
Carrell, R.W. and J. Travis (1985). Trends Biochem. Sci. 10:20-
24. 
Carter, A.D., C.E. Morris and W.T. McAllister (1981). J. Viral. 
37:636-642. 
Chase, T. and E. Shaw (1970). Method. Enzymol. 19:20-27. 
Cheng, Y.S., D.Y. Kwoh, T.J. Kwoh, B.C. Saltveldt and D. Zipser 
(1981). Gene. 14:121-
Chmielewska, J., M. Ranby and B. Wiman (1980). Biochem. J. 
251:327-323. 
Chmielewska, J., M. Ranby and B. Wiman (1988). Biochem. J. 
251:327-332. 
Cohen, A.B., L.D. Greunke, J.C. Craig, and D. Geczy (1977). 
Proc. Natl. Acad. Sci. USA. 74:4311-4314. 
Collen, D. (1976). Eur. J. Biochem. 69:209-216. 
Colucci, M. J.A. Paramo and D. Collen (1985). J. Clin. Invest. 
75:818-824. 
Conner, G.E. and J.A. Udey (1990). Cell Biol. 9:1-9. 
Cook, N.S. and D. Ubben (1990). Trends Pharmacal. Sci. 11:444-
451. 
Curran, J.F. and M. Yarus (1988). J. Mol. Biol. 203:75-83. 
Curran, J.F. and M. Yarus (1989). J. Mol. Biol. 209:65-77. 
Dane, K. and E. Reich (1979). Biochem. Biophys. Acta. 566:138-
151. 
Das, A ( 1·990). Method. Enzymol. 185:93-112 
231 
Davanloo, P., A.H. Rosenberg, J.J. Dunn and F.W. Studier 
(1984). Proc. Natl. Acad. Sci. U.S.A.,81:2035-2039. 
De Boer, H.A., L.J. Comstock and M. Vasser (1983). Proc. Natl. 
Acad. Sci. USA. 80:21-25. 
Declerck, P.J., M. De Mol, M. Alessi, S. Baudner, E. Paques, 
K.T. Preissner, G. Muller-Berghaus and D. Collen (1988) •. J. 
Biol. Chern. 263:15454-15461. 
Deuschle, U., W .· Kammerer, R. Gentz and H. Buj ard ( 1986). EMBO. 
J. 5:2987-
Dexter, D.L. and P. Calabresi (1982). Biochim. Biophys. Acta. 
695:97-112. 
diGuan, C., P. Li, P.D. Riggs and H. Inouye (1988). Gene. 
67:21-30. 
Dix, D.B. and R.C. Thompson (1989). Proc. Natl. Acad. Sci. USA. 
86:6888-6892. 
Ducand, F., J-C. Boulain, 0. Tremeau and A. Menez (1989) Prot. 
Engin. 3:139-143 
Dunn, J.J. and F.W. Studier (1981). J. Mol. Biol. 148:303-330. 
Dunn, J.J. and F.W. Studier (1983). J. Mol. Biol. 166:477-535. 
Duplay, P., H.Bedouelle, A.Fowler, I.Zabin, W.Saurin and 
M.Hofnung (1984). J.Biol.Chem. 259:10606-10613. 
Edelberg, J.M., C.F. Reilly and S.V. Pizzo (1991). J. Biol. 
Chern. 266:7488-7493. 
Eigenbrot, C., M. Randall and A.A. Kossiakoff (1990). Protein 
Eng. 3:591-598. 
Eismann, E., B. von Wilcken-Bergman and G. Muller-Hill (1987). 
J. Mol. Biol. 195:949- · 
Erlich, H.J., R. Klein Gebbink, J. Keijer, M. Linders, K.T. 
Preissner and H. Pannekoek (1990). J. Biol. Chern. 265:13029-
13035. 
Finkenstat, W.R. and M. Laskowski Jr. (1965). J. Biol. Chern. 
240:962-963. 
Flashner, Y. and J. Gralla (1988). Proc. Natl. Acad. Sci. 
U.S.A. 85:8968-8973. 
Freedman, L.P., B.F. Luisi, Z.R. Korszun, R. Basavappa, P.B. 
Zigler and K.R. Yamamoto (1988). Nature. 334:543-546. 
Freundl, R., H. Schwarz, M. Klose, N.R. Movva and V. Henning 
(1985). EMBO J. 4:3593-3598. 
Fujikawa, K. M.E.Legaz and E.W.Davie (1972). Biochem. 11:4892-
4899. 
232 
Galili, G. (19J9). Proc. Natl. Acad. Sci. U.S.A. 86:7756-7760. 
Gaun, C., P.Li, P.D.Riggs and H.Inouye (1988). Gene 67:21-30. 
Goeddel, D.V. (1990). Meth. Enzymol. 185:3-7. 
Gold, L. (1990). Meth. Enzymol. 185:11-
Goldberg, A.L. and S.A. Goff (1986). In Reznikoff, W. and L. 
Gold (Eds). Maximizing gene expression. Butterworths, Boston. 
Golder, J.P. and R.W. Stephens (1983). Eur. J. Biochem. 
136:517522. 
Golomb, M. and M. Chamberlin (1974). J. Biol. Chern. 249:2858-
2863. 
Gottesman, M.E., S. Adhya and A. Das (1980). J. Mol. Biol. 
140:57-65. 
Gouy, M. and C.Gautier (1982). Nucleic Acids Res. 10:7055-7074. 
Gralla, J.D. (1990). Meth. Enzymol. 185:37-54 
Granelli-Piperno, A. and E. Reich (1983). J. Cell Biol. 
97:1029-1037. 
Grieger, M. and B.R. Binder (1984). J. Biol. Chern. 259:2976-
2981. 
Grodberg, J. and J.J. Dunn (1988). J. Bacterial. 170:245-
Grodberg, J., M.D. Lundrigan, D.L. Toledo, W.F. Mangel and J.J. 
Dunn (1988). Nucl. Acid Res. 16:1209. 
Grosjean, H. and W. Fiers (1982). Gene. 18:199-209. 
Gross, E. (1967). Method. Enzymol. 11:.238-255. 
Grossman, A., J. Erickson and C. Gross (1984). Cell. 38:383-
390. 
Grottesmann, S. (1989). Ann. Rev. Genet. 23:163-187. 
Grottesmann, S. (1990). Meth. Enzymol. 185:119-129. 
Haber, E., T. Quetermous, G.R. Matsueda, and M. S. Runge 
(1989). Science. 243:51-56. 
Harris, T.J.R. (1983). In Williamson (Ed). Genetic Engineering. 
vol4. Academic Press, London. 
Hawley, D.K. and W.R. McClure (1983). Nucl. Acids Res. 11:2232-
2239. 
Hayden, M.A. and W. Mandecki (1988). DNA. 8:571-577. 
Hedner, u. (1979). In: Collen, D., B. Wiman and 





Heussen, C., F. Joubert and E.B.D. Dowdle (1984). J. Biol. 
Chern. 259:11635-11638. 
Heussen-Schemmer, c., Merrifield, E.H. and Dowdle, E.B.D. 
(1991). Thromb. Haemostas. 66:226-231. 
Heussen-Schemmer, C. and E.B. Dowdle (1992). S. A. J. Sci. (in 
press). 
Hewick, R.M., M.W. Hunkapillar, L.E. Hood and W.J. Dreyer 
(1981). J. Biol. Chern. 256:7990-7997. 
Horn, T. and Urdea, M.S. (1988). Nucl. Acid. Res. 16:11559-
11571. 
Hoylearts, M. D.C. Rijken, H.R. Lijnen and D. Collen (1982). J. 
Biol. Chem.257:2912-2919. 
Hsiung, H.M., A. Cantrell, J. Luirink, B. Oudega, A.J. Veros 
and G.W. Becker. Bio/technology. 7:267-272. 
Huber, R. and R.W. Carrell (1989). Biochemistry 28:8951-8966. 
Huber, R., D. Kukla, W. Bode, P. Schwager, K. Bartels, S. 
Deisenhofer and w. Steigmann (1974). J. Mol. Biol. 89:73-101. 
Jackson, C.M. (1984). In: Spaet, 
haemostasis and thrombosis, Vol.7. 
York. 
T.H. (Ed), Progress in 
Grune and Stratton, New 
Jallat, S., D. Carvallo, L.H. Tessier, D. Roecklin, C. Roitsch, 
F. Ogushi, R.G. Crystal, and M. Courtney (1986). Protein Eng. 
1:29-35. 
Jordan, R., D. Beeler and R.D. Rosenberg (1979). J. Biol. Chern. 
254: 2902-2913. 
Joubert, F.J. (1982). Int. J. Biochem. 14:187-193. 
Joubert, F.J. (1986). S. Afr. J. Chern. 39:169-175. 
Joubert, F. J. and E. B.D. Dowdle ( 1987) • Thromb. Haemostas. 
57:356-360. 
Joubert, F.J., E.H. Merrifield and E.B.D. Dowdle. (1987). Int. 
J. Biochem. 19:601-606. 
Kalyan, N.K., S.G. Lee, J. Wilhelm, K.P. Fu, W. Hum, R. 
Rappapport, R.W. Hartzell, C. Urbano and P.P. Hung (1988). J. 
Biol. Chern. 263:3971-3978. 
Kato, C., T. Kobayashi, T. Kudo, T. Furuseto, Y. Murakami, T. 
Tanaka, H. Baba, T. Oishi, E. Odtsuka, M. Ikehara, T. Yanagida, 
H. Kato, s. Moriyama and K. Honkoshi (1987). Gene. 54:197-202 
234 
Kellerman, O.K. and T.Ferenci (1982). Method.Enzymol. 90:459-
463. 
Kennell, D.E. (1986). In: Resnikoff, W. and L. Gold (Ed.) 
Maximizing gene expression. Butterworths, Boston. 
Kezdy, F.J. and E.T. Kaiser (1970). Method. Enzymol. 19:3-20. 
Kinsella, A.R. and M. Radman (1980). Proc. Natl. Acad. Sci. USA 
77:3544-3547. 
Klotsky, R.A. and I. Schwartz (1987). Gene. 55:141. 
Knauer, D. J., and D. D. Cunningham ( 1984). Trends Biochem. 
Sci.9:231-233. 
Kniskern, P.J., A. Hagopian, D.L. Montgomery, P. Burke, N.R. 
Dunn, K.J. Hofman, w. J. Miller and R.W. Ellis (1986). Gene. 
46:135-141. 
Kohno, T., D.F. Carmichael, A. Sommer and R.C. Thompson (1990). 
Meth. Enzymol. 185:187-195. 
Kruithof, E.K.O. (1988). Enzyme. 40:113-121. 
Kuhnke G., H.J. Fritz and R. Ehring (1987). EMBO J. 6:507-
Lacroix, M., F.E. Smith and I.B. Fritz (1982). Mol. Cell. 
Endocrinol.26:259-267. 
Laskowski, M. Jr and I. Kato (1980). Ann. Rev. Biochem. 49:593-
626. 
Laug, W.E., B. Dewald, J. Schnyder and M. Baggiolini (1983). 
Cancer Res. 43:22-27. 
Lauritzen, C., E. Tuchsen, P.E. Hansen and 0. Skovgaard (1991). 
Biochemistry, in press, from abstract supplied by Dr. P. Riggs 
New England Biolabs. 
Lawrence, D.A., L. Strandberg, J. Ericson and T. Ny (1990). J. 
Biol. Chern. 265:20293-20301. 
Lawrence, D.A., L. Strandberg, T. Grundstrom and T. Ny (1989). 
Eur. J. Biochem. 186:523-533. 
Lijnen, H.R. and D. Collen (1988). Enzyme 40:90-96. 
Lindahl, T.L., P. Ohlsson and B. Wiman (1990). Biochem. J. 
265:109-113. 
Liotta, L.A., R.H. Goldfarb, R. Brundage, G.P. Siegal, V. 
Terranova and S. Garbisa (1981). Cancer Res. 41:4629-4636. 
Loeberman, H., R. Tokuoka, J. Deisenhofer, and R. Huber (1984). 
J. Mol. Biol. 177:531-556. 
Lorand, L. (1972). Ann. Rev. N.Y. Acad. Sci. 202:6-26. 
Losick, R., J. Pero (1981). Cell. 25:585. 
235 
Lottspeich, F. (1985). J. Chromatog. '326:321~327. 
Lucas, M.A., L.J. Fretto and P.A. McKee (1983). J. Biol. Chern. 
258:4249-4256. 
Madison, E.L., E.J. Goldsmith, R.D. Gerard, M. Gething and J.F. 
Sambrook (1989). Nature. 339:721-724. 
Magnotti, R.A. (1988). Anal. Biochem. 170:228-237. 
Maina, C.V., P.D.Riggs, A.G.Grandea, 
J.A.Tagliamonte, L.A.McReynolds and 
74:365-373. 
B.E.Slatko, L.S.Moran, 
C.Guan (1988). Gene. 
Mandecki, w. (1986) Proc. Natl. Acad. Sci. USA 83, 7177-7181. 
Mandecki, W., M.A. Hayden, M. A. Shallcross and E. Stotland 
(1990). Gene 94:103-107. 
Mann, K.G. (1987). TIBS. 12:229-233. 
Marotti, K.R., D. Belin and S. Strickland (1982). Devel. Biol. 
90:154-159. 
Marston, F.A.O. (1987). In Glover, D.M. (Ed.) DNA cloning 
volume III. IRL Press, Oxford. 
Marston, F.O.A. (1986). Biochem. J. 240:1-12. 
Matsuda, M., S. Iwanaga and S. Nakamura (1972) • Thromb. Res. 
1:619-630. 
McClure, W.R. (1985). Ann. Rev. Biochem. 54:171-
McLachlan, A.D. (1979). J. Mol. Biol. 133:557-563. 
Miller, C.G. (1987). In Neidhardt, F.C. (Ed.). 
coli and Salmonella typhimurium. American 
Microbiology, Washington, D.C. 
Eschrichichia 
Society for 
Mimuro, J. and D.J. Loskutoff (1989). J. Biol. Chern. 264:936-
939. 
Miskin, R. and E. Reich (1980). Cell 19:217-224. 
Moffatt, B.A. and F.W. Studier (1987). Cell. 49:221. 
Monge; J.C., C.L. Lucore, E.T.A. Fry, B.E. Sobel and J.J. 
Billadello (1989). J. Biol. Chern. 264:10922-10925. 
Moroi, M., and N. Aoki (1976). J. Biol. Chern. 251:5956-5965. 
Morrison, D.C. and R.J. U1evitch (1978). Am. J. Pathol. 93:526-
617. 
Moscatelli, D. and D.B. Rifkin (1988). Biochim. Biophys. Acta. 
948:67-85. 
Moses, E. and H. Hinz (1983). J. Mol. Biol. 179:765-776. 
236 
! 
Mosher, D.F. and A. Vaheri (1980). Biochim. Biophys. Acta 
647:113-122. 
Massing, M. and T. Record (1986). Science. 233:889-892. 
Murano, G., D. Aronson, L. Williams and L. Brown (1980). Blood 
55:430-436. 
Nagai, K. and C.Thogersen (1984). Nature. 309:810-812. 
Nagai, K. and H.C.Thogersen (1990). Method. Enzymol. 185:461-
481. 
Nagai, K., M.F.Perutz and C.Poyart (1985). 
Proc.Natl.Acad.Sci.USA. 82:7252-7255 
Nag amine, Y., D. Pearson, M.S. Altus and E. Reich ( 1984). 
Nucleic Acids Res. 12:9525-9541. 
Neurath, H. (1964). Protein-digesting enzymes. 
211(6):68-79. 
Sci. Am. 
Nielsen, L.S., P.A. Andreasen, J. Grondahl-Hansen, L. Skriver 
and K. Dana (1986). FEBS Lett. 196:269-273. 
O'Grady, R.L., L.I. Upfold and R.W. Stephens (1981). Int. J. 
Cancer 28:509-515. 
Oka, T., S. Sakamoto, K.I. Miyoshi, T. Fuwa, K. Yoda, M. 
Yamasaki, G. Tamura and T. Miyake (1985). Proc. Natl. Acad. 
Sci. U.S.A. 82:7212-7216. 
Onesti, s. P., Brick and D.M. Blow (1991). J. Mol. Biol. 
217:153-176. 
Owen, M.C., S.O. Brennan, J.H. Lewis, R.W. Carrell (1985). New 
Engl. J. Med. 309:694-698. 
Ozawa, K., and M. Laskowski Jr. (1966). J. Biol. Chern. 
241:3955-3961. 
Pastan, I., M. Willingham, W. Anderson and M. Gallo ( 1977). 
Cell12:609-617. 
Pedersen, S. (1984). In: Clark, B.F.C. and H.U. Petersen (Ed.). 
Gene expression: the translational step and its control. 
Munksgaard, Copenhagen. 
Pennica, D., W.E. Holmes, W.J. Kohr, R.N. Harkins, G.A. Vehar, 
C.A. Ward, W.F. Bennett, E. Yelverton, P.H. Seeburg, H.L. 
Heynecker, D.V. Goeddel and D. Collen (1983). Nature. 301:214-
221. 
Pohl, G., L. Kaplan, M. Einarsson, P. Wallen and H. Jornvall 
(1984a). FEBS Lett. 169:29-32. 
Pohl, G., M. Kallstrom, N. Bergsdorf, P. Wallen and H. Jornvall 
(1984b). Biochemistry 23:3701-3707. 
I 237 
Preissner, K.T., S. Holzhuter, C. Justus[and G. Muller-Berghaus 
(1989). Blood 74:1989-1996. 
Priestle, J.P., H. Schar and M.G. Grutter (1988). EMBO. 7:339-
343. 
Purvis, I.J., A.J.E. Bettany, T.C. Santiago, J.R. Coggins, K. 
Duncan, R. Easton and A.J.P. Brown (1987). J. Mol. Biol. 
193:413-417. 
Ranby, M. (1982). Biochim. Biophys. Acta. 704:461-469. 
Raven, P.H. (1984). Erythrina (Fabaceae): achievements and 
opportunities. Lloydia. 37:321-331. 
Rijken, D.C. and D. Collen (1981). J. Biol. Chern. 256:7035-
7041. 
Rijken, D.C., G. Wijngaards and J. Welbergen (1981). J. Lab. 
Clin. Med. 97:477-486. 
Rijken, D.C., I. Juhan-Vague and C. Collen (1983) ... J. Lab. 
Clin. Med. 101:285-294. 
Rijken, D.C., M. Hoylaerts and D. Collen (1982). J. Biol. Chern. 
257:2920-2925. 
Robbins, K.C., L. Summaria, B. Hsieh and R.J. Shah (1967) . J. 
Biol. Chern. 242:2333-2342. 
Robbins, K.C., P. Bernabe, L. Arzadon and L. Summaria (1972). 
J. Biol. Chern. 247:6757-6762. 
Robbins, K.C., P. Bernabe, L. Arzadon and L. Summaria (1973). 
J. Biol. Chern. 248:7242-7246. 
Robinson, M., R. Lilley, S.Little, J.S. Emtage, G. Yarranton, 
P. Stevens, A. Millican, M. Easton and G. Humphreys ( 1984). 
Nucl. Acid. Res. 12:6663-6671. 
Rosenberg, A.H., B.N. Lade, D.S. Chui, S.W. Lin, J.J. Dunn and 
F.W. Studier (1987). Gene. 56:125-135. 
Rosenberg, R.D. and P.S. Darnus (1973). J. Biol. Chern. 248:6490-
6505. 
Ruhlmann, A., D. Kukla, P. Schwager, K. Bartels and R. Huber 
(1973). J. Mol. Biol. 77:417-436. 
Russell, J. A.B. Schnieder, J. Katzhendler, K. Kowalski and 
L.M. Sherwood (1979). J. Biol. Chern. 254:2296-2301. 
Saito, H., S. Tabor, F. Tamanoi and C.C. Richardson (1980). 
Proc. Natl. Acad. U. S. A. 77:3917-3921. 
Saksela, o. (1985). Biochim. Biophys. Acta. 823:35-65. 
Saksela, 0., A. Vaheri, w. Schleuning, P. Mignatti and A. 




J. and W. Szybalski (1978). J. Mol. Biol. 124:195L 
Sambrook, J., E.F. Fritsch and T. Maniatis (1989). Molecular 
Cloning a laboratory manual 2nd Edition. CSH Laboratory press. 
Sano, T. and C.R. Cantor (1990). Proc. Natl. Acad. Sci. U.S.A. 
87:142-146. 
Schecter, I. and A. Berger (1967). Biochem. Biophys. Res. 
Commun. 27:157-165. 
Schmeissiner, U., K. McKenney, M. Rosenberg and D. Court 
(1984). J. Mol. Biol. 176:39. 
Schaner, B.E., H.M. Hsiung, R.M. Belagaje, N.G. Mayne and R.G. 
Schaner (1984). Proc. Natl. Acad. Sci. U.S.A. 81:5403-5407. 
Scott, R.W. and J.B. Baker (1983). J. Biol. Chern. 258:10439-
10444. 
Scott, R.W., B.L. Bergman, A. Bajpai, R.T. Hersch, H. 
Rodriguez, B. N. Jones, C. Barreda, S. Watts and J. B. Baker 
(1985). J. Biol. Chern. 260:7029-7034. 
Sedgwick, B. (1989). J. Bacterial. 171:2249-2253. 
Sharp, P.M., E.Cowe, D.G. Higgins, D.C. Shields, K.H. Wolfe and 
F.Wright (1988). Nucl. Acid. Res. 16:8207-8211. 
Sharp, P.M., T.M.F. Tuohy, and K.R. Mosurski (1986). Nucl. 
Acid. Res. 14:5125-5143. 
Shields, X.C. and P.M. Sharp (1987). Nucl. Acid. Res. 15:8023-
8040. 
Shuman, H.A., T.J. Silhavy and J.R. Beckwith (1980). J. Biol. 
Chern. 255:168-174. 
Silhavy, T.J. S.Szrnelcrnan, W.Boos and M.Schwartz (1975). 
Proc.Natl.Acad.Sci.USA. 72:2120-2124. 
Silhavy, T.J., S.A. Benson and S.D. Emr (1983). Microbiol.Rev. 
47:313-344. 
Skriver, L. L.S. Nielsen, R. Stephens and K. Dana (1982). Eur. 
J. Biochem. 124:409-414. 
Smith, A.T., N. Santarna, S. Dacey, M. Edwards, R.C. Bray, 
R.N.F. Thorneley and J.F. Burke (1990). J. Bio1. Chern. 
265:13335-13343. 
Sorensen, M.A., C.G. Kurland and S. Pedersen (1989). J. Mol. 
Biol. 207:365-377. 
Sottrup-Jensen, L., T.M. Stepanik, T. Kristensen, D.M. 
Wierzbicki, C.M. Jones, P.B. Lonblad, S. Magnusson and T.E. 
Petersen (1984). J. Biol. Chern. 259:8318-8327. 
Sprengers, E.D. and C. Kluft (1987). Blood. 69:381-387. 
I 239 
Stader, J.A. and T.J. Silhavy (1990). Method. Enzymol. 185:166-
187. . 
Starkey, P.M. and A.J. 
Proteinases in Mammalian 
Holland, Amsterdam. 
Barrett (1977). In: Barrett (Ed.) 
cells and tissues. Elsevier/North-
Stephens, A.W., B.S. Thalley and C.H.W. Hirs (1987). J. Biol. 
Chern. 262:1044-1048. 
Stormo, G.D. (1986). In: Resnikoff, w. and L. Gold (Eds). 
Maximizing gene expression. Butterworths, Boston. 
Straey, s. and D. Crothers (1987). Cell. 51:699. 
Strauch, K.L., J. Johnson and J. Beckwith (1989). J. Bacteriol. 
171:2689-2694. 
Strickland, S., E. Reich and M.I. Sherman (1976). Cell 9:231-
240. 
Stroud R.M. (1974). A family of protein-cutting proteins. Sci. 
Am. 231(1):74-89. 
Studier, F.W.and B.A.Moffat (1986). J.Mol.Biol. 189:113-130. 
S tudier, J. J. , A. H. Rosenberg, J. J. Dunn and J. W. Dubendorf 
(1990). Meth. Enzymol. 185:60-89. 
Sugita, T., H. Shinagawa, K. Makino and A. Nakata (1985). J. 
Biol. Chern. 99:1247-1250. 
Summaria, L., B. Hsieh and K.C. Robbins (1967). J. Biol. Chern. 
242:4279-4283. 
Sung, W.L., F-L. Yao, D.M. Zahab and S.A. Narang (1986). Proc. 
Natl. Acad. Sci. USA. 83:561-565. 
Swaffield, J.C., I.J. Purvis and A.J.P. Brown (1987). Prot. 
Eng. 1:228. 
Swamy, K.H.S. and A.L. Goldberg (1982). J.Bacteriol. 149:1027-
1033. 
Sweet, R.M., H.T. Wright, J. Janin, C.H. Chothia and D.M. Blow 
(1974). Biochem. 13:4212-4228. 
Swenson, R.P. and J.B. Howards (1979). J. Biol. Chern. 254:4452-
4456. 
Tabor, s. and C.C. Richardson (1985). Proc. Natl. Acad. Sci. 
U.S.A. 82:1074-1078. 
Takahara, H, H. Okamoto and K. Sugawara (1985). J. Biol. Chern. 
260:8378-8383. 
Talmidge, K. and w. Gilbert (1982). Proc. Natl. Acad. Sci. 
U.S.A. 79:1830-1833. 
240 
Travls, J. and G. Salvesan (1983). Annu. Rev. Biochem. 52:655-
709. 
Tschesche, J. and S. Kupfer (1976). Hoppe-Seyler's Z Physiol. 
Chern. 357:769-776. 
Tsunasawa, S., J. W. Steward and F. S. 
J.Biol.Chem. 260:5382-5391. 
Sherman (1985). 
Ullman, A., F. Jacobs and J. Monod ( 1967). J. Mol. Biol. 
24:339-343. 
Urano, S., A.R. Metzger and F.J. Castellano (1989). Proc. Natl. 
Acad. Sci. USA. 86:2568-2571. 
Van de Werf, F., P.A. Ludbrook, S.R. Bergman, A.J. Tiefenbrunn, 
K.A. Fox, H. De Geest, M. Verstraete, D. Collen and B.E. Sobel 
(1984). N. Engl. J. Med. 310:609-613. 
VanLeuven, F. (1982). Trends Biochem. Sci. 7:185-187. 
Van Zonneveld, A. (1986). J. Cell. Biochem. 32:169-178. 
Vaughn, D.E., P.J. DeClerck, M. DeMol and D. Collen (1989). J. 
Clin. Invest. 84:586-591. 
Vetterlein, D., P.L. Young, T.E. Bell and R. Roblin (1979). J. 
Biol. Chern. 254:575-578. 
Wallen, P., G. Pohl, N. Bergsdorf, M. Ranby, T. Ny and H. 
Jornvall (1983). Eur. J. Biochem. 132:681-686. 
Wallen, P., M. Ranby, N. Bergsdorf and P. Kok (1981). Prog. 
Chern. Fibrinolysis Thrombolysis. 5:16-23. 
Walsh, K.A. (1975). Unifying concepts among proteases. In: 
Reich, E., D.B. Rifkin and E. Shaw (eds). Proteases and 
Biological Control. Cold Spring Harbour Laboratory. 
Walther, P.J., H.M. Steinman, R.L. Hill and P.A. McKee (1974). 
J. Biol. Chern. 249:1173-1181. 
Werb, z., M.C. Burleigh, A.J. Barrett and P.M. Starkey (1974). 
Biochem. J. 139:359-368. 
Williams, D.P., D.Regier, D. Akiyoshi, F. Genbauffe and J.R. 
Murphy (1988). Nucl. Acid. Res. 16:10453-10467. 
Wilson, E.L., M.L.B. Becker, E.G. Hoal and E.B.D. Dowdle 
(1980). Cancer Res. 40:933-938. 
Wiman, B, L. Boman and D. Collen (1978). Eur. J. Biochem. 
87:143-146. 
Wiman, B., A. Almquist, 0. Sigurdardottir and T. Lindahl 
(1988). FEBS Lett. 242:125-128. 
Wolff, S.M. and J.V. Bennett (1974). N. Engl. J. Med. 291:733-
734. 
I 
Wun, T. W. Schleuning land 
Chem.257:3276-3283. 
E. Reich (1982). 
241 
J. Biol. 
Wun, T., L. Ossowski and E. Reich (1982). J. Biol. Chern. 
257:7262-7268. 
Yanish-Perron, C., J. Vieira and J. Messing (1985). Gene 
33:103-109. 
Zimmerman, M., J.P. Quigley, B. Ashe, C. Dorn, R. Goldfarb and 
w. Troll (1978).· Proc. Natl. Acad. Sci. USA. 75:750-753. 
